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1. Summary 
Transfer RNAs (tRNAs) play a fundamental role in biology. They decode the messenger 
RNA (mRNA) and carry amino acids to the sites of protein synthesis. Before they can adopt 
their mature, L-shaped conformation, they have to undergo numerous processing steps such 
as 5’ and 3’ end trimming and nucleotide modifications. A subset of vertebrate tRNAs is also 
transcribed as intron-containing precursor molecules (pre-tRNAs). The intervening sequence 
of this tRNA subset needs to be removed by a two-step splicing process. First, the tRNA 
splicing endonuclease (TSEN) complex, consisting of TSEN2, TSEN15, TSEN34, TSEN54, 
and the RNA kinase CLP1, cleaves the pre-tRNA at the 5‘ and 3‘ ends of the intron. This 
cleavage generates 5‘ and a 3‘ tRNA exon halves.  In the yeast-like ligation pathway in 
human cells, the 5‘ hydroxyl terminus of the 3‘ exon is subsequently phosphorylated by 
CLP1, and the 2‘-3‘ cyclic phosphate at the 3’ end of the 5‘ exon is a substrate for a cyclic 
phosphodiesterase, allowing for a canonical 5' phosphate 3' hydroxyl ligation by a still elusive 
tRNA ligase. The remaining endogenous 2‘ phosphate is removed by a 2‘ phospho-
transferase. In the animal pathway, which is predominantly used in vertebrates, the exon 
halves are directly ligated. Thus, CLP1 is dispensable for this type of ligation reaction. From 
the data presented in this work, we hypothesize that CLP1 not only performs phosphorylation 
of the 3’ exon half, but that ATP hydrolysis by CLP1 is additionally required for the preceding 
step, the generation of the exon halves by the TSEN complex. Therefore, CLP1 might be 
relevant for both tRNA splicing pathways. 
 
We show that extracts prepared from mouse embryonic fibroblasts (MEFs) that are devoid of 
CLP1 (“CLP1 knock-out”) or harbor a lysine-to-alanine point mutation (K127A) in CLP1 
rendering the kinase inactive (“kinase-dead”) exhibit largely reduced pre-tRNA cleavage. In 
support of these data, knocking down CLP1 in HeLa cells by small interfering RNAs (siRNAs) 
resulted in a similar reduction in exon generation by the TSEN complex. The deficiency in 
pre-tRNA cleavage could be confirmed with TSEN2-immunoprecipitates from kinase-dead 
MEFs, pinpointing the defect to the pre-tRNA splicing endonuclease complex.  
When we removed ATP from TSEN2-immunoprecipitates from HeLa cells or performed co-
immunoprecipitations with extracts depleted of ATP, we detected reduced tRNA exon 
generation, mimicking the effects previously observed upon interfering with CLP1’s kinase 
function. Interestingly, adding back ATP to the depleted immunoprecipitates restored pre-
tRNA cleavage.  
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In order to further elucidate the pre-tRNA cleavage deficiency phenotype, we used a semi-
purified CLP1-TSEN complex obtained by a one-step purification of a tagged version of wild 
type and K127A CLP1. In addition to reduced exon generation with the mutant CLP1 
complex, we found that the wild type complex requires a β-γ-hydrolyzable NTP for efficient 
pre-tRNA cleavage, confirming results obtained with TSEN2-immunoprecipitates. Mass 
spectrometry analysis of the semi-purified complexes confirmed the presence of the TSEN 
proteins in both CLP1 wild type and K127A samples. Furthermore, we found that GTP, CTP, 
and UTP could efficiently replace ATP in pre-tRNA cleavage. Additional evidence for CLP1’s 
role in pre-tRNA cleavage came when we added a specific CLP1 inhibitor to the semi-
purified complex and subsequently observed reduced exon generation. 
However, the characterization of the CLP1 K127A mutant, regarding its ATP binding or 
hydrolysis competence, did not yield clear results. Moreover, we could not yet determine 
definitely if the disassembly of the complex or a structural rearrangement cause the cleavage 
deficiency. Data from glycerol gradient centrifugations and the results from addition of ATP to 
depleted immunoprecipitates argue against complex disassembly. In contrast, we found that 
in the CLP1 K127A semi-purified complex the levels of TSEN2, TSEN34, and TSEN54 were 
largely diminished, favoring the idea of complex destabilization. Quantitative real-time PCR 
results obtained by comparing wild type and kinase-dead MEFs disproved the hypothesis 
that the cleavage deficiency is caused by reduced TSEN or CLP1 mRNA levels. 
 
There remain several areas for further research on this topic. On the one hand, the reason 
for deficiency in pre-tRNA cleavage needs to be elucidated and the potential complex 
rearrangement must be clarified. On the other hand we could further investigate a putative 
protein kinase function of CLP1 and try to determine the biological role of a possible TSEN 
phosphorylation detected in the semi-purified endonuclease complex. For these two issues 
we could obtain only preliminary data so far; thus, they could be the starting point for new 
research projects. 
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2. Zusammenfassung 
Transfer RNAs (tRNAs) spielen eine wichtige Rolle in der Biologie, denn sie entschlüsseln 
die Erbinformation von Lebewesen, indem sie die Messenger RNA (mRNA) ablesen und die 
korrekten Aminosäuren an den Ort der Proteinsynthese bringen und an die wachsende 
Polypeptidkette anhängen. Bevor tRNAs ihre funktionelle L-Form annehmen, müssen sie am 
5’ und 3’ Ende geschnitten und zahlreiche Nukleotide modifiziert werden. Außerdem 
enthalten manche tRNAs (Vorläufer-tRNAs, prä-tRNAs) intervenierende Sequenzen, die in 
einem zweistufigen Spleißprozess entfernt werden. Dabei schneidet zunächst die tRNA 
Spleißendonuklease, bestehend aus TSEN2, TSEN15, TSEN34, TSEN 54, sowie der RNA 
Kinase CLP1, 5’ und 3’ des Introns, wodurch zwei tRNA-Exonhälften entstehen. Im Hefe-
pathway wird das 5’ Hydroxylende des 3’ Exons von CLP1 phosphoryliert und das  
2’-3’ Cyclophosphatende des 5’ Exons wird von einer Phosphodiesterase geöffnet, wodurch 
die nunmehrigen 5’ Phosphat- und 3’ Hydroxylenden von einer tRNA-Ligase verbunden 
werden können. Das verbliebene 2’ Phosphat wird von einer Phosphotransferase entfernt. 
Im Säugerpathway, der in Wirbeltieren bevorzugt verwendet wird, werden die Exonhälften 
direkt nach dem Schneiden ligiert, d.h. ohne weitere Modifikation durch CLP1. In dieser 
Arbeit wird gezeigt, dass CLP1 nicht nur für die Exonphosphorylierung im Hefepathway 
zuständig ist, sondern bereits an der Schneidereaktion beteiligt ist und damit möglicherweise 
eine Funktion in beiden Pathways erfüllt. 
 
Wir konnten zeigen, dass Mausfibroblasten, aus denen CLP1 entfernt wurde („CLP1 knock-
out“) oder die eine mutierte Version von CLP1 besitzen, dessen Kinasefunktion durch eine 
Lysin-zu-Alanin Punktmutation (K127A) zerstört wurde, eine stark verminderte prä-tRNA-
Endonukleaseaktivität zeigen. Ein ähnlicher Effekt wurde mit einer durch kleine 
interferierende RNAs (siRNAs) ausgelösten mRNA-Depletion in HeLa-Zellen erzielt. Diese 
Reduktion der entstehenden Exonmengen wurde mittels TSEN2-Koimmunpräzipitation 
funktionell auf den Spleißendonukleasekomplex eingeschränkt. Durch die Depletion von ATP 
aus Zellextrakten und anschließende Immunpräzipitation oder direkt an TSEN2-
Immunpräzipitaten wurde ebenfalls eine reduzierte prä-tRNA-Endonukleaseaktivität erreicht, 
die den beschriebenen CLP1-Effekten ähnelt. Die Rückgabe von ATP zu depletierten Proben 
bewirkte die Wiederherstellung hoher Exonmengen.  
Zur Charakterisierung des Prozessierungsdefekts wurde ein teilaufgereinigter CLP1-TSEN-
Komplex durch eine Affinitätsreinigung einer mit Fusionsproteinen versehenen Version von 
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Wildtyp- und K127A-CLP1 hergestellt. Die reduzierte prä-tRNA-Endonukleaseaktivität von 
K127A-CLP1 konnte bestätigt werden, wobei diese nicht auf die Abwesenheit eines oder 
mehrerer TSEN-Proteine zurückzuführen war, wie durch massenspektrometrische Analysen 
festgestellt werden konnte. Für eine effiziente prä-tRNA-Endonukleasereaktion war im 
verwendeten System ein β-γ-hydrolysierbares NTP nötig, was auch mit TSEN2-
Immunpräzipitaten bestätigt werden konnte. Neben ATP konnte auch in Gegenwart von 
GTP, CTP oder UTP eine effiziente Prozessierung der prä-tRNA beobachtet werden. Durch 
die spezifische Inhibierung der Kinasefunktion von CLP1 im teilgereinigten Komplex durch 
eine synthetische Verbindung wurde ebenfalls eine reduzierte Endonukleaseaktivität 
beobachtet, was erneut für eine Beteiligung von CLP1 an diesem Prozess spricht. 
Die Charakterisierung der CLP1 K127A-Mutante hinsichtlich ihrer Fähigkeit, ATP zu binden 
bzw. zu hydrolysieren, erbrachte keine eindeutigen Resultate. Weiters konnten wir bisher 
nicht mit Sicherheit feststellen, ob eine Destabilisierung des Komplexes oder eine strukturelle 
Reorganisation die reduzierte prä-tRNA-Schneideaktivität verursacht. Daten aus 
Glyzeringradienten-Zentrifugationsexperimenten und die Wiederherstellung der Aktivität 
nach ATP-Zugabe zu depletierten Immunpräzipitaten widerlegen diese Hypothese. Im 
Gegensatz dazu fanden wir heraus, dass im teilgereinigten CLP1 K127A-Komplex TSEN2, 
TSEN34 und TSEN54 in drastisch reduzierten Mengen vorliegen, was wiederum für eine 
strukturelle Reorganisations des Komplexes spricht. In einer Analyse der mRNA-Mengen 
von Wildtyp- und K127A-Mausfibroblasten mittels quantitativer Echtzeit-PCR konnte 
überdies keine erniedrigte Konzentration von CLP1 oder TSEN-mRNAs festgestellt werden, 
die diesen Effekt erklären würden. 
 
Trotz der bereits erbrachten Erkenntnisse verbleiben noch zahlreiche offene Fragen 
bezüglich der reduzierten prä-tRNA-Endonukleaseaktivität. Einerseits muss geklärt werden, 
ob der Grund dafür tatsächlich in einer strukturellen Veränderung des Komplexes liegt, und 
falls nicht, muss die wirkliche Ursache gefunden werden. Andererseits könnte man 
Untersuchungen darüber anstellen, inwiefern CLP1 auch Proteinkinaseaktivität besitzt und 
dies die Exonentstehung beeinflussen könnte. Schließlich konnten wir auch Hinweise für 
eine Phosphorylierung der TSEN-Proteine finden, die den Ausgangspunkt eines völlig neuen 
Forschungsprojekts darstellen könnte. 
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3. Abbreviations 
Measurement units (e.g. ml), chemical elements or formulas (e.g. NaCl) and Greek letters 
(e.g. µ) are not included. 
 
A Adenine, Adenosine 
ADP Adenosine diphosphate 
AEBSF 4-(2-Aminoethyl)benzenesulfonylfluoride hydrochloride 
Amp Ampicillin 
AMP Adenosine monophosphate 
AMPcPP Adenosine-5’-[(α,β)-methyleno] triphosphate 
AMPPcP Adenosine-5’-[(β,γ)-methyleno] triphosphate 
AMPPnP Adenosine-5’-[(β,γ)-imido] triphosphate 
approx. approximately 
APS Ammonium persulfate 
ATP Adenosine triphosphate 
BSA Bovine serum albumine 
C Cytosine, Cytidine 
C. elegans Caenorhabditis elegans 
Cam Chloramphenicol 
cDNA complementary DNA 
CLP1 Cleavage/Polyadenylation Factor IA Subunit 
CTP Cytidine triphosphate 
d.h. das heißt 
DAPI 4',6-diamidino-2-phenylindole 
DEPC Diethylpyrocarbonate 
DHFR Dihydrofolate reductase 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
ds double stranded 
DTT Dithiothreitol 
E. coli Escherichia coli 
e.g. example given 
ECL Enhanced chemiluminescence 
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EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescence activated cell sorting 
G Guanine, Guanosine 
GST Glutathione S-transferase 
GTP Guanosine triphosphate 
HeBS HEPES buffered saline (also abbreviated as HBS) 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP Horseradish peroxidase 
Hs Homo sapiens 
i.e. id est 
ILK Integrin-linked kinase 
IMBA Institute of Molecular Biotechnology of the Austrian Academy of Sciences 
IMP Research Institute of Molecular Pathology 
IPTG Isopropyl-β-D-1-thiogalactopyranoside 
Kan Kanamycin 
LNA Locked nucleic acid 
M. jannaschii Methanocaldococcus jannaschii 
MEFs Mouse embryonic fibroblasts 
Mm Mus musculus 
mRNA messenger RNA 
MWCO Molecular weight cut off 
NAD Nicotinamide adenine dinucleotide 
NP 40 Nonidet P 40 substitute 
nt nucleotide 
NTAP N-terminal tandem affinity purification (tag) 
NTC Non-template control 
NTP Nucleoside triphosphate 
OD600 Optical density at 600 nm 
PAA Polyacrylamide 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PBST PBS-Tween 
PCR Polymerase chain reaction 
PDB Protein database 
Phe Phenylalanine 
PMSF Phenylmethylsulfonyl fluoride 
pre/prä-tRNA precursor tRNA 
Abbreviations 
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PTK Protein tyrosine kinase 
qRT-PCR quantitative real-time PCR 
RBS Ribosome binding site 
RIPA Radioimmunoprecipitation assay 
RISC RNA-induced silencing complex 
RNA Ribonucleic acid 
RNAi RNA interference 
rRNA ribosomal RNA 
S. cerevisiae Saccharomyces cerevisiae 
SBP Streptavidin binding peptide 
SDS Sodium dodecyl sulfate 
ss single stranded 
SSC Saline sodium citrate 
SV40 Simian virus 40 
T Thymine, Thymidine 
TAP Tandem affinity purification (tag) 
TBE Tris/borate/EDTA 
TCA Trichloroacetic acid 
TE Tris/EDTA 
TEMED Tetramethylethylenediamine 
TEV Tobacco etch virus 
TLC Thin layer chromatography 
tRNA transfer RNA 
TSEN tRNA splicing endonuclease 
U Uracil, Uridine 
UTP Uridine triphosphate 
UTR Untranslated region 
UV Ultraviolet 
VSV Vesicular stomatitis virus 
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4. Introduction 
4.1. Transfer RNAs 
Transfer RNAs (tRNAs) have a central role in biology as adaptor molecules in protein 
synthesis in any living organism. They transfer the correct amino acids to the nascent 
polypeptide chain by translating codons on the messenger RNA (mRNA). For fulfilling their 
specialized tasks, tRNAs have a highly conserved, L-shaped structure that allows attachment 
of a particular amino acid to one end and decoding the mRNA at the other (Fig. 1A).  
Mature tRNA molecules are synthesized as large precursor tRNAs (pre-tRNAs) that 
have to undergo several maturation steps after being transcribed by RNA polymerase III and 
before functioning in protein synthesis. The 5’ leader sequence is removed by the 
endoribonuclease RNase P (reviewed in Marvin and Engelke, 2009) and the 3’ trailer is 
processed by tRNase Z (ELAC1/2) (Hartmann et al., 2009; Schiffer et al., 2002; Takaku et 
al., 2003) before the CCA triplet can be added to the discriminator base left after tRNAse Z 
cleavage, allowing for subsequent attachment of the correct amino acid. This is performed by 
a tRNA nucleotidyltransferase (reviewed in Xiong and Steitz, 2006). In addition to 5’ and  
3’ end processing, numerous nucleotides are posttranscriptionally modified (reviewed in 
Phizicky and Hopper, 2010), among them the pseudouridine (Ψ), after which the TΨC loop in 
the cloverleaf-shaped two-dimensional representation (Fig. 1B) was named. 
 
4.2. Pre-tRNA Splicing 
In addition to the various posttranslational processing steps, a subset of pre-tRNAs contains 
intervening sequences that need to be removed in order to produce functional mature tRNAs. 
Intron-containing pre-tRNAs are found in all three domains of life, the bacteria, the archea, 
and the eukarya, where they represent from 6% in humans (Lowe and Eddy, 1997) to 
approximately 25% of all tRNA genes in lower eukaryotes (Trotta et al., 1997). The 
eukaryotic intervening sequences vary in length between 14 and 60 nucleotides and are 
positioned one nucleotide 3’ to the anticodon (Ogden et al., 1984) as depicted in Fig. 1C.  
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Fig. 1: tRNA Structure. (A) 3-dimensional structure of the mature tRNAPhe from Saccharomyces cerevisiae. 
(PDB: 1EHZ; Structure by Shi and Moore, 2000). (B) 2-dimensional representation of the cloverleaf-shaped 
tRNAPhe from S. cerevisiae. Names of the arms are indicated, blue lines represent positions of the 5’ leader and 3’ 
trailer before trimming by RNase P and tRNase Z. The CCA triplet is added after cleavage. The anticodon (GAA) 
is indicated in green, modified nucleotides are marked in red (m2G  = 2-metyhl-guanosine; D = 5,6-dihydrouridine; 
m2,2G = N2-dimethylguanosine; Cm = O2'-methyl-cytdine; Gm = O2'-methyl-guanosine; T = 5-methyluridine 
(ribothymidine); Y = wybutosine (Y-base); Ψ = pseudouridine; m5C = 5-methyl-cytidine; m7G = 5-methyl-
guanosine; m1A = 1-methyl-adenosine). Black lines indicate hydrogen bonds. (C) The intron sequence of the pre-
tRNAPhe from S. cerevisiae is shown. The intron is positioned one nucleotide 3’ to the anticodon as indicated by 
the black lines. 
 
4.2.1. The Pathway of pre-tRNA Splicing in Yeast 
Whereas bacteria remove their tRNA introns via a primitive self splicing mechanism that is 
autocatalyzed be the RNA molecule itself (Biniszkiewicz et al., 1994; Reinhold-Hurek and 
Shub, 1992), the eukaryotic pre-tRNA splicing pathway, first and most extensively studied in 
Saccharomyces cerevisiae, has been shown to occur in multiple steps (Peebles et al., 1979) 
involving several enzymatic activities (Fig. 2A).  
First, the tRNA splicing endonuclease complex, a tetrameric enzyme consisting of 
Sen2p, Sen15p, Sen34p, and Sen54p, cleaves the pre-tRNA at the 5’ and 3’ ends of the 
intron (Trotta et al., 1997). The products of the endonuclease reaction are a 5’ and a 3’ tRNA 
exon half, as well as the intron (Knapp et al., 1979). The exon halves and the intron have 5’ 
hydroxyl and 2’-3’ cyclic phosphate ends (Peebles et al., 1983) that are the substrate for the 
subsequent ligation reaction, catalyzed by the multi-functional tRNA ligase Trl1p (Phizicky et 
al., 1986; Westaway et al., 1988) that exhibits cyclic phosphodiesterase, polynucleotide 
kinase, and RNA ligase activities (Xu et al., 1990). Trl1p first opens the 2’-3’ cyclic phosphate 
by hydrolysis, yielding a 2’ phosphate and 3’ hydroxyl end. Second, the 5’ hydroxyl end of the 
3’ tRNA exon half is phosphorylated by Trl1p using the γ-phosphate of GTP (Belford et al., 
1993; Westaway et al., 1993). As a ligation intermediate, AMP is transferred to the 5’ end of 
the 3’ exon (Greer et al., 1983), Trl1p catalyzes the formation of the 5’-3’ phosphodiester 
bond, and AMP is released (Phizicky et al., 1986; Xu et al., 1990). The 2’ phosphate 
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remaining at the former 5’ exon half is removed by the NAD-dependent phosphotransferase 
Tpt1p and transferred to NAD (Culver et al., 1997; McCraith and Phizicky, 1990, 1991).  
The pathway initially described for S. cerevisiae has been shown to be also active in 
plants (Englert and Beier, 2005). 
 
 
Fig. 2: Pre-tRNA Splicing in Yeast (A) and Vertebrates (B). (A) In yeast, the intron-containing pre-tRNA is 
cleaved by the tRNA splicing endonuclease (Sen2p, Sen15p, Sen34p, Sen54p), leaving a 5’ and 3’ tRNA exon 
half. The kinase domain of Trl1p subsequently phosphorylates the 5’ hydroxyl terminus of the 3’ exon using GTP. 
Then, the 2’-3’ cyclic phosphate is opened by the phosphodiesterase activity of Trl1p, which also catalyzes the 
canonical 5’ phosphate 3’ hydroxyl ligation. Finally, the remaining 2’ phosphate is removed by a separate  
2’ phosphotransferase. (B) In the predominant tRNA splicing pathway in animals (upper panel), the exon halves 
generated by the tRNA splicing endonuclease (TSEN2, TSEN15, TSEN34, TSEN54) are directly ligated by a 
recently identified ligase that uses the 2’-3’ cyclic phosphate and 5’ hydroxyl termini as substrates. In the yeast-
like pathway (lower panel), splicing is mechanistically the same as described for yeast. Phosphorylation of the  
5’ hydroxyl end is carried out by CLP1, and ligation is performed by unidentified enzymatic activities 
corresponding to yeast Trl1p. 
 
4.2.2. Two distinct pre-tRNA Splicing Pathways exist in Vertebrates 
In contrast to yeast, two different pre-tRNA splicing mechanisms have been described for 
animals (Fig. 2B). The predominant pathway, hence called “animal pathway”, differs from the 
mechanism described for yeast especially in the origin of the phosphate incorporated into the 
splice junction. Whereas in yeast this phosphate is transferred to the 5’ hydroxyl end of the  
3’ exon half from an exogenous molecule of GTP as described, vertebrates make use of the 
2’-3’ cyclic phosphate terminus of the 5’ exon half and, therefore, do not incorporate an 
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exogenous phosphate, as was described using extracts from Xenopus laevis (Laski et al., 
1983; Nishikura and De Robertis, 1981) and HeLa cells (Filipowicz and Shatkin, 1983). 
Consequently, an RNA kinase activity is dispensable for this type of tRNA exon half ligation. 
Thus, the 3’ and 5’ tRNA exon halves can be ligated directly after the cleavage reaction that 
is performed by the conserved tetrameric TSEN protein complex similar to yeast (Paushkin 
et al., 2004). The vertebrate tRNA ligase has recently been identified (Popow et al., 
submitted). The ligation mechanism described for vertebrates is also used in archea (Kjems 
and Garrett, 1988; Zofallova et al., 2000). 
However, in addition to the animal pathway, in mammals a second splicing 
mechanism was shown to exist that is similar to the yeast pathway, especially regarding the 
origin of the splice junction phosphate (Winicov and Button, 1982; Zillmann et al., 1991, 
1992). After the pre-tRNA cleavage by the TSEN proteins, the 5’ hydroxyl end of the 3’ exon 
half needs to be phosphorylated as a prerequisite for ligation by the yet unidentified yeast-
like tRNA ligase enzyme. In addition to its ligase activity, this enzyme may or may not have 
cyclic phosphodiesterase activity, which could equally well have been taken over by a 
separate enzyme (Weitzer and Martinez, 2007a). However, the elusive 5’ hydroxyl RNA 
kinase was identified as the CLP1 protein (Weitzer and Martinez, 2007b), which was found to 
be associated with the TSEN protein complex (Paushkin et al., 2004). 
 
4.2.3. Localization of pre-tRNA Splicing 
The components of the pre-tRNA splicing machinery have been shown to localize to the 
nucleus in Xenopus (De Robertis and Olson, 1979), mouse (Winicov and Button, 1982), and 
human cells (Laski et al., 1983; Paushkin et al., 2004; Peebles et al., 1983; Rauhut et al., 
1990). This body of evidence fueled the current model that pre-tRNA splicing takes place in 
the nucleus in higher eukaryotes. However, evidence has emerged that pre-tRNA splicing in 
yeast occurs in the cytoplasm (Yoshihisa et al., 2007; Yoshihisa et al., 2003) although the 
splicing endonuclease was initially identified as a membrane protein (Peebles et al., 1983) 
and the tRNA ligase was shown to localize to the inner nuclear membrane (Clark and 
Abelson, 1987). These data might suggest that pre-tRNA processing between higher and 
lower eukaryotes not only differs in the mechanism but also in the subcellular compartments 
where the reactions take place.  
Another layer of complexity regarding the localization of pre-tRNA splicing is added 
by the fact that the transport between nucleus and cytoplasm also seems to take part in pre-
tRNA processing (Hopper et al., 2010; reviewed in Hopper and Shaheen, 2008). On the one 
hand, the tRNA export receptor exportin-t has been shown to interact with 5’ and 3’ end 
processed and modified pre-tRNAs, regardless if they are spliced or unspliced (Lipowsky et 
al., 1999). On the other hand, yeast with mutations in nucleoporins mutants, as well as in 
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other components of the nuclear pore complex (Simos et al., 1996), is defective in pre-tRNA 
splicing (Sharma et al., 1996),. Additionally, nuclear export of the La protein, which is 
involved in tRNA trafficking, affects tRNA maturation (Bayfield et al., 2007). Interestingly, 
tRNAs can even be re-imported into the nucleus from the cytoplasm in a retrograde 
movement (reviewed in Dahlberg and Lund, 2005). 
 
4.3. The Splicing Endonuclease Complex 
The yeast tRNA splicing endonuclease was initially characterized as an integral membrane 
protein (Peebles et al., 1983) involved in pre-tRNA splicing (Winey and Culbertson, 1988). 
The enzyme is only present at low levels, approximately 150 copies per cell (Abelson et al., 
1998). After tedious purifications, the splicing endonuclease turned out to be a 
heterotetramer, consisting of Sen15p, Sen2p (44 kDa), Sen34p, and Sen54p, named for their 
respective molecular weights (Rauhut et al., 1990; Trotta et al., 1997). Sen2p contains a 
transmembrane domain so that the endonuclease complex is probably anchored to the 
nuclear membrane via this subunit (Abelson et al., 1998). From the analysis of splicing 
mutants exhibiting cleavage on only one end of the pre-tRNA intron sequence, it was 
deduced that Sen2p and Sen34p carry out cleavage at the 5’ and 3’ end of the intron, 
respectively (Ho et al., 1990; Trotta et al., 1997; Winey and Culbertson, 1988), further 
supported by a 130 amino acid homologous domain in both proteins (Abelson et al., 1998).  
However, the catalytic sites of both subunits seems to be required for each cleavage reaction 
(Fig. 3A) by one contributing a “cation-π-sandwich” to the other one’s catalytic center so that 
a composite active site is formed (Trotta et al., 2006). Two-hybrid studies demonstrated that 
Sen2p and Sen54p strongly interact with each other, as well as Sen34p and Sen15p, 
respectively (Trotta et al., 1997). 
 
4.3.1. Complex Architecture in Yeast and Archea 
It was found that the conserved domains of Sen2p and Sen34p of the eukaryotic tRNA 
splicing endonuclease show significant homology to several archeal endonucleases (Abelson 
et al., 1998; Kleman-Leyer et al., 1997). Structural studies and the first endonuclease crystal 
structures demonstrated that archeal tRNA splicing endonucleases occur either as 
homodimers that act as pseudotetramers, as for example in Haloferax volcanii and 
Archaeoglobus fulgidus (Kleman-Leyer et al., 1997; Li and Abelson, 2000), or as 
homotetramers as in Methanocaldococcus jannaschii (Li et al., 1998; Lykke-Andersen and 
Garrett, 1997).  
These findings have led to the proposal of a structural model, not only for the archeal 
tRNA splicing endonuclease (Fig. 3B), but in analogy also for the eukaryotic one (Fig. 3C) 
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(Abelson et al., 1998; Li et al., 1998). In the M. jannaschii monomers, the highly conserved 
C-terminal domain contains a β strand (β9) that, together with a loop (L8), interacts with the 
symmetrically aligned domains of another monomer by hydrogen bonding (Abelson et al., 
1998). This dimerization mechanism is supposed to be analogous to the stable interactions 
detected between Sen34p and Sen15p and between Sen2p and Sen54p in yeast (Calvin and 
Li, 2008). Thus, the dimeric unit consisting of one structural and one catalytic subunit, which 
are identical in M. jannaschii, has been conserved in evolution (Abelson et al., 1998). 
Tetramerization occurs via heterologous electrostatic interactions between two 
dimers. Thereby, the acidic L10 loops of the structural subunits are inserted into a basic 
pocket on the opposite catalytic subunit (Calvin and Li, 2008), which results in the structural 
arrangement allowing for the correct positioning of the catalytic subunits to perform accurate 
cleavage of the pre-tRNA (Abelson et al., 1998). Although these electrostatic interactions are 
probably less stable than the hydrogen bonds between the monomers (Li et al., 1998; Lykke-
Andersen and Garrett, 1997; Trotta et al., 1997), they seem to be equally well conserved 
(Abelson et al., 1998).  
Up to now, a number of structural and biochemical analyses of crenarcheal and 
euryarcheal endonucleases (reviewed in Heinemann et al., 2010) have supported this model 
of conserved structure and mechanism that has supposedly arisen from the simple 
homotetrameric structure (reviewed in Calvin and Li, 2008) and led to the notion of a unified 
cleavage mechanism (Abelson et al., 1998). 
 
 
Fig. 3: Archeal and Yeast tRNA Splicing Endonuclease Complexes. (A) Hypothetical model of the cation-π- 
sandwich of the eukaryotic tRNA-splicing endonuclease. Cleavage at the 5’ site requires the active site of Sen2p 
and the cation-π-sandwich (shaded in green) of Sen34p and cleavage at the 3’ site would need the active site of 
Sen34p and the cation-π-sandwich of Sen2p.  Each cation-π-sandwich consists of an arginine (Arg) and a 
tryptophan (Trp) residue surrounding a flipped-out adenine (A) base (modified from Trotta et al., 2006). (B) Model 
of the subunit arrangement in the Methanocaldococcus jannaschii splicing endonuclease homotetramer. 
Important features discussed in the text are indicated: C = catalytic subunit; S = structural subunit; L10 = acidic 
L10 loop; +++ = basic pocket; β9 = β9 strand (+ L8 loop). (C) Proposed structural model for the S. cerevisiae 
splicing endonuclease heterotetramer. Labeling as in (B). (B,C: Modified from Abelson et al., 1998; Li et al., 
1998). 
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4.3.2. Catalytic Mechanism 
The catalytic mechanism of the cleavage reactions is similar to the reaction catalyzed by 
RNase A (reviewed in Raines, 1998). The catalytic triad of the tRNA splicing endonuclease 
consists of conserved histidine, lysine, and tyrosine residues, which are clustered around the 
scissile phosphodiester bond (Xue et al., 2006). The tyrosine is supposed to deprotonate the 
2’ hydroxyl group of the ribose, generating 2’O- as a nucleophile that subsequently attacks 
the neighboring phosphodiester bond. The lysine residue stabilizes the negative charge of 
the transition state and, finally, the histidine protonates the leaving 5’ oxygen to form the  
5’ hydroxyl and 2’-3’ cyclic phosphate termini (Calvin et al., 2008; Xue et al., 2006). 
 
4.3.3. Substrate Recognition 
Although both mechanism and structure of the tRNA splicing endonuclease complex have 
been kept through evolution from archea to eurkaryotes, the substrate recognition 
mechanisms seem to differ. In eukaryotes, only the mature domain in the pre-tRNA is 
conserved (Abelson et al., 1998). Experiments in which additional nucleotides were inserted 
into the pre-tRNA to change the length of the anticodon stem resulted in a corresponding 
shift of the cleavage sites (Mattoccia et al., 1988; Reyes and Abelson, 1988). This led to the 
model that the eukaryal endonucleases bind to invariant nucleotides in the mature RNA 
(Greer et al., 1987; Reyes and Abelson, 1988) and measure the distance to the intron-exon 
junctions, probably via the basic protein Sen54p interacting with Sen2p (Fig. 4A,B) (Abelson 
et al., 1998; Trotta et al., 1997). In addition to the fixed distance, the yeast and Xenopus 
endonucleases depend on base-pairing between a conserved purine residue in the intron 
close to the 3’ cleavage site and a pyrimidine at position 32 in the anticodon loop, the so-
called anticodon-intron pair (A-I pair) (Bufardeci et al., 1993), showing that the intron is not 
completely passive in pre-tRNA splicing (Baldi et al., 1992; Di Nicola Negri et al., 1997). 
However, the recognition of the 5’ splice site seems to depend on different features (Di 
Nicola Negri et al., 1997). 
 In contrast, archeal endonucleases are neither dependent on the position of the intron 
nor on the structure of the mature domain (Thompson and Daniels, 1988), so that introns 
found elsewhere than in the anticodon loop (Marck and Grosjean, 2003; Thompson et al., 
1989) or multiple introns in one pre-tRNA can be excised as well (Tocchini-Valentini et al., 
2009). However, the archeal splice sites are found in a strictly conserved bulge-helix-bulge 
(BHB) motif (Fig. 4A,B), consisting of two three-nucleotide bulges separated by a four-base-
pair helix (Thompson and Daniels, 1988). This BHB structure defines the intron-exon 
boundaries in archeal pre-tRNAs (Thompson and Daniels, 1990). However, various 
additional substrate structures and corresponding endonuclease conformations have been 
identified in archea and crenarchea (Tocchini-Valentini et al., 2005a, b, 2007). 
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Fig. 4: Substrate Recognition and Subunit Positioning in Yeast and Archea. (A) Consensus sequence and  
2-D-structure of yeast and archeal pre-tRNA splicing endonuclease substrates. Splice sites are indicated by 
arrows; O, X = nonconserved bases in conserved and variable regions, respectively; Y = pyrimidines; R = 
purines. Yeast endonuclease interacts with the mature domain of the pre-tRNA and measures the distance to the 
cleavage sites. In archaea, the endonuclease recognizes a bulge-helix-bulge motif (shaded area). (B) 
Comparison of 3-D endonuclease models in yeast and archea (C1, C2 = catalytic subunits). (From Li et al., 1998). 
 
In general, archeal pre-tRNAs are not recognized by the eukaryal endonuclease, and vice 
versa (Thompson and Daniels, 1990). Therefore, it was proposed that archeal and eukaryal 
endonucleases employ different mechanisms for cleavage, despite their structural similarity 
(Abelson et al., 1998). Surprisingly, it was found that hybrid pre-tRNA substrates containing 
eukaryal and archaeal sequences can be cleaved by eukaryotic endonucleases (Di Segni et 
al., 2005; Fabbri et al., 1998). Thus, the eukaryotic endonuclease seems to have retained the 
ability to recognize archaeal pre-tRNAs. Fabbri et al. hypothesize that this is due to the fact 
that the A-I pair generates a three-nucleotide bulge resembling half of the BHB motif (Fabbri 
et al., 1998).  In support of this, it was shown that the Xenopus endonuclease can cleave 
pre-tRNA-like substrates lacking the mature domain and non-tRNA substrates containing a 
BHB motif (Fruscoloni et al., 2001). These data indicate that there may have been a common 
ancestral mechanism for recognition of pre-tRNA that is still used by the archaeal enzymes. 
 
4.3.4. The Human Endonuclease Complex 
Meanwhile, the plant (Akama et al., 1999, 2000; Englert and Beier, 2005) and human 
(Paushkin et al., 2004) tRNA splicing endonucleases have been identified. The human 
endonuclease consists, similar to its yeast counterpart, of four different subunits that were 
annotated analogously as TSEN2, TSEN15, TSEN34, and TSEN54. Tetramerization seems 
to occur similar to yeast as well, because the most conserved domains in the structural 
subunits TSEN15 and TSEN54 are located at their C-terminus and correspond to the β9 and 
L10 regions in yeast (Paushkin et al., 2004). Thus, the overall configuration of yeast and 
human endonucleases seems to be highly similar and, together with the fact that the catalytic 
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activity also resides in TSEN2 and TSEN34, the splicing mechanism is likely to be conserved 
as well.  
Interestingly, a second complex with an alternatively spliced isoform of TSEN2 was identified 
(Paushkin et al., 2004). The alternative TSEN2 is lacking exon 8, a region that is probably 
involved in the formation of the basic pocket into which the L10 loop is inserted (Bujnicki and 
Rychlewski, 2000; Li et al., 1998; Paushkin et al., 2004). The complex containing the 
alternative TSEN2 isoform is still capable of cleaving the pre-tRNA, though less accurately, 
resulting in cleavage of only the 3’ site and additionally within the intron (Paushkin et al., 
2004). These data suggest that the alternative endonuclease complex might be involved in a 
different biological process not yet identified.  
In this context it is remarkable that another component previously believed to be 
unrelated to pre-tRNA splicing co-purified with the TSEN proteins (Paushkin et al., 2004): 
The cleavage/polyadenylation factor IA subunit (CLP1), initially implicated in the 3’ end 
formation of mRNAs (de Vries et al., 2000; Minvielle-Sebastia et al., 1997). Thus, a 
biochemical link between pre-tRNA splicing and mRNA 3’ end processing seems to exist, 
suggesting that both machineries may have arisen from a common ancestor (discussed in 
(Paushkin et al., 2004). 
In addition to pre-tRNA splicing and possibly mRNA 3’ end formation, impairing 
(t)RNA processing was shown to be the cellular basis for neurological disorders, in that 
mutations in TSEN proteins cause pontocerebellar hypoplasia in human patients (Budde et 
al., 2008). 
 
4.4. CLP1- the Cleavage/Polyadenylation Factor IA Subunit 
CLP1 is a protein highly conserved during evolution (Fig. 5) (de Vries et al., 2000). It was 
originally termed HEAB (human homolog to a hypothetical Caenorhabditis elegans ATP/ 
GTP-binding protein) when the corresponding gene was implicated in a chromosome 
rearrangement causing acute monoblastic leukemia (Tanabe et al., 1996). Tanabe et al. 
showed that CLP1 harbors a Walker-A and Walker-B motif (Fig. 5), both associated with 
ATP/GTP binding (Walker et al., 1982). 
CLP1 received its name because it was identified as a component of the Cleavage 
Factor (CF) I that, together with other proteins, is involved in mRNA 3’ end processing in  
S. cerevisiae (Minvielle-Sebastia and Keller, 1999; Minvielle-Sebastia et al., 1997; Preker et 
al., 1997). Within the CF I complex, Clp1p has been shown to interact with Rna15p and 
Pcf11p (Gross and Moore, 2001a; Gross and Moore, 2001b). The interaction with Pcf11p is 
very stable; thus, yeast Clp1p was co-crystallized with the Clp1p-binding domain of Pcf11p 
(Noble et al., 2007). The crystal structure confirmed the presence of the nucleotide binding 
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sites but, surprisingly, nucleotide hydrolysis by Clp1p’s active site was not observed (Noble 
et al., 2007). Yeast Clp1p contains three domains, a small N-terminal β sandwich domain, a 
C-terminal domain containing an unusual α/β-fold and a central ATP-binding domain (Fig. 5) 
that is similar to SIMIBI-class ATPase subunits found in various multisubunit complexes 
(Noble et al., 2007). Additionally, the P-loop domain (reviewed in Leipe et al., 2002) 
containing the ATP-binding site displays similarity to T4 Polynucleotide Kinase (PNK) 
(Ramirez et al., 2008). 
In human mRNA 3’ end formation, CLP1 is part of CF IIAm and probably acts as a 
bridge between CF Im and CPSF (de Vries et al., 2000). It was found to be associated to 
PCF11 like in yeast (de Vries et al., 2000). Surprisingly, human CLP1 alone (without PCF11) 
was identified as a component of the pre-tRNA splicing endonuclease complex (Paushkin et 
al., 2004) and finally, the function of an RNA kinase could be assigned to CLP1 (Weitzer and 
Martinez, 2007b). Subsequently, CLP1’s task in 5’ hydroxyl phosphorylation at the 3’ tRNA 
exon was elucidated (Weitzer and Martinez, 2007b). Interestingly, the yeast CLP1 homolog 
neither plays a role in pre-tRNA splicing, where Trl1p carries out the 5’ hydroxyl 
phosphorylation, nor possesses kinase activity (Ramirez et al., 2008). Nonetheless, Clp1p is 
essential for yeast growth (Ramirez et al., 2008). Various additional functional differences 
between yeast and human CLP1 have been characterized: Whereas complementation of a 
kinase-defective Trl1p yeast strain by HsCLP1 is abolished by mutations in the active site, 
equivalent mutations of the S. cerevisiae Clp1p ATP-binding site do not show the same 
effect (Ramirez et al., 2008). Moreover, overexpression of Clp1p cannot rescue the Trl1p 
mutants (Ramirez et al., 2008). However, HsCLP1 cannot complement growth of a yeast 
strain lacking its CLP1 gene (Ramirez et al., 2008), suggesting that CLP1 fulfils different 
tasks in yeast and humans. Thus, Ramirez et al. postulate a global role of CLP1 as a general 
RNA repair enzyme, not necessarily restricted to tRNA splicing or mRNA 3’ end processing 
(Ramirez et al., 2008). 
The evolutionary conservation of CLP1 extends from eukaryotes to archea, since an 
archeal CLP homolog, purified from Pyrococcus horikoshii, exhibited thermostable  
5’ hydroxyl RNA kinase activity that could complement Trl1p kinase deficiency in yeast (Jain 
and Shuman, 2009). Hence, this archeal CLP1 homolog might represent an ancestral form of 
CLP1 and, upon further investigation, might shed light on its functions (Jain and Shuman, 
2009). In plants, the CLP1 ortholog CLP1-SIMILAR PROTEIN3 was shown to function in 
gametophyte, embryo, and postembryonic development in Arabidopsis thaliana (Xing et al., 
2008). 
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Fig. 5: Sequence Alignment of the CLP1 Gene in Eukaryotes. Colored lines indicate the three domains; 
positions of structural elements (α helices and β sheets) are displayed. Important functional motifs are boxed 
(DxxQ = Walker-B motif). S.c. = Saccharomyces cerevisiae; S.p. = Schizosaccharomyces pombe; C.e. = 
Caenorhabditis elegans; D.m. = Drosophila melanogaster; X. l. = Xenopus laevis; G.g. = Gallus gallus; H.s. = 
Homo sapiens; M.m. = Mus musculus. (From Noble et al., 2007). 
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4.5. Aim of the Project 
Since the initial identification of CLP1 as an RNA kinase implicated in pre-tRNA splicing 
(Weitzer and Martinez, 2007b), our laboratory focused on a further characterization of this 
protein, part of which constitutes the present diploma thesis. 
 
To further characterize functions of CLP1 in vivo, the group of Josef Penninger generated a 
CLP1 mouse model. CLP1 knock-out mice died before birth (Toshikatsu Hanada and Josef 
Penninger, unpublished data). A knock-in mouse was generated in which the wild type CLP1 
was replaced with a mutated version harboring a lysine-to-alanine point mutation in the 
Walker-A motif, rendering the RNA kinase inactive. The resulting mice developed a motor 
neuron phenotype (Toshikatsu Hanada and Josef Penninger, unpublished data). The 
biochemical link between the disease and the mutation in CLP1 remain unclear but the 
finding is especially interesting beacause mutations in the TSEN proteins have been shown 
to cause a neurological phenotype as well (Budde et al., 2008). 
 
The aim of my diploma project was to further elucidate CLP1’s role in pre-tRNA splicing. 
Preliminary data in our laboratory have shown a possible dependence of pre-tRNA cleavage 
on the presence ATP (data not shown), which I then set out to investigate in more detail. On 
the one hand, it seemed to be necessary to elucidate the links between the RNA kinase 
mutation and the described mouse phenotypes. On the other hand, I reasoned that new 
insights into the mechanism of pre-tRNA splicing might help to identify the missing pathway 
components and might also shed light on possible roles of CLP1 in different biological 
processes.  
Data presented here postulate a novel role of CLP1 in pre-tRNA splicing. Based on 
analysis of cells harboring mutant CLP1 alleles, knock-down experiments, and biochemical 
assays at different ATP concentrations, we show that CLP1’s kinase activity impacts on the 
cleavage of precursor tRNA molecules. 
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5. Materials & Methods 
5.1. Materials 
5.1.1. Bacterial and Eukaryotic Expression and Entry Vectors 
Name Type Tag Source Resistance 
pDONR 201 Gateway Entry - Invitrogen Kan 
gcDNA 3.1 myc Eukaryotic 
expression 
Myc at N-terminus Group Beug,  
IMP Vienna 
Amp 
pDEST15 Bacterial expression GST at N-terminus Invitrogen Amp 
pRV-NTAP Expression in stable 
cell lines  
(retrovirus infection) 
TAP at N-terminus Group Superti-
Furga, CeMM 
Vienna 
Amp 
pRV-NTAP HsCLP1 Expression in stable 
cell lines  
(retrovirus infection) 
TAP at N-terminus Group Superti-
Furga, CeMM 
Vienna 
Amp 
pVSV-G Retroviral infection 
(viral G protein 
expression for 
pantropism) 
- Group Superti-
Furga, CeMM 
Vienna 
Amp 
Table 1: Summary of Plasmids used in the Experiments. 
 
5.1.2. Escherichia coli Strains 
Name Used for Source Antibiotics 
DH5α Amplification of plasmid DNA IMP/IMBA Service Department - 
DB3.1 Amplification of Gateway vectors without 
insert (contains the gyrA462 allele which 
renders the strain resistant to the toxic 
effects of the ccdB gene) 
IMP/IMBA Service Department - 
Rosetta Expression of eukaryotic proteins 
(supplies tRNAs rarely used in E. coli on 
a compatible chloramphenicol resistant 
plasmid) 
Novagen Cam 
Table 2: Summary of E. coli Strains used in the Experiments. 
 
5.1.3. Mammalian Cell Lines 
Name Type and Features Source 
iMEFs CLP1  
wild type/K127A 
primary fibroblast cultures from wt and CLP1 
mutant embryos transfected with an SV40 
large T antigen expression vector; cultured in 
medium with 10 mg/ml of puromycin for 7 
days; growing cells used as bulk-
immortalized cells. 
 
Toshikatsu Hanada,  
group Penninger,  
IMBA Vienna 
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HeLa human cervical epithelial carcinoma cell line, 
originally isolated from Henrietta Lack’s 
uterine in 1951; first continuous immortalized 
cell line; profound differences compared to 
“normal” human cells but most common cell 
culture model system (helacells.com) 
originally from  
group Jenuwein,  
IMP Vienna 
HEK 293 obtained by transformation of primary human 
embryonic kidney cell cultures with 
adenovirus 5 DNA; also show properties of 
immature neurons (Shaw et al., 2002). 
originally from  
group Beug,  
IMP Vienna 
HEK gp293 “Packaging cell line”; HEK 293 cells stably 
expressing the retroviral gag and pol genes 
to produce infectious virus (after co-
transfection with the pVSV-G vector) used for 
transfecting target cells 
Group Superti-
Furga, CeMM 
Vienna 
HEK 293 + pRVNTAP(GS) 
Clp1_murine sorted 
HEK 293 cells stably overexpressing NTAP-
MmCLP1 wild type from the integrated pRV-
NTAP vector; generated by viral infection as 
described in section 5.2.18. 
Tilmann 
Bürckstümmer, 
group Superti-Furga, 
CeMM Vienna 
HEK 293 + pRVNTAP(GS) 
Clp1_murine K127A sorted 
HEK 293 cells stably overexpressing NTAP-
MmCLP1 K127A from the integrated pRV-
NTAP vector; generated by viral infection as 
described in section 5.2.18. 
Tilmann 
Bürckstümmer, 
group Superti-Furga, 
CeMM Vienna 
Table 3: Summary of Mammalian Cell Lines used in the Experiments. 
 
5.1.4. Oligonucleotides and Substrates 
Single-stranded RNA Oligonucleotides (by Dharmacon) 
o 20.25: 5’-U.C.G.A.A.G.U.A.U.U.C.C.G.C.G.U.A.C.G.U-3’ 
o 21.5: 5’-C.G.U.A.C.G.C.G.G.A.A.U.A.C.U.U.C.G.A.A.A-3’ 
o 21.7: 5’-G.U.G.C.A.U.G.C.G.C.C.U.U.A.U.G.A.A.G.C.U-3’ 
o 21.14: 5’-C.A.C.G.U.A.C.G.C.G.G.A.A.U.A.C.U.U.C.G.A-3’ 
o A4: 5’-A.A.A.A-3’ 
 
Double-stranded RNA Oligonucleotides (annealed, red pC added during labeling) 
o 20.25/21.5: 
5’-    HOU.C.G.A.A.G.U.A.U.U.C.C.G.C.G.U.A.C.G.U.C -3’  
3’- A.A.A.G.C.U.U.C.A.U.A.A.G.G.C.G.C.A.U.G.C -5’ 
o 21.7/21.5: 
5’-    HOU.C.G.A.A.G.U.A.U.U.C.C.G.C.G.U.A.C.G.U.G.C -3’ 
3’- A.A.A.G.C.U.U.C.A.U.A.A.G.G.C.G.C.A.U.G.C -5’ 
o 21.14/20.25: 
5’- C.A.C.G.U.A.C.G.C.G.G.A.A.U.A.C.U.U.C.G.A -3’ 
3’- C.U.G.C.A.U.G.C.G.C.C.U.U.A.U.G.A.A.G.C.UOH -5’ 
 
siRNA Duplexes (annealed) 
o siGFPs/as: 
5’-     A.C.U.U.C.A.G.G.G.U.C.A.G.C.U.U.G.C.C.G.U -3’  
3’- U.U.U.G.A.A.G.U.C.C.C.A.G.U.C.G.A.A.C.G.G -5’ 
o siClp1_UTR1s/as: 
5’-     A.C.U.G.U.G.G.A.C.U.A.G.U.A.G.A.A.A.G.U.U -3’  
3’- U.U.U.G.A.C.A.C.C.U.G.A.U.C.A.U.C.U.U.U.C     -5’ 
o siClp1_UTR2s/as: 
5’-     C.C.A.U.G.A.G.A.C.U.G.U.A.A.U.U.G.G.U.U.U -3’  
3’- U.U.G.G.U.A.C.U.C.U.G.A.C.A.U.U.A.A.C.C.A     -5’ 
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5.1.5. Centrifuges and Power supplies 
• Heraeus Fresco 21 Centrifuge (Thermo Scientific) 
• Heraeus Biofuge pico 
• Heraeus Megafuge 11 Centrifuge (Thermo Scientific) 
• Eppendorf Centrifuge 5417 R 
• Heraeus Multifuge 3 S-R (Thermo Electron Corporation) 
• Sorvall RC 5C Plus (Thermo Electron Corporation) 
 
• Bio-Rad PowerPack 3000 
• Bio-Rad PowerPack HV 
• Bio-Rad PowerPack HC 
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5.2. Biochemistry and Molecular Biology Methods 
5.2.1. Gels 
Agarose Gel Electrophoresis 
For a 1% agarose gel, the respective amount of agarose was dissolved in the microwave in  
50-200 ml 0.5x TBE Buffer (diluted from 10x TBE Buffer) according to gel size and thickness. 
10000x Ethidium Bromide Stock Solution (5 mg/ml) was added to 1x dilution and the gel was 
left to harden in the Bio-Rad Sub Cell gel system (different sizes of chambers, trays and 
combs used). If RNA was loaded onto the gel, combs, trays and chambers were washed with 
H2O and with 70% (v/v) ethanol before use. Samples (2 µl of a PCR product for analysis,  
50 µl for preparative gels, 1-2 µl of plasmid DNA and extracted RNA) were loaded after 
mixing with the correctly diluted loading dye (filled up with H2O if necessary). The gel was run 
in 0.5x TBE buffer at 80-200 V. As sizes markers, 1-10 µl of the Fermentas Gene Ruler 1 kb 
DNA Ladder, DNA Ladder Mix, 100 bp DNA Ladder Plus, or bacteriophage lambda DNA 
digested with HindIII/Eco (IMP/IMBA Service Department) were used. After the run, the gel 
was analyzed under UV light (Alpha Innotech AlphaImager and corresponding software). 
Eventually, the correct bands were cut out and extracted. 
 
10x TBE Buffer (IMBA Media Kitchen) 890 mM Tris, 20 mM EDTA pH 8.0, 890 mM boric 
acid 
Loading Dyes:  
6x DNA Load 36% (v/v) glycerol, 6x TBE Buffer, bromophenol blue 
and xylene cyanol ad libitum. Stored at -20°C. 
10x Orange G 30% (v/v) glycerol, 200 mM EDTA pH 8.0, 2 mg/ml 
Orange G. Stored at -20°C. 
5x Loading Dye 30% (w/v) sucrose, xylene cyanol ad libitum. Stored 
at -20°C. 
Fermentas 6x DNA Loading Dye  
 
SDS-PAGE 
Gels were cast and run using glass plates, seals, combs and apparatuses of the Whatman 
Biometra Multigel system. Two different gel sizes and different combs (10 or 20 and 12 or  
24 slots) were used. The glass plates were cleaned with detergent, H2O and 70% (v/v) 
ethanol first. Gels were cast according to the following table: 
 
Separation Gels 7.5% 10% 15% 5% Stacking Gel 
4x Separation Buffer 2.5 ml 2.5 ml 2.5 ml - 
8x Stacking Buffer - - - 1.25 ml 
30%/0.8% (w/v) acrylamide/bisacrylamide1 2.5 ml 3.33 ml 5 ml 1.66 ml 
H2O 4.95 ml 3.5 ml 2.5 ml 7 ml 
10% (w/v) APS2 50 µl 50 µl 50 µl 50 µl 
TEMED3 5 µl 5 µl 5 µl 10 µl 
     
Total volume 10 ml 10 ml 10 ml 10 ml 
1 Ultra Pure ProtoGel (National Diagnostics) 
2 Ultra Pure Ammonium Persulfate (National Diagnostics) 
3 National Diagnostics 
Table 4: Composition of SDS Polyacrylamide Gels used for Protein Separation. 
After pouring the separation gel, it was overlaid with 2-butanol. Once polymerization was 
completed, the 2-butanol was removed and the stacking gel was poured on top. Samples (at 
least 10 µg protein or TEV eluates) were mixed with respective amounts of 2x or 5x SDS 
Sample Buffer, boiled 5 min at 95°C and loaded into the wells. As protein standards, 3-10 µl 
of the Page Ruler Prestained Protein Ladder (Fermentas) or the Precision Plus Protein 
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Standards Dual Color (Bio-Rad) were used. Gels were run in 1x SDS-PAGE Running Buffer 
at 15-50 mA until the bromophenol blue reached the bottom of the gel. 
 
4x Separation Buffer 1.44 M Tris-HCl pH 8.8, 0.4% (w/v) SDS 
8x Stacking Buffer 0.92 M Tris-HCl pH 6.8, 0.8% (w/v) SDS 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) 
glycerol, 50 mM DTT, bromophenol blue ad libitum. 
Stored at -20°C. 
5x SDS Sample Buffer 62.5 mM Tris-HCl pH 6.8, 25 mM EDTA pH 8.0, 5% (w/v) 
SDS, 5% (v/v) 2-mercaptoethanol, 50% (v/v) glycerol, 
bromophenol blue ad libitum. Stored at -20°C. 
1x SDS-PAGE Running Buffer Diluted from Ultra Pure 10x Tris/Glycine/SDS PAGE 
Buffer (National Diagnostics). 
 
Urea-PAGE 
Gels were cast and run using glass plates, spacers, combs and apparatuses from CBS 
Scientific CO (Nucleic Acid Sequencing system). Two different gel sizes (17 cm x 23 cm or  
17 cm x 38 cm), different spacers (0.4, 0.5, and 1 mm) and different combs (17 or 32 and 16, 
20, or 28 slots) were used. The glass plates were cleaned with detergent, H2O and 70% (v/v) 
ethanol first and were then treated with Sigmacote (Sigma) to allow easy removal of gels. 
The gels were cast according to the following table (all ingredients by National Diagnostics): 
 
 6% 10% 12% 15% 
Concentrate1 7.2 ml 12 ml 14.4 ml 18 ml 
Diluent1 20 ml 15 ml 12.5 ml 9 ml 
Buffer1 3 ml 3 ml 3 ml 3 ml 
10% (w/v) APS2 240 µl 240 µl 240 µl 240 µl 
TEMED 12 µl 12 µl 12 µl 12 µl 
     
Total volume 30 ml 30 ml 30 ml 30 ml 
1 Ultra Pure Sequagel UreaGel System 
2 Ultra Pure Ammonium Persulfate  
Table 5: Composition of Urea Polyacrylamide Gels used for RNA Separation. 
RNA samples were mixed with respective amounts of 1x/2x FA Buffer or 2x STOP Buffer, 
boiled 5 min at 95°C and loaded into the wells. As a size marker, 1-4 µl of a 1:40 Decade 
Marker dilution (Decade Marker System, AB Ambion) was used. Gels were run in 0.5x TBE 
Buffer (diluted from 10x TBE Buffer) at 30-50 W until the bromophenol blue reached the 
desired height. 
 
2x FA Buffer 10% (v/v) EDTA pH 8.0, 90% (v/v) formamide 
(Merck), bromophenol blue and xylene cyanol ad 
libitum. Stored at -20°C. 
1x FA Buffer Diluted from 2x FA Buffer. 
2x STOP Buffer 50 mM Tris-HCl pH 8.0, 8 M urea, bromophenol 
blue ad libitum. Stored at -20°C. 
10x TBE Buffer (IMBA Media Kitchen) 890 mM Tris, 20 mM EDTA pH 8.0, 890 mM boric 
acid 
 
5.2.2. Coomassie Staining 
After running a standard SDS-PAGE, the gel was stained 8 min shaking in 5 ml 20% (v/v) 
acetic acid + 5 ml PhastGel Blue R (Pharmacia Biotech; 1 tablet dissolved in 80 ml H2O + 
120 ml methanol). For destaining, it was incubated >30 min in 10% (v/v) acetic acid/ 
30% (v/v) methanol/H2O and then further destained in H2O. The gel was transferred to 
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Whatman filter paper (Whatman Chromatography Paper 3 mm Chr), covered with Saran 
wrap and vacuum dried for 30 min to 2 h at 80°C in a Bio-Rad Model 583 Gel Dryer. 
5.2.3. Silver Staining 
Samples to be examined (e.g. 20 µl NTAP-HsCLP1 wild type or K127A TEV eluates; as 
highly concentrated as possible, taken up in 3x Sample Loading Buffer Silver Stain) were 
loaded onto a NuPAGE 4-12% Bis-Tris Gel (Invitrogen Novex; 1.5 mm, 10 wells). It was run 
at 200 V in Nu PAGE MOPS Running Buffer (Invitrogen, diluted from 20x stock with H2O) in 
a Novex XCell SureLock Mini Electrophoresis Cell (Invitrogen). The gel was fixed 20 min 
shaking in a new plastic box in the solution given below. Then, the gel was washed 2x 5 min 
in 50% (v/v) ethanol and another 5 min in 30% (v/v) ethanol. The gel was incubated 60 s in 
0.8 mM Na2S2O3 (diluted from 0.8 M stock solution, always prepared fresh) and then washed 
3x 20 s in H2O. Then it was stained 20 min in FA/AgNO3 Solution and washed again 3x 20 s 
in H2O. The stain was developed in Na2CO3/FA/NA2S2O3 Solution until the bands were 
visible and finally, the reaction was stopped 1 h in 5% (v/v) acetic acid. The gel was 
transferred to Whatman filter paper (Whatman Chromatography Paper 3 mm Chr), covered 
with Saran wrap and vacuum dried 30 min to 2 h at 80°C in a Bio-Rad Model 583 Gel Dryer 
or stored in 5% (v/v) acetic acid at 4°C. If radioactive samples were loaded, the dried gel was 
exposed to a Storage Phosphor Screen (Amersham Biosciences) in an X-ray cassette 
(CAWO Photochemisches Werk or Rego X-Ray). The marker bands were visualized on the 
screen by putting a droplet of an old radioactive sample next to them. After 30 min to over 
night exposure, screens were scanned on a Typhoon Trio Variable Mode Imager (Amersham 
Biosciences) and analyzed using Typhoon Scanner Control v5.0 and ImageQuant TL 7.0 
software (Amersham). 
 
3x Sample Loading Buffer Silver Stain 240 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 30% (v/v) 
glycerol, 16% (v/v) 2-mercaptoethanol, bromo-
phenol blue ad libitum. Stored at 4°C. 
Fixation methanol : acetic acid : H2O = 50 : 12 : 38 (v/v/v) 
FA/AgNO3 Solution 0.2 g AgNO3, 70 µl 37% (v/v) formaldehyde, H2O 
ad 100 ml. Always prepared fresh. 
Na2CO3/FA/NA2S2O3 Solution 6 g Na2CO3, 50 µl 37% (v/v) formaldehyde, 2 ml 0.8 
mM Na2S2O3, H2O ad 100 ml. Always prepared 
fresh. 
 
5.2.4. Radioactive Labeling 
Pre-tRNA Body Labeling  
The pre-tRNAPhe substrate used for most splicing assays was internally (“body-”)-labeled in a 
T7 in vitro transcription reaction. 2 µl each of 10x Buffer, ATP, GTP, UTP, and CTP (all from 
T7 In Vitro Transcription MegaShortscript Kit, Ambion) were mixed with 3 µl (approx.  
3 pmole) template pre-tRNAPhe PCR product including a T7 promoter (generated by Stefan 
Weitzer by PCR from S. cerevisiae genomic DNA using a 5’ primer including the T7 
polymerase promoter (5’-AATTTAATACGACTCACTATAGGGGATTTA GCTCAGTTGGG-
3’), 3’ primer (5’-TGGTGGGAATTCTGTGGATCGAAC-3’); after sequencing identified as 
tRNA3-Phe GAA at chromosome 13). 5 µl [α-32P]-UTP, [α-32P]-GTP or [α-32P]-ATP (all 3000 
Ci/mmol 10 mCi/ml; PerkinElmer) and 2 µl T7 Polymerase Enzyme Mix (T7 In Vitro 
Transcription MegaShortscript Kit, Ambion) were added. The reaction was incubated at 37°C 
for 4 h. Then, 20 µl 2x FA or 2x STOP Buffer were added, the reaction was boiled at 95°C for 
5 min and resolved in a 6% or 10% Urea-PAGE (17 x 23 x 1 mm, run approx. 2 h at 40 W). 
The gel was wrapped in Saran from both sides, fixed on a plastic sheet and exposed to an 
autoradiography film (Amersham Hyperfilm MP High Performance Autoradiography Film, GE 
Healthcare) for 1 min. The band was marked, cut out and into smaller pieces, and eluted with 
300 µl 0.3 M NaCl (eventually DEPC treated) at 4°C and 1300 rpm over night in a siliconized 
DNA Lo-bind Eppendorf tube. After elution, the tube was spun shortly and the supernatant 
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was transferred to a new tube and precipitated with 900 µl 100% (v/v) ethanol for >30 min at 
-20°C. Samples were centrifuged 30 min at 14000 rpm at 4°C, the supernatant was 
discarded, the pellet was air-dried and dissolved thoroughly in 20 µl 1x Lysis Buffer (diluted 
from 2x Lysis Buffer). Concentration was measured and the solution was diluted to 1 µM. 
Eventually, all labeled pre-tRNA substrates were extracted with 300 µl Phenol-Chloroform-
Isoamyl alcohol pH 8 (Applichem; P:C:I = 25:24:1) as described below after gel elution and 
before ethanol precipitation and/or washed once with 70% (v/v) ethanol before resuspending 
the pellet after the gel elution and precipitation. 
 
Pre-tRNA 3’ End Labeling  
The in vitro transcription was carried out as for the body-labeled substrate, except that 
instead of a radioactive NTP H2O was used. The product was resolved on a gel (band 
marked under 254 nm UV light) and eluted as described above. The pellet was resuspended 
in 10 µl H2O. 5 µl of this suspension were mixed with 3 µl 32pCp (3000 Ci/mmol 10 mCi/ml; 
PerkinElmer), 3 µl DMSO (pure, taken from any PCR kit), 2 µl 10x T4 RNA Ligase 1 Reaction 
Buffer (New England Biolabs), 1 µl T4 RNA Ligase 1 (20000 U/ml; New England Biolabs), 
and 10 µl H2O. The reaction was incubated at 16°C for >1.5 h. Then, 20 µl 2x FA Buffer or  
2x STOP Buffer were added and the products were resolved on a gel and eluted as 
described for the body-labeled substrate. The pellet was resuspended in 107 µl H2O, 12 µl 
Buffer 3 (New England Biolabs Restriction Enzymes) and 1 µl Alkaline Phosphatase (high 
conc. 20 U/µl; Roche) were added and the dephosphorylation reaction was incubated at 
37°C for 30 min. 80 µl Proteinase K Buffer, 8 µl 5 M NaCl, and 1 µl Proteinase K Solution 
were added and samples were incubated 20 min at 65°C. 150 µl Phenol-Chloroform-Isoamyl 
alcohol pH 8 (Applichem; P:C:I = 25:24:1) were added and the tubes were vortexed 
vigorously for 20 s to extract RNA. For phase separation, samples were centrifuged 2 min at 
maximum speed and 4°C. The upper, aqueous phase was transferred to a new tube and  
3 volumes of 100% (v/v) ethanol were added. The tubes were vortexed briefly and 
precipitation was carried out at -20°C for >30 min.  Samples were centrifuged at full speed 
and 4°C for >30 min and the supernatant was discarded. The pellets were air or eventually 
vacuum dried in an Eppendorf Concentrator 5301 for 5-10 min and then resuspended in  
20 µl 1x Lysis Buffer (diluted from 2x Lysis Buffer). Concentration was measured and the 
solution was diluted to 1 µM. 
 
Pre-tRNA 5’ End Labeling 
The in vitro transcription was carried out as for the body-labeled substrate, except that 
instead of a radioactive NTP H2O was used. The product was resolved on a gel (band 
marked under 254 nm UV light) and eluted as described above. The pellet was resuspended 
in 107 µl H2O, 12 µl Buffer 3 (New England Biolabs Restriction Enzymes) and 1 µl Alkaline 
Phosphatase (high conc. 20 U/µl; Roche) were added and the dephosphorylation reaction 
was incubated at 37°C for 30 min. 80 µl Proteinase K Buffer, 8 µl 5 M NaCl, and 1 µl 
Proteinase K Solution were added and samples were incubated 20 min at 65°C. 150 µl 
Phenol-Chloroform-Isoamyl alcohol pH 8 (Applichem; P:C:I = 25:24:1) were added and the 
tubes were vortexed vigorously for 20 s to extract RNA. For phase separation, samples were 
centrifuged 2 min at maximum speed and 4°C. The upper, aqueous phase was transferred to 
a new tube and 3 volumes of 100% (v/v) ethanol were added. The tubes were vortexed 
briefly and precipitation was carried out at -20°C for >30 min.  Samples were centrifuged at 
full speed and 4°C for >30 min and the supernatant was discarded. The pellets were air or 
eventually vacuum dried in an Eppendorf Concentrator 5301 for 5-10 min and then 
resuspended in 10 µl H2O. 5 µl of this suspension were mixed with 1 µl T4 Polynucleotide 
Kinase (10000 U/ml; New England Biolabs), 5 µl [γ-32P]-ATP (6000 Ci/mmol 10 mCi/ml; 
PerkinElmer), 2 µl 10x T4 Polynucleotide Kinase Reaction Buffer (New England Biolabs), 
and 7 µl H2O. The reaction was incubated 30 min at 37°C. Then, 20 µl 2x FA Buffer or  
2x STOP Buffer were added and the samples were resolved on a gel, eluted and diluted as 
described for the body-labeled substrate. 
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Kinase Substrate 3’ End Labeling  
- Labeling:  
A single stranded RNA oligonucleotide was radioactively labeled at its 3’ end to allow 
assaying for phosphorylation at its 5’ end after annealing it to a second strand. For  
3’ end labeling, 1 µl of 100 µM ssRNA was mixed with 3 µl 32pCp (3000 Ci/mmol  
10 mCi/ml; PerkinElmer), 3 µl DMSO (pure, taken from any PCR kit), 2 µl 10x T4 
RNA Ligase 1 Reaction Buffer (New England Biolabs), 1 µl T4 RNA Ligase 1 (20000 
U/ml; New England Biolabs), and 10 µl H2O. The reaction was incubated at 16°C for 
>1.5 h. Then, 20 µl 2x FA Buffer or 2x STOP Buffer were added and the samples 
were loaded onto a 12% or 15% Urea-PAGE. (17 x 23 x 1 mm, run approx. 2 h at  
40 W). The gel was wrapped in Saran from both sides, fixed on a plastic sheet and 
exposed to an autoradiography film (Amersham Hyperfilm MP High Performance 
Autoradiography Film, GE Healthcare) for 1 min. The band was marked, cut out and 
into smaller pieces, and eluted with 300 µl 0.3 M NaCl (eventually DEPC treated) at 
4°C and 1300 rpm over night in a siliconized DNA Lo-bind Eppendorf tube. After 
elution, the tube was spun shortly and the supernatant was transferred to a new tube 
and precipitated with 900 µl 100% (v/v) ethanol for >30 min at -20°C. Samples were 
centrifuged 30 min at 14000 rpm at 4°C, the supernatant was discarded, and the 
pellet was air-dried and dissolved thoroughly in 107 µl H2O.  
 
- Dephosphorylation:  
12 µl Buffer 3 (New England Biolabs Restriction Enzymes) and 1 µl Alkaline 
Phosphatase (high conc. 20 U/µl; Roche) were added and the dephosphorylation 
reaction was incubated at 37°C for 30 min. 80 µl Proteinase K Buffer, 8 µl 5 M NaCl, 
and 1 µl Proteinase K Solution were added and samples were incubated 20 min at 
65°C.  
150 µl Phenol-Chloroform-Isoamyl alcohol pH 8 (Applichem; P:C:I = 25:24:1) were 
added and the tubes were vortexed vigorously for 20 s to extract RNA. For phase 
separation, samples were centrifuged 2 min at maximum speed and 4°C. The upper, 
aqueous phase was transferred to a new tube and 3 volumes of 100% (v/v) ethanol 
were added. The tubes were vortexed briefly and precipitation was carried out at  
-20°C for >30 min.  Samples were centrifuged at full speed and 4°C for >30 min and 
the supernatant was discarded. The pellets were air or eventually vacuum dried in an 
Eppendorf Concentrator 5301 for 5-10 min and then resuspended in 200 µl H2O. 
 
- Rephosphorylation:  
If a 5’ phosphate group was desired, the pellet was resuspended in 400 µl H2O.  
200 µl were mixed with 5 µl 100 mM ATP, 23 µl 10x T4 Polynucleotide Kinase 
Reaction Buffer (New England Biolabs), and 2 µl T4 Polynucleotide Kinase  
(10000 U/ml; New England Biolabs), and incubated 30 min at 37°C. Then, 160 µl 
Proteinase K Buffer, 16 µl 5 M NaCl, and 2 µl Proteinase K Solution were added. 
Incubation, P:C:I extraction (300 µl), and ethanol precipitation were carried out as 
described above. 
 
- Annealing:  
For duplex annealing, 100 µl 3’ end labeled ssRNA (approximately 80 pmol) were 
mixed with 20 µl 1 µM unlabeled ssRNA oligonucleotide, 80 µl H2O, and 200 µl  
2x Lysis Buffer. The mixture was distributed to 4 PCR tubes and annealed by 
incubating 2 min at 95°C, followed by 1 h at 37°C and finally at 4°C in the  
MJ Research PTC-200 Peltier Thermal Cycler DNA Engine. The final substrate was 
stored at -20°C. The reaction volumes were scaled up and down appropriately. 
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Northern Blot DNA Probe Labeling 
For the probe labeling reaction, 1 µl 100 µM DNA oligonucleotide was mixed with 2 µl [γ-32P]-
ATP (3000 Ci/mmol 10 mCi/ml; PerkinElmer), 2 µl 10x T4 Polynucleotide Kinase Reaction 
Buffer (New England Biolabs), 1 µl T4 Polynucleotide Kinase (10000 U/ml; New England 
Biolabs), and 14 µl H2O. The reaction was incubated >30 min at 37°C. 80 µl H2O were added 
and the mixture was applied to a Quick Spin Column for radiolabeled RNA purification 
(Sephadex G-25, fine; Roche; emptied by gravity, centrifuged 2 min at 11000x g in a 1.5 ml 
tube without lid, both together put into a 15 ml Falcon tube first). The column was transferred 
to a corresponding tube (Roche) and spun 5 min at 11000x g in a 15 ml Falcon tube. The 
flow-through (= probe) was collected and stored at 4°C.  
 
2x FA Buffer 10% (v/v) EDTA pH 8.0, 90% (v/v) formamide (Merck), 
bromophenol blue and xylene cyanol ad libitum. Stored at  
-20°C. 
2x STOP Buffer 50 mM Tris-HCl pH 8.0, 8 M urea, bromophenol blue ad 
libitum. Stored at -20°C. 
2x Lysis Buffer 60 mM HEPES-KOH pH 7.3, 4 mM MgCl2, 200 mM KCl. 
Stored at -20°C. 
Proteinase K Buffer 200 mM Tris-HCl pH 7.5, 25 mM EDTA pH 8.0, 300 mM 
NaCl, 2% (w/v) SDS 
Proteinase K Solution 100 mg Proteinase K (Applichem) in 7.14 ml Proteinase K 
Storage Buffer. Stored at -20°C. 
Proteinase K Storage Buffer 50 mM Tris-HCl pH 8.0, 5 mM CaCl2, 50% (v/v) glycerol 
 
5.2.5. Cloning 
HsCLP1 PCR Mutagenesis 
Site-directed mutagenesis was performed via overlapping PCRs, introducing attB-sites for 
Gateway cloning (Invitrogen). The products from the first PCR were purified on a 1% agarose 
gel; final products were also checked on a 1% agarose gel. 5 µl of the final PCR product 
were used for Gateway recombination. 
 -­‐ First PCR Setup: 
2 µl forward primer (10 µM; attB1 or hClp1_new_mutX_1) 
2 µl reverse primer (10 µM; hClp1_new_mutX_2 or attB2) 
100 ng template (pDONR 201 + HsCLP1 wild type) 
5 µl dNTP Mix (Novagen; 2 mM each) 
5 µl 10x KOD Buffer #1 for DNA Polymerase (Novagen) 
2 µl MgCl2 (Novagen; 25 mM) 
0.4 µl KOD DNA Polymerase (Novagen; 2.5 U/µl) 
H2O ad 50 µl 
 -­‐ Second PCR Setup: 
2 µl forward primer (10 µM; attB1) 
2 µl reverse primer (10 µM; attB2) 
2 µl fragment A (PCR1 product) 
2 µl fragment B (PCR1 product) 
5 µl dNTP Mix (Novagen; 2 mM each) 
5 µl 10x KOD Buffer #1 for DNA Polymerase (Novagen) 
2 µl MgCl2 (Novagen; 25 mM) 
0.4 µl KOD DNA Polymerase (Novagen; 2.5 U/µl) 
H2O ad 50 µl 
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-­‐ Primers (by Life Technologies and MWG Biotech): 
o attB1: 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’ 
o attB2: 5’-GGGGACCACTTTGTACAAGAAAGCTGGGT-5’ 
o hClp1_new_mut1_1: 5’-CCACTTATGTGGAGGCGGATGTGGGCCAGGGT-3’ 
o hClp1_new_mut1_2: 5’-ACCCTGGCCCACATCCGCCTCCACATAAGTGG-3’ 
o hClp1_new_mut2_1: 5’-CTTATGTGGAGCTGGCTGTGGGCCAGGGTTCT-3’ 
o hClp1_new_mut2_2: 5’-AGAACCCTGGCCCACAGCCAGCTCCACATAAG-3’ 
o hClp1_new_mut3_1: 5’-AGCTGGATGTGGGCGCGGGTTCTGTGTCCATC-3’ 
o hClp1_new_mut3_2: 5’-GATGGACACAGAACCCGCGCCCACATCCAGCT-3’ 
o hClp1_new_mut4_1: 5’-GCTGTGTCATTAACGCCTGTGGCTGGGTCAAG-3’ 
o hClp1_new_mut4_2: 5’-CTTGACCCAGCCACAGGCGTTAATGACACAGC-3’ 
o hClp1_new_mut5_1: 5’-AATCTGGGGGTGTGGCGGAGCGCTCCAAGGAC-3’ 
o hClp1_new_mut5_2: 5’-GTCCTTGGAGCGCTCCGCCACACCCCCAGATT-3’ 
 -­‐ PCR Protocol (MJ Research PTC-200 Peltier Thermal Cycler DNA Engine): 
98°C  2 min 
98°C  15 s     
60°C  5 s       20 cycles  
72°C  20 s     
4°C 
 
DNA Extraction/Purification from Agarose Gels or PCRs 
DNA bands were cut out from a preparative agarose gel and eluted using the QIAquick Gel 
Extraction Kit (Qiagen) according to manufacturer’s instructions. DNA was eluted with 30 µl 
H2O. The PCR Purification Kit (Qiagen) was used for purifying PCRs according to 
manufacturer’s instructions. 
 
DNA Sequencing 
The IMP/IMBA Sequencing Service performed sequencing of DNA samples. 30 µl primer(s) 
were supplied as 5 µM solution. At least 150 ng plasmid DNA or 10-50 ng PCR product DNA 
were needed. 
 -­‐ Primers (by MWG Biotech; in addition to PCR primers): 
o 201_FP: 5’-TCGCGTTAACGCTAGCATGGATCTC-3’ (pDONR 201) 
o 201_RP: 5’-GTAACATCAGAGATTTTGAGACAC-3’ (pDONR 201) 
o UCKL_SEQ1: 5’-GGCTAGCGTTTAAACTTAAGC-3’ (gcDNA 3.1 myc) 
o SBP_seq_oligo: 5’-GACTGGCCGGTGAGCTGGAGCAGCTACG-3’ (pRV-NTAP) 
 
Gateway Cloning 
The Gateway cloning technique (Invitrogen; all reaction ingredients) uses a reversible 
recombination reaction instead of restriction enzymes, ligases, etc. This technique is based 
on the bacteriophage lambda site-specific recombination pathway into bacterial DNA via attP 
and attB sites. After recombination (“BP recombination”) and integration of the phage DNA 
into the bacterial genome, attL and attR sites consisting of the attB and attP sequences flank 
the phage genome. Reverse recombination between the attL and attR sites (“LR 
recombination”) can excise the phage DNA. In the cloning system, directionality of the insert 
is guaranteed by using attB1 and attB2 sites that only recombine with their attP1 or attP2 
counterpart. 
 
1) Entry Clone Construction: 
An Entry vector contains the gene of interest flanked by attL sequences. This is 
achieved by generating a PCR product with primers containing attB1 and attB2 
sequences, which is subsequently shuttled into a pDONR vector with attP1 and attP2 
sites through a BP recombination reaction mediated by the BP Clonase II enzyme 
mix:  
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 5 µl PCR product containing attB1 and attB2 sites (approx. 100 ng) 
 100-150 ng pDONR 201 
 3 µl BP Reaction Buffer 
 2 µl BP Clonase II 
The reaction was incubated 1 h at 25°C. Then, 1 µl Proteinase K was added and the 
samples were incubated 10 min at 37°C. 5 µl of the final reaction volume were used 
for transformation into competent E. coli for vector amplification. 
 
2) Expression Clone Construction:  
Recombination between attL sites of an Entry vector (pDONR + insert) and attR sites 
of the Destination vector (gcDNA 3.1 myc or pRV-NTAP) generates an Expression 
clone containing the insert of interest. The LR Clonase II enzyme mix carries out this 
excision-integration-reaction: 
 100 ng gcDNA 3.1 myc or 2373 (or 1 µl of Mini-/Maxiprep) 
 100 ng Entry vector (or 1 µl of Mini-/Maxiprep) 
 6 µl TE Buffer 
 2 µl LR Clonase II (Invitrogen) 
The reaction was incubated 1 h at 25°C. Then, 1 µl Proteinase K was added and the 
samples were incubated 10 min at 37°C. 5 µl of the final reaction volume were used 
for transformation into competent E. coli for vector amplification. 
 
1x TE Buffer (IMBA Media Kitchen) 10 mM Tris, 1 mM EDTA. pH adjusted to 8.0 with HCl. 
 
5.2.6. Concentration Determination 
Protein Quantification by Bradford Assay 
Bio-Rad Protein Assay (“Bradford Solution”) was diluted 1:5 with H2O. 1 ml solution was used 
as blank sample for spectrophotometer calibration. For standard curve preparation, 2, 4 and 
8 µl of a 0.1% (w/v) BSA solution (= 1 mg/ml; Roche) were added to 1 ml Bradford Solution 
and the samples were mixed by inversion on parafilm. Absorption was measured at 595 nm 
in a spectrophotometer (SmartSpec Plus, Bio-Rad). For sample measurement, 1-10 µl were 
added to 1 ml Bradford Solution, inverted and measured as above. Measurements were 
performed in Sarsted 10 x 4 x 45 mm cuvettes. 
 
DNA and RNA Concentration Determination -­‐ NanoDrop:  
After cleaning and blanking the NanoDrop ND-1000 Spectrophotometer (Peqlab), 1 µl 
sample was applied to the pedestal and measurement was started via the 
corresponding ND-1000 V3.5.2 software. According to the settings, DNA and RNA 
contents were calculated automatically, using the conversion factors 50 and 40, 
respectively. After each measurement, the pedestals were cleaned carefully. 
 -­‐ Spectrophotometer: 
For measuring DNA or RNA content of a sample, 1 µl sample was added to 100 µl 
H2O in an Eppendorf UVette and A260 was measured (SmartSpecTM Plus, Bio-Rad). 
DNA and RNA concentration were calculated using the conversion factors 50 and 40, 
respectively. Additionally, the ratio A260/A280 was measured to determine RNA quality. 
 
5.2.7. DEPC Treatment 
For treating solutions with DEPC against RNase contamination, DEPC (Sigma) was diluted 
1:1000 in the respective solution that was then stirred for some hours and finally autoclaved. 
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5.2.8. Western Blot 
A PVDF membrane (Millipore Immobilon-P, 0.45 µm pore size) was cut according to the size 
of the SDS-PAA gel containing the protein samples of interest, and activated in methanol, 
then transferred to H2O and finally soaked in 1x Semidry Transfer Buffer. It was put on top of 
3 equally sized and soaked Whatman filter papers (Whatman Chromatography Paper 3 mm 
Chr). The gel was put on top of the membrane and overlaid with 3 soaked Whatman filter 
papers. The blotting sandwich was assembled on a Bio-Rad Trans Blot SD Semi-Dry 
Transfer Cell (from anode to cathode) and air bubbles were removed. A bit of 1x Semidry 
Transfer Buffer was applied to the cathode lid. Blotting was performed for 2 h at 1.2 mA  
per cm2 of membrane. Then, the membrane was taken out, the protein standards were 
marked and the membrane was eventually stained in Ponceau S Solution (Sigma) to 
visualize transferred proteins. Before blocking, it was destained in PBST and H2O. Blocking 
was carried out with PBST + 5% (w/v) milk powder for at least 1 h or over night shaking at 
room temperature.  Then, the primary antibody was diluted in PBST + 5% (w/v) milk powder 
and left on the membrane for 1.5 h shaking at room temperature. The membrane was then 
washed 3x 10 min with PBST and subsequently incubated with the HRP-coupled secondary 
antibody (diluted 1:5000 in PBST + 5% (w/v) milk powder) for 45 min shaking at room 
temperature. The membrane was again washed 3x 10 min with PBST. Detection was 
performed using the Amersham ECL Western Blotting Detection Reagents (GE Healthcare): 
For 1 membrane, 1.5 ml of Detection Reagent 1 and 1.5 ml of Detection Reagent 2 were 
mixed and left on the membrane for 1 min. The reagents were removed with tissues; the 
membrane was wrapped in Saran and fixed in a 24 cm x 30 cm X-ray cassette (CAWO 
Photochemisches Werk or Rego X-Ray). An ECL film (Amersham Hyperfilm ECL High 
Performance Chemiluminescence Film, GE Healthcare) was put on top and developed on a 
Kodak X-omat 5000RA Processor or an Agfa Curix 60 after 1 min to over night exposure. 
Eventually, new ECL reagents were applied after the first round of detection to allow for 
longer exposure times. After detection, the membrane could be stripped to remove the 
signal. This was carried out using pre-warmed (50°C) WB Strip Buffer and incubating the 
membrane rotating for 20 min at 50°C. Afterwards, it was blocked again and incubated with a 
different primary antibody. In case the expected proteins to be detected migrated at different 
sizes in the gel, stripping was not necessary. 
 
1x Semidry Transfer Buffer Methanol : 10x Semidry Transfer Buffer : H2O = 1 : 1 : 8 
(v/v/v) 
10x Semidry Transfer Buffer 57.6 g glycin, 12 g Tris Base, 4 ml 20% (w/v) SDS, H2O ad 
400 ml 
PBST 0.1% (v/v) TWEEN 20 (Sigma-Aldrich) in 1x PBS 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
WB Strip Buffer 62.5 mM Tris-HCl pH 6.7, 2% (w/v) SDS, 100 mM  
2-mercaptoethanol (added fresh) 
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Primary Antibodies 
 ID Source Dilution Raised in 
α-MmCLP1 - Toshikatsu Hanada, group 
Penninger, IMBA Vienna 
1:1000 and 1:500 Rabbit 
α-HsTSEN2 1064/1715 G Gramsch Laboratories 1:1000 and 1:500 Rabbit 
α-HsTSEN2 1064/1715 M Gramsch Laboratories 1:1000 Rabbit 
α-HsTSEN34 1071/1719 M Gramsch Laboratories 1:2000 to 1:500 Rabbit 
α-HsTSEN54 1078/1722 M Gramsch Laboratories 1:1000 and 1:500 Rabbit 
α-HsTSEN15 1068/1717 G Gramsch Laboratories 1:1000 and 1:500 Rabbit 
α-HsTSEN2 TSEN2 Antibody PTG Proteintech Group 1:1000 Rabbit 
α-HsTSEN15 SEN15 (49-K) Santa Cruz Biotechnology 1:1000 Mouse 
α-HsTSEN2 1063/1715 Gramsch Laboratories 1:1000  Rabbit 
α-c-myc - Sigma 1:1000 Rabbit 
“α-SBP” ECL 
Streptavidin 
Horseradish 
Peroxidase 
Conjugate 
Amersham  
(GE Healthcare) 
1:1000 - 
α-rec. HsCLP1 1779 (full-
length) 
Gramsch Laboratories 1:1000 Rabbit 
Table 6: Summary of Primary Antibodies used for Protein Detection on Western Blots. 
 
Secondary Antibodies 
 ID Source Dilution Raised in 
α-rabbit HRP Goat anti-Rabbit IgG - HRP Invitrogen 1:5000 Goat 
α-mouse HRP Goat anti-Mouse IgG - HRP Invitrogen 1:5000 Goat 
Rabbit TrueBlot Anti-Rabbit IgG HRP eBioscience 1:3000 - 
Table 7: Summary of Secondary Antibodies used for Signal Visualization. 
 
5.2.9. Northern Blot 
10-30 µg extracted RNA were mixed with 2x FA Buffer and loaded onto a 17 cm x 23 cm x  
1 mm 15% Urea-PAGE. The gel was run at 40 W and stopped before the bromophenol blue 
front reached the bottom. To transfer the RNAs from the gel to a Amersham Hybond-N+ 
membrane (positively charged nylon transfer membrane, GE Healthcare), a “sandwich” was 
assembled on a Bio-Rad Trans Blot SD Semi-Dry Transfer Cell in the cold room as follows 
(from anode to cathode) after soaking each component in cold 0.5x TBE Buffer (diluted from 
10x TBE Buffer): 3 pieces of Whatman filter paper (Whatman Chromatography Paper 3 mm 
Chr) – membrane – gel – 3 pieces of Whatman filter paper. Air bubbles were removed 
between all the layers and the transfer was carried out at 350 mA for 3 h in the cold room. 
After the transfer, the membrane was taken down onto a sheet of Whatman filter paper and 
UV-crosslinked with 1250 µJ x100 (2x “Autocrosslink” on a Stratagene UV Stratalinker 1800). 
The membrane was put into a 100 ml cylindrical glass hybridization bottle and was eventually 
baked 10-60 min at 80°C. 15 ml pre-warmed Hybridization Solution (becomes clear after pre-
warming >20 min at 50°C) were added and the membrane was incubated rotating 1 h at 
50°C for pre-hybridization in case a DNA oligonucleotide was used as a probe (80°C for 
LNA). The radioactively labeled probe (approx. 100 µl) was boiled at 95°C for 5 min and then 
added to another 15 ml Hybridization Solution. The mixture was added to the membrane 
after removing the (pre-)Hybridization Solution from the previous step, and left rotating at 
50°C (80°C) over night. The Hybridization Solution was discarded and the membrane was 
washed twice with 100 ml pre-warmed (50°C) Washing Solution I by shaking the cylindrical 
glass bottle for 1 min. The membrane was transferred to a flat plastic box and washed once 
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with pre-warmed (50°C) Washing Solution II by shaking the box for 1 min. Finally, the 
membrane was dried with paper towels and wrapped in Saran. It was exposed to a Storage 
Phosphor Screen (Amersham Biosciences) in a 24 cm x 30 cm X-ray cassette (CAWO 
Photochemisches Werk or Rego X-Ray). After >3 h exposure, screens were scanned on a 
Typhoon Trio Variable Mode Imager (Amersham Biosciences) and analyzed using Typhoon 
Scanner Control v5.0 and ImageQuant TL 7.0 software (Amersham). For stripping off the 
probe, the membrane was washed 5 min in 2 l boiling H2O (+ 0.1% (w/v) SDS for DNA/LNA 
probes). 
 
10x TBE Buffer (IMBA Media Kitchen) 890 mM Tris, 20 mM EDTA pH 8.0, 890 mM boric 
acid 
2x FA Buffer 10% (v/v) EDTA pH 8.0, 90% (v/v) formamide 
(Merck), bromophenol blue and xylene cyanol ad 
libitum. Stored at -20°C. 
Hybridization Solution 7.5 ml 20x SSC, 21 ml 10% (w/v) SDS, 0.6 ml 1 M 
NaPi pH 7.2, 0.6 ml H2O, 0.3 ml Sonicated Salmon 
Sperm DNA (Stratagene, 10 mg/ml; pre-heated to 
95°C for 5 min before adding to clear solution) 
20x SSC (IMBA Media Kitchen) 3 M NaCl, 300 mM tri-sodium citrate dihydrate. pH 
adjusted to 7.0 with HCl. 
Washing Solution I 5x SSC (diluted from 20x SSC), 5% (w/v) SDS 
Washing Solution II 1x SSC (diluted from 20x SSC), 1% (w/v) SDS 
 
5.2.10. Co-Immunoprecipitation 
20 µl settled Protein A Sepharose 4 Fast Flow beads per reaction (GE Healthcare; on ice 
and in siliconized Eppendorf DNA LoBind Tubes) were washed three times with 1 ml RNAi 
Buffer (or any buffer used for cell lysis) by multiple inversion, centrifugation (2000x g, 1 min, 
4°C) and supernatant removal (1 ml syringe + 0.5 mm x 16 mm needle at water pump). The 
washed beads were incubated with 3-6 µl antiserum and 60 µl RNAi Buffer for 90 min or over 
night at 4°C, rotating at 13 rpm. The supernatant was discarded and beads were washed 
three times with RNAi Buffer + 1% (v/v) NP 40 (Nonidet P 40 Substitute, Fluka). If more than 
one reaction was performed, beads were taken up in a defined volume of buffer and split 
appropriately at this step. Cell extracts (800-1000 µl, volume adjusted with RNAi buffer if 
necessary) were bound to the beads for 90 min at 4°C, rotating at 13 rpm. Either stored 
(prepared by group Lührmann, Göttingen; thawed from -80°C) or fresh prepared, pre-cleared 
(14000 rpm, 10 min, 4°C; supernatant used) HeLa whole cell extract or MEF nuclear or 
cytoplasmic extracts were used. After binding, the beads were washed five times with RNAi 
Buffer + 1% (v/v) NP 40 and all remaining liquid was removed. For performing enzymatic 
assays, the beads were split if necessary and 10 µl RNAi Buffer were added. For Western 
Blot analysis, the beads were taken up in 2x SDS Sample Buffer.  
Alternatively, beads already coupled to anti-c-myc IgG (Anti c-Myc-Agarose Affinity Gel, 
Sigma) were used for immunoprecipitation (30-60 µl suspension per reaction). Therefore, the 
first binding step could be omitted. Beads were washed three times with 0.5 ml RNAi Buffer + 
1% (v/v) NP 40 and samples were loaded. The subsequent procedure was carried out 
analogous to the one described above. 
 
RNAi Buffer 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM MgCl2, 
10% (v/v) glycerol, 1 mM DTT (added fresh), 0.1 mM AEBSF 
serine protease inhibitor (Sigma; added fresh). Stored at 4°C. 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) glycerol,  
50 mM DTT, bromophenol blue ad libitum. Stored at -20°C. 
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Antisera 
 ID Source Raised in 
Preimmune serum - Gramsch Laboratories Rabbit 
α-HsTSEN2 1063/1715 Gramsch Laboratories Rabbit 
α-HsTSEN2 TSEN2 Antibody PTG Proteintech Group, Inc Rabbit 
α-HsCLP1 0988/1691 Gramsch Laboratories Rabbit 
α-c-myc - Sigma Rabbit 
Table 8: Summary of Antibodies and Antisera used for coupling to Protein A Sepharose. 
 
5.2.11. ATP Depletion 
Before or without Immunoprecipitations  
For ATP depletion by apyrase, 4 mM CaCl2 were added to pre-cleared cell extract or TEV 
eluate. Then 0.5 µl Apyrase (from potato, Sigma; dissolved to 100 U/ml) were added per ml 
sample and incubated 30 min at 37°C and 1300 rpm. For ATP depletion by hexokinase,  
5 mM glucose were added to pre-cleared cell extract or TEV eluate. Then 10 U/ml 
Hexokinase (from S. cerevisiae; Sigma-Aldrich; dissolved in H2O to 2 U/µl) were added and 
incubated 10 min at 25°C and 1300 rpm. 
 
After Immunoprecipitations  
After extract binding to the desired beads, they were washed three times with RNAi Buffer +  
4 mM CaCl2. 50 µl RNAi Buffer + 4 mM CaCl2 + 0.5 µl Apyrase (from potato, Sigma; 
dissolved to 100 U/ml) were added to the beads which were then incubated at 37°C and 
1300 rpm for 30 min. Afterwards the beads were washed five times with RNAi Buffer + 1% 
NP 40 (Nonidet P 40 Substitute, Fluka) and all remaining liquid was removed. For performing 
enzymatic assays, 10 µl RNAi Buffer was added to the beads. 
 
RNAi Buffer 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM MgCl2, 10% (v/v) 
glycerol, 1 mM DTT (added fresh), 0.1 mM AEBSF serine protease inhibitor 
(Sigma; added fresh). Stored at 4°C. 
 
 
5.2.12. Glycerol Gradient Centrifugation  
5% and 15%, 20% or 30% Glycerol Solutions were prepared as given below. Centrifugation 
tubes (Science Services Offene Zentrifugenröhrchen Polyclear 50, Sorvall PA 12 ml, or 
Sorvall PA Thinwall 4.4 ml) were marked using an SW 40 or SW 60 Ti marker block (different 
markers for short and long caps). The tubes were filled to the marker line with 5% Glycerol 
Solution and underlain with 15%, 20% or 30% Glycerol Solution using a 10 ml syringe with a 
spinal needle (1.2 mm x 90 mm).  The tubes were closed with fitting rubber caps without 
including air bubbles. On the Biocomp Gradient Master 107 ip, the magnetic gradient plate 
was adjusted. The tubes were placed to the magnetic plate in a metal rack and the 
appropriate program was run (e.g. long/short, SW40, 5%  20% glycerol). After mixing, the 
gradient was equilibrated >1 h at 4°C without moving. 
In the meantime, standards (GE Healthcare Gel Filtration Calibration Kit High Molecular 
Weight) and samples were prepared: -­‐ Standard 1: 25 µl Aldolase (158 kDa, 7.3 S) 5 mg/ml (10% (v/v) glycerol) and 25 µl 
Thyroglobulin (669 kDa, 19 S) 5 mg/ml (10% (v/v) glycerol) were mixed with 150 µl 
RNAi Buffer w/o Glycerol to reduce glycerol content to 2.5% (v/v). The solution was 
centrifuged 10 min at 14000 rpm and 4°C and 180 µl of the supernatant were 
carefully loaded onto the gradient.  -­‐ Standard 2: 25 µl Ovalbumin (44 kDa, 3.5 S) 5 mg/ml (10% (v/v) glycerol) and 25 µl 
Catalase (250 kDa, 11.3 S) 5 mg/ml (10% (v/v) glycerol) were mixed with 150 µl RNAi 
Buffer w/o Glycerol to reduce glycerol content to 2.5% (v/v). The solution was 
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centrifuged 10 min at 14000 rpm and 4°C and 180 µl of the supernatant were 
carefully loaded onto the gradient.  -­‐ Alternatively, only one standard protein per gradient or different combinations of them 
were used. Standards were also used at 10 mg/ml stock solutions in 150 mM KCl,  
50 mM Tris pH 8.0. In addition to the standard proteins mentioned above, 
Conalbumin (75 kDa, 5.4 S), Ferritin, and Chymotrypsinogen (25 kDa, 2.5 S) were 
used. Up to 100 µl per standard solution per gradient were used. -­‐ Cell extracts (whole cell, cytoplasmic, nuclear) were diluted with RNAi Buffer w/o 
Glycerol, prepared with RNAi Buffer with reduced glycerol or microdialyzed 1 h 
against a 2.5% Glycerol Solution to reduce glycerol content to max. 5% (v/v). Before 
microdialysis, extracts were centrifuged 10 min at 14000 rpm and 4°C. Eventually, 
ATP depletion was performed and aliquots were taken for input analysis on Western 
Blot or in pre-tRNA splicing and kinase assays. Remaining extracts were carefully 
loaded onto the gradient. 
Gradient tubes were fixed in pre-cooled SW 40 or SW 60 Ti rotor tubes and these were put 
onto the corresponding rotors (Beckmann SW 40 Ti /Sorvall TH641 or Sorvall TH660 rotors). 
Centrifugation was performed in a pre-cooled Beckmann Optima L-90 K Ultracentrifuge 
(Thermo Scientific) or Sorvall Discovery 90SE (Hitachi) ultracentrifuge for 20-25 or 14-15 h at 
37000 or 35000 rpm, respectively, and 4°C under vacuum.  Acceleration and deceleration 
were set to level 9. 
After centrifugation, the tubes were carefully transferred to ice and 1 ml or 300-400 µl 
fractions were taken from the top. Standard fractions were analyzed by Bradford protein 
concentration determination (10-20 µl for measurement) and/or SDS-PAGE and Coomassie 
staining.  300 or 100 µl of sample fraction proteins were precipitated with 4 volumes of ice-
cold (-20°C on day before) acetone over night at -20°C. Alternatively, proteins were also 
precipitated with TCA. Remains of fractions were frozen in liquid nitrogen and stored at -80°C 
for enzymatic assays. After precipitation, samples were centrifuged 30 min at 14000 rpm and 
4°C. The supernatant was discarded carefully and pellets were air-dried at room 
temperature. Afterwards, they were dissolved in 10-20 µl 2x SDS Sample Buffer and 
analyzed by Western Blot. 
 
2.5% Glycerol Solution (100 ml) 10 ml 10x Buffer, 5 ml 50% (v/v) glycerol, 85 ml H2O,  
0.5 mM DTT (added fresh). Stored at 4°C. 
5% Glycerol Solution (100 ml) 10 ml 10x Buffer, 10 ml 50% (v/v) glycerol, 80 ml H2O, 
0.5 mM DTT (added fresh). Stored at 4°C. 
15% Glycerol Solution (100 ml) 10 ml 10x Buffer, 30 ml 50% (v/v) glycerol, 60 ml H2O, 
0.5 mM DTT (added fresh). Stored at 4°C. 
20% Glycerol Solution (100 ml) 10 ml 10x Buffer, 40 ml 50% (v/v) glycerol, 50 ml H2O, 
0.5 mM DTT (added fresh). Stored at 4°C. 
30% Glycerol Solution (100 ml) 10 ml 10x Buffer, 60 ml 50% (v/v) glycerol, 30 ml H2O, 
0.5 mM DTT (added fresh). Stored at 4°C. 
10x Buffer 300 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl,  
5 mM MgCl2, 1 mM AEBSF serine protease inhibitor 
(Sigma). Stored at 4°C. 
RNAi Buffer w/o Glycerol 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM 
MgCl2, 1 mM DTT (added fresh), 0.1 mM AEBSF serine 
protease inhibitor (Sigma; added fresh). Stored at 4°C. 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) 
glycerol, 50 mM DTT, bromophenol blue ad libitum. 
Stored at -20°C. 
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5.2.13. TCA Protein Precipitation 
1 volume of 100% (w/v) TCA was added to 4 volumes of protein samples that were 
subsequently incubated on ice for >10 min. Samples were centrifuged 20 min at 14000 rpm 
and 4°C and the supernatant was aspirated off. The white, fluffy pellet was washed once with 
1 ml ice-cold acetone and spun down as before. The pellet was dried 5-10 min at 37°C and 
centrifuged 5 min at 14000 rpm. 10 µl 2x SDS Sample Buffer were added, the samples were 
boiled and examined on SDS-PAGE and Western Blot. 
 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) glycerol,  
50 mM DTT, bromophenol blue ad libitum. Stored at -20°C. 
 
5.2.14. Microdialysis 
Up to 200 µl of sample were dropped onto microdialysis membranes (Millipore MF- 
Membrane Filters, 0.025 µm VSWP) in <50 µl droplets. The membranes were floating on top 
of a layer of the dialysis buffer of interest, contained in a petri dish. After 1 h dialysis in the 
cold room, the droplets were transferred to a tube and used for protein concentration 
determination, enzymatic assays or storage. 
 
5.2.15. Concentrating Proteins 
For increasing protein concentration in a given sample by reducing its volume, the Sartorius 
Stedim Vivaspin 500 system was used. First, 500 µl H2O were loaded and centrifuged 10 min 
at 15000x g. The flow through was discarded. Then, 500 µl of the sample to be concentrated  
(e.g. E1 eluates from recombinant protein purification) were loaded and centrifuged 
approximately 1x 5 min and 2x 3 min or 2x 5 min at 15000x g and 4°C, until 50 µl (or the 
desired volume) sample were left in the tube. This equates to a 10-fold increase in protein 
concentration. 
 
5.2.16. Thin Layer Chromatography 
In order to find out whether the HsCLP1 K127A could hydrolyze ATP and release ADP, we 
performed a kinase assay followed by product separation by TLC. First, 0.5 µl [α-32P]-ATP 
(3000 Ci/mmol 10 mCi/ml; PerkinElmer), 1 µl recombinant GST-HsCLP1 protein (0.5-1 
mg/ml) or T4 Polynucleotide Kinase (10000 U/ml; New England Biolabs), 2.5 µl 20 µM 
21.5/21.7 duplex or H2O, 0.5 µl 10x RNAi Buffer, and 0.5 µl H2O were mixed and incubated 
60 min at 30°C. As standards, 3.5 mM ADP and ATP solutions and 0.5 µl [α-32P]-ATP (3000 
Ci/mmol 10 mCi/ml; PerkinElmer) + 4.5 µl H2O were used. 1-2 µl of the reactions (eventually 
diluted 1:100 with H2O) and standards were applied to a 10 cm x 10 cm HPTLC Cellulose 
glass plate (Merck) or a PEI Cellulose plate (cut from TLC plastic sheets 20x20 cm PEI 
Cellulose F, Merck; directionality of plate to be considered), 1 cm apart from each other and 
2 cm above the lower rim. The plate was air dried and then put into a fitting TLC glass 
chamber filled with approx. 50 ml 2.5 M LiCl or Running Buffer to a height of about 1.5 cm. 
The TLC was carried out until the liquid front reached 1 cm below the upper edge. The front 
was marked with a pencil and, after drying, with a droplet of an old radioactive sample. The 
TLC plate was wrapped in Saran end exposed to a 254 nm UV lamp. The unlabeled ADP 
and ATP standards were marked and then, the plate was exposed to a Storage Phosphor 
Screen (Amersham Biosciences) in an X-ray cassette (CAWO Photochemisches Werk or 
Rego X-Ray). After 30 min to over night exposure, screens were scanned on a Typhoon Trio 
Variable Mode Imager (Amersham Biosciences) and analyzed using Typhoon Scanner 
Control v5.0 and ImageQuant TL 7.0 software (Amersham).   
 
Running Buffer Saturated (NH4)2SO4 : 3 M NaOAc pH 7.0 (Applichem) : isopropanol = 80 : 
6 : 2 (v/v/v) 
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10x RNAi Buffer 300 mM HEPES-KOH pH 7.4 (at 6°C), 1 M KCl, 50 mM MgCl2, 10 mM 
DTT, 1 mM AEBSF serine protease inhibitor (Sigma; added fresh), 
glycerol ad 1 ml. Stored at 4°C. 
 
5.2.17. UV Protein-ATP Crosslinking 
To determine whether HsCLP1 wild type and K127A are able to bind ATP, we tried to 
crosslink the bound ATP to the protein via UV irradiation. 10 µl E1 recombinant protein eluate 
(approx. 135 µg/ml protein) or 3 µl concentrated E1 eluate (approx. 0.5 mg/ml protein) were 
mixed with 1 µl [α-32P]-ATP (3000 Ci/mmol 10 mCi/ml; PerkinElmer), 1 µl 20 µM siRNA GFP 
or H2O, and 8 µl RNAi Buffer. Either, the samples were incubated 30 min at 30°C and  
1300 rpm and equal volumes of 2x SDS Sample Buffer were added. Or, the samples were 
pre-incubated 20 min at 4°C in a 96-well plate, and then crosslinked 15 min on ice under a  
254 nm UV lamp. Equal volumes of 2x SDS Sample Buffer were added. All the samples 
were boiled 5 min at 95°C, and loaded onto a 10% SDS-PAA gel. After the run the gel was 
eventually Coomassie stained and/or transferred to Whatman filter paper (Whatman 
Chromatography Paper 3 mm Chr), covered with Saran wrap, vacuum dried 30 min to 2 h at 
80°C in a Bio-Rad Model 583 Gel Dryer and finally exposed to a Storage Phosphor Screen 
(Amersham Biosciences) in an X-ray cassette (CAWO Photochemisches Werk or Rego  
X-Ray). The marker bands were visualized on the screen by putting a droplet of an old 
radioactive sample next to them. After 30 min to over night exposure, screens were scanned 
on a Typhoon Trio Variable Mode Imager (Amersham Biosciences) and analyzed using 
Typhoon Scanner Control v5.0 and ImageQuant TL 7.0 software (Amersham).  
 
RNAi Buffer 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM MgCl2, 
10% (v/v) glycerol, 1 mM DTT (added fresh), 0.1 mM AEBSF 
serine protease inhibitor (Sigma; added fresh). Stored at 4°C. 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) glycerol, 50 mM 
DTT, bromophenol blue ad libitum. Stored at -20°C. 
 
5.2.18. Tandem Affinity Purification 
5 confluent 15 cm dishes of cells stably overexpressing the TAP-tagged protein of interest 
were trypsinized and taken up in medium. The cell suspensions were pooled and cells were 
spun down 3 min at 1200 rpm. The pellet was resuspended in 0.75 ml Lysis Buffer and 
transferred to a 1.5 ml tube. The samples were incubated on ice for 10 min and then 
centrifuged 15 min at 15000x g and 4°C. The supernatant was centrifuged 20 min at  
14000 rpm and 4°C. 40 µl (settled volume) IgG Sepharose 6 Fast Flow beads (GE 
Healthcare) were washed three times with 1 ml Lysis Buffer by multiple inversion, 
centrifugation (2000x g, 1 min, 4°C) and supernatant removal (1 ml syringe + 0.5 mm x  
16 mm needle at water pump). The cleared cell lysate was added to the beads and 
incubated 2 h rotating at 13 rpm and 4°C. The beads were collected by centrifugation at 600 
rpm and 4°C for 3 min and the supernatant was discarded (or kept for testing). The beads 
were then taken up in 500 µl Lysis Buffer, transferred to a Pierce Spin Column Snap Cap 
(Thermo Scientific), and washed twice with 500 µl Lysis Buffer by spinning 1 min at 2000 
rpm. Then, the beads were washed twice with 500 µl TEV Cleavage Buffer + 0.2% (v/v) NP 
40 (Nonidet P 40 Substitute, Fluka). 180 µl TEV Cleavage Buffer + 2 µl AcTEV Protease 
(Invitrogen, 10 U/µl) were added to the beads and the column was incubated 2 h at 16°C 
shaking at 800 rpm. Finally, the column was spun 1 min at 2000 rpm to collect the eluate, to 
which 10% (v/v) glycerol were added. It was then stored at -80°C or directly used for 
biochemical assays. The beads were kept for Western Blot analysis. 
At desired steps, aliquots of beads and supernatants were taken for Western Blot analysis 
and/or biochemical assays. Eventually, a second purification step could be carried out via the 
SBP-tag (but generally was not done here, because activity was lost). For this, 200 µl TEV 
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Cleavage Buffer + 0.2% (v/v) NP 40 were added to the TEV eluates to increase the volume. 
40 µl (settled volume) Streptavidin Magnetic Particles (Roche) were washed three times with 
TEV Cleavage Buffer + 0.2% (v/v) NP 40 using the magnetic device provided with the beads. 
The diluted TEV eluate was added to the beads that were then incubated 1 h at 4°C rotating 
at 13 rpm. The supernatant was discarded and the beads were again washed three times 
with TEV Cleavage Buffer + 0.2% (v/v) NP 40. 50 µl 1 mM Biotin Solution were added to the 
beads and after incubating 5 min at 16°C, the supernatant was taken. The procedure was 
repeated and the 2x 50 µl were pooled. Eventually, the eluates were microdialyzed 1 h 
against Biotin Buffer. 10% (v/v) glycerol were added to the eluates (microdialyzed or non-
microdialyzed) that were then stored at -80°C or directly used in biochemical assays. The 
beads were kept for Western Blot analysis. 
 
Lysis Buffer 50 mM Tris-HCl pH 7.5, 5% (v/v) glycerol, 0.2% NP 40 (Nonidet P 
40 Substitute, Fluka), 1.5 mM MgCl2, 100 mM NaCl, Complete 
Protease Inhibitor (Roche; 1 tablet per 50 ml buffer), 1 mM DTT 
(added fresh). Stored at 4°C. 
TEV Cleavage Buffer 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5 mM EDTA. Stored at 
4°C. 
Biotin Solution First, a saturated biotin solution was prepared (0.244 g biotin 
(Sigma) in 10 ml H2O). The 1 mM biotin working solution was 
obtained by diluting 1:100 in Biotin Buffer. 
Biotin Buffer 10 mM Tris-HCl pH 7.5, 10 mM NaCl 
 
5.2.19. In Vitro Transcription and Translation of HsCLP1 wild type and K127A 
The synthesis reaction was performed using the New England Biolabs PurExpress In Vitro 
Protein Synthesis Kit E6800S. Reactions were performed according to manufacturer’s 
instructions.  
 
First PCR Setup (to introduce a RBS and ATG start codon upstream of HsCLP1) 
2 µl forward primer (10 µM; Clp1_PurExpress_fw1) 
2 µl reverse primer (10 µM; Clp1_PurExpress_rv1) 
100 ng template (gcDNA 3.1 myc HsCLP1 wild type or K127A) 
5 µl dNTP Mix (Novagen; 2 mM each) 
5 µl 10x KOD Buffer #1 for DNA Polymerase (Novagen) 
2 µl MgCl2 (Novagen; 25 mM) 
0.4 µl KOD DNA Polymerase (Novagen; 2.5 U/µl) 
H2O ad 50 µl 
 
Second PCR Setup 
2 µl forward primer (10 µM; PurExpress_Uni) 
2 µl reverse primer (10 µM; Clp1_PurExpress_rv1) 
100 ng template (product of first PCR) 
5 µl dNTP Mix (Novagen; 2 mM each) 
5 µl 10x KOD Buffer #1 for DNA Polymerase (Novagen) 
2 µl MgCl2 (Novagen; 25 mM) 
0.4 µl KOD DNA Polymerase (Novagen; 2.5 U/µl) 
H2O ad 50 µl 
 
Primers (by Life Technologies) 
o Clp1_PurExpress_fw1: 5’-TAACTTTAAGAAGGAGATATACCAatgggagaagaggctaat-3’ 
o Clp1_PurExpress_rv1: 5’-TATTCATTActacttcagatccatgaacc-3’ 
o PurExpress_Uni: 5’-GAAATTAATACGACTCACTATAGGGAGACCACAACGGTT 
TCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCA-3’ 
(X= required for translation; x= gene specific) 
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PCR Protocol (MJ Research PTC-200 Peltier Thermal Cycler DNA Engine) 
98°C  2 min 
98°C  15 s 
60°C  5 s       20 cycles 
72°C  20 s 
4°C 
 
After the first PCR, the products were run on a 1% preparative agarose gel and bands were 
extracted. After the second PCR, products were checked on a 1% agarose gel and the 
remains were purified using the Qiagen PCR Purification Kit. 
For the protein synthesis reaction, the kit components were thawed and aliquoted on ice.  
10 µl Reagent A, 7.5 µl Reagent B, 1 µl RNasin RNase inhibitor (Promega) and H2O ad a 
total volume of 25 µl were mixed in this order. Then, 250 ng template (product from PCR 2 or 
DHFR control template) were added. The reaction was incubated 3 h at 37°C and then 
stopped by putting the tubes to ice. Protein activity was tested in a standard kinase assay 
(see Fig. 6). Samples were snap frozen in liquid nitrogen and stored at -80°C.  
 
 
Fig. 6: Testing Proteins transcribed and translated in vitro for Kinase Activity. The DHFR control protein 
and HsCLP1 K127A do not show kinase activity, whereas HsCLP1 is slightly active, confirming the success of the 
transcription-translation process. Kinase activity was assayed by incubating 3’ labeled 21-nt RNA duplex 60 min 
with the extracts used in (A). Positions of 5’ phosphorylated (5’ P) and unphosphorylated (5’ OH) duplexes on a 
15% denaturing polyacrylamide gel are indicated. 
 
5.2.20. Affinity Purification of Rabbit Antisera 
Antibodies were raised in rabbits in cooperation with Gramsch Laboratories. For every 
protein, two peptides were used for immunizing two rabbits each, resulting in four sera per 
protein as displayed in Table 9.  
The antisera obtained from the rabbits were thawed over night at 4°C. 10 ml aliquots of the 
final bleeds were affinity purified using the corresponding peptides immobilized on a column. 
Antibodies were eluted with MgCl2 and glycine. Affinity purification was performed by Mathias 
Madalinksi (IMP/IMBA Protein Chemistry Facility). The eluates were dialyzed over night 
against cold 1x PBS. For this, 20 cm of dialysis membrane (Spectra/Por molecular porous 
membrane tubing 4, 16 mm diameter, MWCO 12-14000) were pre-wetted in cold 1x PBS, 
closed at one end with a knot and a clip (Spectra/Por Closures), and the eluate was loaded 
with a pipette. Then, the other end was also closed with a knot and a clip, and in addition, a 
labeled tube was clipped onto the tubing as a marker. The tubings were put into a 5 l beaker 
filled with 3 l cold 1x PBS, covered with aluminium foil, and left in the cold room over night 
under constant stirring. Two pipettes were put into the beaker to prevent swirling of the 
tubings. After dialysis, the membranes were cut open carefully and the solution was 
transferred to a new Falcon tube. The antibodies were tested on a Western Blot with HeLa 
extract (30 µg protein loaded, see Fig. 7). 
 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
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Protein Size Peptide Sequence Location Rabbit A Rabbit B 
425 AA 1691 MGEEANDDKKPTTKFELERETEL AA 1-23 0988 0990 
HsCLP1 
 1692 LGRRPTYVELDVGQGSVS AA 141-158 0992 0986 
465 AA 1715 NGDSGKSGGVGDPREPLG AA 174-191 1063 1064 
HsTSEN2 
 1716 APKRKRRVYETYESPLP AA 8-24 1065 1066 
171 AA 1717 CNRIREILKASRKLQGDPDLP AA 116-136 1067 1068 
HsTSEN15 
 1718 MEERGDSEPTPGC AA 1-13 1069 1070 
310 AA 1719 AKKQKLEQASGASSSQEAGS AA 122-141 1071 1072 
HsTSEN34 
 1720 QASGEQEEAGPSSSQAGPSNG AA 154-174 1099 1074 
526 AA 1721 ESGRAENGVTGAGKRRWN AA 280-297 1075 1076 
HsTSEN54 
 1722 RSRSQKLPQRSHGPKDFLPD AA 27-46 1077 1078 
Recombinant 
Hs His6-CLP1 
431 AA - Full-length protein - 1779 - 
Table 9: Details of Antisera raised in Rabbits against Peptides as indicated. 
 
Fig. 7: Affinity purified Antisera achieving best Results in binding to their respective Targets. Antisera 
were tested on Western blots with 30 µg Hela extract. The five sera were subsequently used for Western blots 
and immunofluorescence. All other sera tested did not show comparable sensitivity and specificity. 
 
5.2.21. cDNA Synthesis 
RNA extracted from mammalian cells was diluted to 1 µg/µl and run on a 1% agarose gel to 
check quality. 1 µg RNA was mixed with 1 µl 10 mM dNTP Mix, 1 µl oligo dT-Primer (all 
SuperScript First Strand Synthesis System for RT-PCR, Invitrogen), and 7 µl H2O. The 
reaction was incubated 5 min at 65°C and 1 min on ice. 2 µl 10x RT Buffer, 4 µl 25 mM 
MgCl2, 2 µl 0.1 M DTT (all SuperScript First Strand Synthesis System for RT-PCR, 
Invitrogen) and 1 µl RNasin RNase inhibitor (Promega) were mixed and added to the 
reaction on ice. The samples were incubated 2 min at 42°C, then 1 µl SuperScript II RT 
Enzyme (SuperScript First Strand Synthesis System for RT-PCR, Invitrogen) was added. 
The reaction was incubated 50 min at 42°C and 15 min at 70°C. Finally, 1 µl RNase H 
(SuperScript First Strand Synthesis System for RT-PCR, Invitrogen) was added, followed by 
20 min incubation at 37°C. The cDNA was stored at -20°C. 
Alternatively, cDNA synthesis was performed using the GE Healthcare First-Strand cDNA 
Synthesis Kit as follows: The RNA was heat-denatured 10 min at 65°C and then chilled on 
ice. 3 µl RNA (1 µg/µl) were mixed with 5 µl H2O, 5 µl Bulk First Strand Reaction Mix, 1 µl 
DTT Solution, and 1 µl Random Hexamers. The reaction was incubated 1 h at 37°C, and the 
cDNA was stored at -20°C. 
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5.2.22. Quantitative Real-Time PCR 
Primers (by Life Technologies and MWG Biotech) 
o mCLP1fw200: 5’-AGCGAGGAATCCAATGATGA-3’ 
o mCLP1rev200: 5’-CAAGTGAAAACAGCCACCTT-3’ 
o mTSEN15fw200: 5’-GAGGAGCGCAGCGATTCCGA-3’ 
o mTSEN15rev200: 5’-ATGAGATCCAGGTAAACCAA-3’ 
o mTSEN2fw200: 5’-GCAGAGGCAGTCTTCCGTGC-3’ 
o mTSEN2rev200: 5’-TTTCCAAAGTAACCCTTCCC-3’ 
o mTSEN34_new_fw: 5’-TTCTTCATCTCCCCAACCAG-3’ 
o mTSEN34_new_rev: 5’-CTCTCCCACAGGTCTCGGTA-3’ 
o mTSEN54_new_fw: 5’-CAGAAGAGGGCTTTGTGGAG-3’ 
o mTSEN54_new_rev: 5’-CAAGGTGTCCTCTGTCAGCA-3’ 
o Tub_5pr: 5’-CAATGCCTGCTTTGAGCCAG-3’ 
o Tub_3pr: 5’-GTATTCCTCTCCTTCTTCCT-3’ 
o rt_gapdh_f: 5’-TGCACCACCAACTGCTTAG-3’ 
o rt_gapdh_r: 5’-GATGCAGGGATGATGTTC-3’ 
o Qh18S_fw: 5’-AAACGGCTACCACATCCAAG-3’ 
o Qh18S_rev: 5’-CCTCCAATGGATCCTCGTTA-3’ 
 
PCR Primer Test 
Primers were tested in the following standard PCR using the Taq DNA Polymerase Kit (5 
Prime) and the MJ Research PTC-200 Peltier Thermal Cycler DNA Engine. Products were 
checked on a 1% agarose gel. 
 -­‐ PCR Setup: 
0.5 µl forward primer (10 µM) 
0.5 µl reverse primer (10 µM) 
2 µl template cDNA (GE Healthcare cDNA Synthesis Kit, diluted 1:10) 
0.5 µl dNTP Mix (5 Prime) 
2.5 µl 10x Taq Buffer advanced (5 Prime) 
0.5 µl Taq DNA Polymerase (5 Prime; 5 U/µl) 
H2O ad 25 µl 
 -­‐ PCR Protocol: 
94°C  3 min 
94°C  45 s      
50/60°C  30 s      35 cycles 
72°C  1 min    
72°C  10 min 
4°C 
 
Q-RT PCR 
The quantitative real-time PCR was carried out in a Peqlab 96-well PCR plate, covered with 
a Thermo Scientific cover foil, in the Bio-Rad iQ5 qPCR machine. The reaction amounts (per 
well) were as follows: 
 
1 µl forward primer (10 µM) 
1 µl reverse primer (10 µM) 
3 µl template cDNA (GE Healthcare cDNA Synthesis Kit, diluted 1:10) 
12 µl GoTaq qPCR Mix (Promega) 
H2O ad 25 µl 
 
Each primer pair was examined in duplicates (from left to right in PCR plate, central 
wells used). Additionally, a non-template control (NTC; H2O instead of cDNA) was 
included for each primer pair. The plate was tightly closed with the cover foil by using 
a roller, shaken, and spun down 1 min at 1000 rpm. 
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-­‐ Protocol: 
50°C  10 min 
95°C  5 min 
94°C  10 s 
60°C  30 s      55 cycles (data 
acquisition) 
95°C  1 min 
55°C  1 min 
65°C + 0.5°C/10 s    61 times (melting curve 
acquisition) 
15°C 
  -­‐ Fluorophore: SYBR Green (all others deselected) 
 
After the run was completed, the dissociation, melting, and PCR curves were 
checked for irregularities and the CT threshold was set in a linear range of the curve. 
Data were exported to Microsoft Excel and analyzed by using the ΔΔCT Method 
including a reference gene. The calculation of mRNA levels and error bars was 
performed as follows (mut is displayed relative to wt):  
 
 mRNA Levels Error Bars 
1 ΔCTwt = CTwt(target) - CTwt(reference) 
ΔCTmut = CTmut(target) - CTmut(reference) 
σ(ΔCTwt) = √[σ(CTwt(target))2 + σ(CTwt(reference)2] 
σ(ΔCTmut) = √[σ(CTmut(target))2 + σ(CTmut(reference)2] 
2 ΔΔCTwt/wt = ΔCTwt - ΔCTwt = 0 
ΔΔCTmut/wt = ΔCTmut - ΔCTwt 
σ(ΔΔCTwt) = 0 
σ(ΔΔCTmut) = √[σ(ΔCTmut)2 + σ(ΔCTmut)2] 
3 wt/wt = 2^(-ΔΔCTwt/wt) = 1 
mut/wt = 2^(-ΔΔCTmut/wt) 
upper error = 2^{-[ΔΔCTmut/wt - σ(ΔΔCTmut)]} - mut/wt 
lower error = mut/wt - 2^{-[ΔΔCTmut/wt + σ(ΔΔCTmut)]} 
Table 10:  qRT-PCR Data Analysis. Stepwise calculation of relative mRNA levels and corresponding error bars. 
CT = threshold cycles, from qRT-PCR measurement; σ = standard deviation. Values used for calculation 
(beginning at step 1) are the average from duplicate or triplicate measurements with their corresponding standard 
deviations. 
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5.3. Mammalian Cell Methods and Tissue Culture 
5.3.1. Tissue Culture 
All cell lines used were grown in Dulbecco’s Modified Eagle Medium 1X (DMEM; Invitrogen 
Gibco) + 10% (v/v) FCS (Sigma) + 1% (v/v) penicillin/streptomycin (Penicillin Streptomycin 
Solution, Sigma; 10000 U/ml penicillin, 10 mg/ml streptomycin), 20 mM HEPES-KOH pH 7.3 
(IMBA Media Kitchen; 1 M stock), and 3 mM L-Glutamine (Sigma; 200 mM stock) at 37°C 
and 5% CO2 (Heracell 150, Thermo Scientific). Cell splitting was carried out as follows: The 
medium was removed and the cells were washed with 1x PBS. Cells were detached from the 
culture dish surface using 1x Trypsin-EDTA (diluted with 1x PBS from 0.5% Trypsin-EDTA 
10x, Invitrogen Gibco) at 37°C for some minutes. The trypsin reaction was stopped with the 
10-fold amount of medium. Of this cell suspension, aliquots were transferred to a new dish 
as needed and supplied with the appropriate amount of medium. 
 
Culture dish 
diameter 
Culture dish 
supplier 
1x PBS for 
washing 
1x Trypsin-EDTA  
for detaching 
Medium for 
stopping 
Culture  
medium 
15 cm Greiner Bio-One 10 ml 1 ml 19 ml 20 ml 
10 cm Nunc 5 ml 1 ml 9 ml 10 ml 
6 cm Nunc 2.5 ml 0.5 ml 4.5 ml 5 ml 
3.5 cm (6-well) Nunc 1 ml 200 µl 2 ml 2-3 ml 
2.25 cm (12-well) Corning 0.5 ml 100 µl 1 ml 1 ml 
Table 11: Summary of Reagent Amounts used in Mammalian Tissue Culture. 
Cell stocks were frozen as follows: Medium was removed and cells were washed, trypsinized 
and taken up in medium as described above. They were spun 2 min at 1200 rpm and the 
pellet was taken up in 1 ml FCS + 10% (v/v) DMSO (Sigma Aldrich) per dish. The 
suspension was transferred to a cryotube (Nunc CryoTube Vial), frozen at -80°C and 
eventually moved to -187°C for longer storage. 
Frozen cell stocks were thawed in a 37°C water bath. Immediately after the freezing medium 
had melted, the suspension was taken up in 10 ml medium. Cells were spun down 3 min at 
1200 rpm and the supernatant was removed. The cell pellet was taken up in 10 ml fresh 
medium and transferred to the culture dish. 
If contamination problems occurred, 0.25 µg/ml Amphotericin B (Biochrom AG; from 1000x 
stock) and 2 mg/ml Ciproxin (Bayer; from 100x stock) could be added to the medium. 
 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
 
5.3.2. DNA/siRNA/RNA Transfection of Mammalian Cells 
Lipofectamine 2000 Tranfsfection Reagent (Invitrogen; standard protocol)  
Transfections were performed according to manufacturer’s instructions. DNA/siRNA/RNA 
and Lipofectamine amounts were used as recommended by the manufacturer, except that 
the plating medium (Opti-MEM Reduced Serum Medium (1X), Invitrogen Gibco) for 10 cm 
dishes was reduced to 10 instead of 15 ml. For 15 cm dishes, the 10 cm protocol was used 
(10 or 15 ml plating medium). Before adding DNA/siRNA/RNA-Lipofectamine complexes to 
the cells, the dishes were washed twice with 1x PBS and the appropriate amount of  
Opti-MEM was added. Medium was changed after 4 h.  After 48 h, RNA was extracted or 
cells were lysed and extracts were used for enzymatic assays. 
 
Calcium Phosphate (according to Current Protocols in Cell Biology) 
Exponentially growing cells were split the day before transfection. The DNA (10-50 µg per  
10 cm dish) or siRNA/RNA (according to DharmaFECT and Lipofectamine 2000 protocols) to 
be transfected was taken up in H2O (total volume 450 µl per 10 cm dish) and 50 µl of 2.5 M 
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CaCl2 were added. Then, the same total volume of 2x HeBS was placed into a tube and 
bubbled with a pipette while the DNA/siRNA/RNA-CaCl2 solution was added dropwise. The 
solution was vortexed immediately for 5 s. The precipitate was allowed to sit 20 min at room 
temperature and then distributed evenly over the cells, which were gently agitated to mix 
precipitate and medium. The medium was removed, cells were washed with 1x PBS and new 
medium was added 16 h after transfection. 48 h after transfection RNA was extracted or cells 
were lysed and extracts were used for enzymatic assays. 
 
DharmaFECT siRNA Transfection Reagent (Thermo Scientific Dharmacon) 
Transfection was performed according to manufacturer’s instructions. siRNA/RNA and 
DharmaFECT amounts were used as recommended by the manufacturer. Before adding 
siRNA/RNA-DharmaFECT complexes to the cells, the dishes were washed twice with  
1x PBS and the appropriate amount of Opti-MEM (Opti-MEM Reduced Serum Medium (1X), 
Invitrogen Gibco) was added. Medium was added after 4 h.  After 48 h, RNA was extracted. 
 
2x HeBS 0.28 M NaCl, 0.05 M HEPES, 1.5 mM Na2HPO4, NaOH ad 
pH 7.05. Stored at -20°C. 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
 
5.3.3. Mammalian Cell Extraction 
For Enzymatic Assays  
The cells were washed twice with 1x PBS, dishes were put to ice and 200-500 µl (10 and  
15 cm dishes) or 50 µl (6-well) RNAi Lysis Buffer were added. The cells were harvested by 
scraping with a rubber cell scraper (BD Falcon or Sarstedt) and transferred to tubes. The 
cells were lysed by vortexing twice for 30 s or by sucking them through a 1 ml syringe +  
0.5 mm x 16 mm needle five times (air was removed first). Cell debris was spun down 10 min 
at 14000 rpm and 4°C and the supernatant was frozen in liquid nitrogen and stored at -80°C 
or used for Western Blot analysis or enzymatic tests immediately. 
 
For Western Blot Analysis Only 
The cells were trypsinized and the reaction was stopped with medium. The cells were spun 
down 3 min at 1200 rpm and the cell pellet was taken up in the desired amount of RIPA 
Buffer. Eventually, cell lysis was performed in the culture dishes as described above. The 
cells were incubated 10 min on ice and vortexed for 30 s. Cell debris was spun down 10 min 
at 14000 rpm and 4°C. The supernatant was diluted 1:2 for protein concentration 
determination. The protein concentrations were normalized, the appropriate amount of  
2x SDS Sample Buffer was added, the samples were boiled and 20 µg protein were finally 
loaded onto an SDS-PAGE and examined by Western Blot. 
 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
RNAi Lysis Buffer 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM 
MgCl2, 10% (v/v) glycerol, 1 mM DTT (added fresh), 0.1 mM 
AEBSF serine protease inhibitor (Sigma; added fresh),  
0.1-1% (v/v) NP 40 (Nonidet P 40 Substitute, Fluka). Stored 
at 4°C. When extracts were used on glycerol gradients, buffer 
was prepared with reduced or without glycerol. 
RIPA Buffer 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0,  
1 mM PMSF serine protease inhibitor (Sigma), 1% (v/v) Triton 
X-100 (Fluka), 0.1% (w/v) SDS, 1% (w/v) sodium 
deoxycholate. Stored at 4°C. 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) glycerol,  
50 mM DTT, bromophenol blue ad libitum. Stored at -20°C. 
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5.3.4. RNA Extraction from Mammalian Cells 
For extracting RNA from cells, a confluent 10 cm dish was washed with 1x PBS. 1 ml Trizol 
Reagent (Invitrogen) was added and the cells were scraped into a tube with a rubber cell 
scraper (BD Falcon or Sarstedt). The mixture was vortexed briefly and incubated 5 min at 
room temperature. 200 µl chloroform were added, the tubes were shaken manually for 15 s 
and incubated at room temperature for another 2 min. Afterwards, the samples were 
centrifuged 15 min at 9000x g and 4°C. The aqueous phase was transferred to a new tube 
and 0.5 ml isopropanol were added. The contents were mixed by inverting, followed by 10 
min incubation at room temperature. The samples were centrifuged 10 min at 9000x g and 
4°C. The pellet was washed once with 75% (v/v) ethanol and spun at 7500x g and 4°C for 5 
min, dried at room temperature, resuspended in 20 µl H2O, and stored at -20°C. 
 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
 
5.3.5. Nuclear Extract Preparation from Mammalian Cells 
Cells (at least 2 confluent 15 cm dishes needed for MEFs, 1 for HeLa cells) were detached 
from the culture dish with 2 ml 1x Trypsin-EDTA (diluted with 1x PBS from 0.5% Trypsin-
EDTA 10x, Invitrogen Gibco) at 37°C. At least 6 ml 1x PBS were added per dish and 
eventually transferred from dish to dish, taking up detached cells. The suspension was spun 
in Falcon tubes for 2 min at 1200 rpm. The cell pellet was washed once with 12 ml 1x PBS 
and the suspension was again spun 2 min at 1200 rpm. The pellet was resuspended in 1 ml 
1x PBS and transferred to a 1.5 ml tube. The tubes were centrifuged 5 min at  
1200-2000 rpm. The pellet was resuspended in 1 volume Buffer A and incubated 15 min on 
ice. A 1 ml syringe + 0.5 mm x 16 mm needle was filled with Buffer A and the air was 
removed. The cells were lysed by slowly sucking up and rapidly ejecting the suspension 
against the tube wall (five times). The samples were spun 20-60 s at 13000 rpm and the 
supernatant (= cytoplasmic extract) was supplied with 10% (v/v) glycerol. Protein 
concentration was determined and normalized with Buffer A. The samples were snap frozen 
in liquid nitrogen and stored at -80°C. The pellet remaining after the short spin was 
resuspended in 2/3 volumes Buffer C and transferred to a 2 ml tube. There, the samples 
were stirred 30 min on ice with a small magnetic stirrer. Afterwards, the suspension was 
transferred back to a 1.5 ml tube and centrifuged 5 min at 12000 rpm and 4°C. The 
supernatant (= nuclear extract) was microdialyzed against RNAi Buffer or mRNA Dialysis 
Buffer A for 1 h in the cold room. Afterwards, protein concentrations were determined and 
normalized with the buffer used for microdialysis. Then, the extracts were used for enzymatic 
assays or stored at -80°C. 
 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
Buffer A 10 mM HEPES-KOH pH 8.0, 1 mM MgCl2, 10 mM KCl,  
1 mM DTT (added fresh). Stored at 4°C. 
Buffer C 20 mM HEPES-KOH pH 8.0, 1.5 mM MgCl2, 25% (v/v) 
glycerol, 420 mM NaCl, 0.2 mM EDTA, 0.1 mM PMSF 
serine protease inhibitor (Sigma), 1 mM DTT (added 
fresh). Stored at 4°C. 
RNAi Buffer 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM 
MgCl2, 10% (v/v) glycerol, 1 mM DTT (added fresh),  
0.1 mM AEBSF serine protease inhibitor (Sigma; added 
fresh). Stored at 4°C. 
mRNA Dialysis Buffer A 2 mM MgCl2, 30 mM Tris-HCl pH 8.0, 10% (v/v) glycerol, 
80 mM KCl, 0.1 mM AEBSF serine protease inhibitor 
(Sigma), 2 mM DTT (added fresh). Stored at 4°C. 
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5.3.6. Generation of Stable HeLa Cell Lines Expressing a TAP-Construct 
The genes of interest were introduced into the pRV-NTAP vector via Gateway  
LR-Shuttling (Invitrogen) and amplified in E. coli. In parallel, the HEK gp293 packaging cell 
line was propagated. On the first day, ~70% of gp293 cells from a confluent 10 cm dish were 
split to a new 10 cm dish in the morning. In the afternoon (~6h later), the gp293 cells were 
transfected with Lipofectamine 2000 (Invitrogen; standard transfection protocol) with 5 µg 
pRV-NTAP vector + 1 µg pVSV-G plasmid (ratio 5:1) + 1.5 ml Opti-MEM Reduced Serum 
Medium (1X) (Invitrogen Gibco) and 15 µl Lipofectamine 2000 + 1.5 ml Opti-MEM, 
respectively. The next morning, the medium containing Lipofectamine and DNA was 
removed and 6 ml normal medium were added. The target cells (e.g. HeLa) were split to a  
6-well plate such that they would reach confluency in ~3 days (e.g. 1:10 from confluent dish). 
On day 3, the supernatant containing recombinant virus was collected from the gp293 cells in 
the afternoon. It was cleared by centrifugation (3 min, 1200 rpm) to remove the cells. The 
virus supernatant was sterile-filtrated using a 10 ml syringe + 0.45 µm pore filters (Acrodisc 
Syringe Filters, Pall Corporation). The medium was removed from the target cells and 2 ml 
virus supernatant + 8 µg/ml Polybrene (Sigma; 100x stock; stored at -20°C, storage at 4°C 
for short periods only) were added. In turn, 6 ml fresh medium were added to the gp293 
cells. 2 h later, the virus supernatant was aspirated off the target cells and 2 ml fresh, filtrated 
virus supernatant (stored at 4°C in the meantime) were added. Another 2 h later, the 
procedure was repeated. The next morning, the infection procedure was repeated by taking 
the new virus supernatant from the gp293 cells and filtrating it as before. In the evening, the 
virus supernatant was aspirated off the target cells and 2 ml filtrated virus supernatant 
(stored at 4°C in the meantime) were added. The packaging cells were discarded. The next 
morning, the virus supernatant was exchanged to fresh medium on the target cells. On day 
7, medium was changed again. As soon as the cells were confluent enough, they were split 
to larger dishes, frozen stocks were prepared, and cells (500 µl of 5 ml cell suspension from  
3 confluent 15 cm dishes) were lysed with RIPA Buffer and extracts were used for Western 
Blots to check for expression of the protein of interest. GFP-positive cells containing the 
insert (TAP constructs express GFP via an internal ribosome entry site) were sorted by 
FACS (500 µl of 5 ml cell suspension from 3 confluent 15 cm dishes), expanded, and used 
for purification of the TAP-tagged protein of interest. 
 
RIPA Buffer 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 1 mM PMSF 
serine protease inhibitor (Sigma), 1% (v/v) Triton X-100 (Fluka), 0.1% (w/v) 
SDS, 1% (w/v) sodium deoxycholate. Stored at 4°C. 
 
5.3.7. Fluorescence Activated Cell Sorting 
3 confluent 15 cm dishes were washed with 1x PBS and trypsinized extensively. 10 ml 
medium were added per dish and the 3x 10 ml from 3 dishes were pooled. The cells were 
spun down 3 min at 1200 rpm and the cell pellet was taken up in 5 ml medium. 500 µl of the 
suspension were filtered into FACS tubes (BD Falcon, blue caps) and sorted by the IMBA 
Biooptics Department into 4 ml medium in a 15 ml Falcon tube. The cells were spun down as 
before, the medium was removed carefully and the pellet was resuspended in approx. 100 µl 
remaining medium. The cells were transferred to a 6-well plate, 2 ml medium were added, 
and cells were expanded. As a calibration sample for FACS, untransfected HeLa cells or 
HeLa cells expressing the vector without a specific insert were used. 
 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
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5.3.8. siRNA Mediated Knock-Down in Mammalian Cells 
HeLa cells were seeded in a 6-well plate. At approx. 40% confluency, they were transfected 
as described with the desired siRNAs (e.g. siRNA CLP1 UTR1 + siRNA CLP1 UTR2 or 
siRNA GFP as a control). One well was left untransfected. 48 h later, cells were split 1:4 to a 
new plate and again transfected with the siRNAs (together with DNA vectors in case a 
rescue was desired) the next day. 48 h after transfection, cells were harvested as described, 
and biochemical assays and/or Western Blots were performed. 
 
5.3.9. Immunofluorescence in Mouse Embryonic Fibroblasts 
MEFs were grown in a 12 well dish on UV-sterilized 19 mm cover slips to 50-70% 
confluency. First, the cells were washed with 1x PBS, and then fixed in 450-800 µl 3% (v/v) 
paraformaldehyde in 1x PBS for 20 min at room temperature. After washing twice with  
1x PBS, the cells were permeabilized with 800 µl pre-chilled 0.3% (v/v) Triton X-100 (Fluka) 
in 1x PBS for 5 min on ice. The cover slips were washed 3x 5 min with 1x PBS and 
incubated with 800 µl Blocking Solution for 30-60 min at room temperature. The primary 
antibodies were centrifuged 10 min at 14000 rpm and 4°C to remove particles, diluted in  
800 µl blocking solution and left on the cover slips for 45 min at room temperature. After the 
incubation with the first antibody, the cover slips were washed 3x 5 min with 0.1% (w/v) BSA 
in 1x PBS. Cells were incubated with the secondary antibodies diluted in 800 µl Blocking 
Solution for 45 min at room temperature in the dark. Before use, the secondary antibodies 
were centrifuged as above.  Two controls were included where only the secondary antibodies 
were applied to examine unspecific staining. After the incubation, the cells were washed 2x  
5 min with 0.1% (w/v) BSA in 1x PBS and once with 1x PBS. The cover slips were dried, put 
upside down onto a slide with 2 µl of Vectashield with DAPI (Vector Laboratories Inc.), dried 
and then sealed with nail polish. The slides were stored in the dark at 4°C and finally 
examined (excitation at 495 nm, emission at 519 nm) using an Axioplan 2 Imaging 
microscope (Zeiss) with a Coolsnap HQ camera (Photometrics) and MetaMorph 7.7.1 
software (Molecular Devices Inc.). 
 
Primary Antibodies 
 ID Source Dilution Raised in 
α-MmCLP1 - Toshikatsu Hanada, group 
Penninger, IMBA 
1:250 Rabbit 
α-HsTSEN2 1064/1715 G Gramsch Laboratories 1:250 and 1:100 Rabbit 
α-HsTSEN34 1071/1719 M Gramsch Laboratories 1:250 and 1:100 Rabbit 
α-HsTSEN54 1078/1722 M Gramsch Laboratories 1:250 and 1:100 Rabbit 
α-HsTSEN15 1068/1717 G Gramsch Laboratories 1:250 Rabbit 
α-HsTSEN2 TSEN2 Antibody PTG Proteintech Group, Inc. 1:250 Rabbit 
α-HsTSEN15 SEN15 (49-K) Santa Cruz Biotechnology 1:250 Mouse 
Table 12: Summary of Primary Antibodies used for Protein Detection in Immunofluorescence. 
 
Secondary Antibodies 
 Source Dilution Raised in 
Alexa Fluor 488 anti-rabbit IgG Invitrogen 1:1000 Donkey 
Alexa Fluor 488 anti-mouse IgG  Invitrogen 1:1000 Donkey 
Table 13: Summary of Secondary Antibodies used for Signal Visualization. 
 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
Blocking Solution 3% (w/v) BSA (Albumin Fraktion V (pH 7.0), Applichem) in 
1x PBS 
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5.4. Bacteria Methods 
5.4.1. Transformation of Competent Escherichia coli 
The competent E. coli were thawed (from -80°C storage) on ice, 10-100 µl bacteria were 
mixed with 0.5-1 µl vector DNA or 5 µl Gateway recombination product and incubated 10 min 
on ice. Then, the bacteria were heat-shocked at 42°C for 2 min, transferred back to ice and 
incubated for 3 min. 1 ml LB Medium without antibiotics was added and bacteria were 
incubated approx. 45 min at 37°C shaking at approx. 200 rpm. The cells were spun down 2 
min at 6000 rpm afterwards, the supernatant was decanted and the pellet was resuspended 
in the liquid left after decanting. The suspension was plated onto agar plates containing the 
antibiotic corresponding to the resistance gene in the plasmid. For re-transformations, 
spinning was not necessary, 100 µl of bacterial suspension were plated directly. Appropriate 
positive and negative growth controls were included (e.g. empty Gateway vectors containing 
the ccdB “death gene” that does not allow E. coli DH5α to grow). 
 
LB Medium (IMBA Media Kitchen) 10 g/l bacto tryptone, 5 g/l yeast extract, 85.5 mM NaCl 
LB Agar Plates + Kan/Amp  
(IMBA Media Kitchen) 
10 g/l bacto tryptone, 5 g/l yeast extract, 85.5 mM 
NaCl, 13 g/l agar, 100 µg/ml ampicillin or 30 µg/ml 
kanamycin (from 1000x stocks) 
 
5.4.2. Preparation of Plasmids from Escherichia coli (“Miniprep”, “Maxiprep”) 
For a small-scale plasmid preparation from E. coli, 5 ml of LB Medium containing the 
antibiotic corresponding to the resistance gene present in the plasmid were inoculated with 
one bacterial colony grown on an agar plate and harboring the plasmid of interest. In general, 
4 preparations per construct were inoculated. Bacteria were grown over night in 14 ml Falcon 
snap-cap tubes shaking at 37°C and approx. 200 rpm. The next day, cultures were spun 
down 5 min at 3000 rpm and plasmid DNA was prepared using the QIAprep Spin Miniprep 
Kit (Qiagen) according to manufacturer’s instructions. The additional washing step 7 was left 
out. Eventually, DNA was checked on a 1% agarose gel and/or sequenced. 
For a large-scale plasmid preparation, 300 ml of selective LB Medium were inoculated with 
one bacterial colony as described above. Bacteria were grown over night in 1 l beakers 
shaking at 37°C and approx. 200 rpm. The next day, cultures were spun and plasmid DNA 
was prepared using the Plasmid Maxi Kit (Qiagen) according to manufacturer’s instructions. 
The second centrifugation step 8 was skipped and the lysate was filtered through a filter 
before loading it onto the column instead. Plasmid DNA was eluted into Corex glass tubes 
with 1x TE Buffer and the following centrifugations were carried out at max. 6000 rpm. 
Eventually, DNA was checked on a 1% agarose gel and/or sequenced. 
 
LB Medium (IMBA Media Kitchen) + Amp  10 g/l bacto tryptone, 5 g/l yeast extract, 85.5 
mM NaCl, 100 µg/ml ampicillin  
(from 1000x stock) 
LB Medium (IMBA Media Kitchen) + Kan 10 g/l bacto tryptone, 5 g/l yeast extract, 85.5 
mM NaCl, 30 µg/ml kanamycin  
(from 1000x stock) 
1x TE Buffer (IMBA Media Kitchen) 10 mM Tris, 1 mM EDTA. pH adjusted to 8.0 
with HCl. 
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5.4.3. Purification of Recombinant GST-HsCLP1 Protein from Escherichia coli 
For expressing and purifying the GST-HsCLP1 protein from E. coli, 100 ml LB Amp+Cam 
were inoculated with E. coli Rosetta (transformed with pDEST15 HsCLP1 wild type and 
K127A and stored at -80°C) and incubated over night shaking at 200 rpm and 37°C. The next 
morning, the OD600 of the cultures was measured (1:10 dilution) and the cultures were diluted 
to an OD600 of approximately 0.1 in 2x 600 ml LB Amp+Cam. Bacteria were grown shaking at 
200 rpm and 37°C to an OD600 of 0.4-0.8. Then, 1 ml uninduced sample was taken out, 
bacteria were spun down 2 min at 6000 rpm and 4°C, and the pellet was taken up in 50 µl  
2x SDS Sample Buffer and stored at -20°C. The remaining cultures were induced with  
0.1 mM IPTG (Sigma, prepared fresh from 1 M stock) for 2 h (shaking at 37°C). A small 
aliquot was taken and prepared for the gel as above. Bacteria were harvested by 20 min 
centrifugation at 4000 rpm and 4°C. The pellets were resuspended in 15 ml 1x PBS per 
centrifugation bucket and transferred to 50 ml Falcon tubes. They were centrifuged 15 min at 
3000 rpm and 4°C and the pellet was stored at -80°C (and later thawed on ice) or directly 
resuspended in 30 ml Buffer A. The cells were lysed by 3x 2 min sonication (Omni-Ruptor 
250 Ultrasonic Homogenizer, Omni International Inc.) at “50% pulse” and “40% power”, 
pausing 2 min on ice in between. The samples were centrifuged 30 min at 16000 rpm and 
4°C (SS34 rotor). In the meantime, 1 ml Glutathione Sepharose FF bead suspension 
(Amersham) was washed three times with 10 ml Buffer A by spinning 1 min at 2000 rpm and 
4°C. The bacterial supernatant was bound to the beads by incubating rotating at 13 rpm and 
4°C for 2 h. Then, the supernatant was discarded, the beads were washed twice with 20 ml 
Buffer A. The washing solutions were kept for gel analysis. The beads were spun down 3 min 
at 1000 rpm and 4°C, and transferred to a Bio-Rad Poly-Prep Chromatography Column that 
had been washed once with H2O before. The column was washed five times with  
2 ml Buffer C; the flow through was collected for gel analysis. The recombinant protein was 
finally eluted in 1 ml Buffer D for 10 min (E1). The elution was repeated (E2). Protein 
concentrations in the eluates were determined. Eluates were eventually microdialyzed, 
concentrated, examined on SDS-PAGE followed by Coomassie staining, and/or tested for 
activity in a kinase assay.  
At desired steps, aliquots of beads and supernatants were taken for analysis by SDS-PAGE. 
 
LB Medium (IMBA Media 
Kitchen) + Amp + Cam 
10 g/l bacto tryptone, 5 g/l yeast extract, 85.5 mM NaCl,  
100 µg/ml ampicillin, 34 µg/ml chloramphenicol (from 1000x 
stocks) 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) glycerol, 
50 mM DTT, bromophenol blue ad libitum. Stored at -20°C. 
1x PBS (IMBA Media Kitchen) 137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.47 mM 
KH2PO4. pH adjusted to 7.3 with HCl. 
Buffer A 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.1% (v/v) TWEEN 
20 (Sigma-Aldrich), 5 mM MgCl2, 1 mM DTT, 0.1 mM 
AEBSF serine protease inhibitor (Sigma). Stored at 4°C. 
Buffer C 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 mM MgCl2, 1 mM 
DTT, 0.1 mM AEBSF serine protease inhibitor (Sigma). 
Stored at 4°C. 
Buffer D 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.1% (v/v) TWEEN 
20 (Sigma-Aldrich), 5 mM MgCl2, 1 mM DTT, 0.1 mM 
AEBSF serine protease inhibitor (Sigma), 20 mM reduced 
glutathione (Sigma). pH was adjusted to 8.0 with NaOH and 
10% (v/v) glycerol were added. Stored at 4°C. 
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5.5. Biochemical Assays 
5.5.1. Pre-tRNA Splicing Assay 
Reaction Buffer 1 or 2 and 1 µM body-labeled S. cerevisiae pre-tRNAPhe were mixed 4:1, 
denatured at 95°C for 90 s and incubated 20 min at room temperature. 0.015 µl RNasin 
RNase inhibitor (Promega) per 10 µl solution were added. Cell extracts (with normalized 
protein concentration), TEV eluates or beads in RNAi Buffer were added to the reaction mix 
in equal amounts and the reaction was incubated at 30°C and 1300 rpm. At given time 
points, 5 µl were taken out of the tube and the reaction was quenched in 150 µl Proteinase K 
Assay Solution. The reaction aliquots were then incubated at 65°C and 1300 rpm for 30 min 
to digest proteins contained in the sample.  150 µl Phenol-Chloroform-Isoamyl alcohol  
pH 8 (Applichem; P:C:I = 25:24:1) were added and the tubes were vortexed vigorously for  
20 s to extract RNA. For phase separation, the samples were centrifuged 2 min at maximum 
speed and 4°C. The upper, aqueous phase was transferred to a new tube and 3 volumes of 
100% (v/v) ethanol were added. The tubes were vortexed briefly and precipitation was 
carried out at -20°C for >30 min, over night or over a weekend.  Samples were centrifuged at 
full speed and 4°C for >30 min and the supernatant was discarded. The pellets were vacuum 
dried in an Eppendorf Concentrator 5301 for 5-10 min and then resuspended in 10 µl 1x FA 
Buffer. 3-5 µl were boiled at 95°C for 5 min and separated in a 10% Urea-PAGE. Gels were 
transferred to Whatman filter papers (Whatman Chromatography Paper 3 mm Chr), covered 
with Saran wrap, vacuum dried 30 min to 2 h at 80°C in a Bio-Rad Model 583 Gel Dryer and 
finally exposed to a Storage Phosphor Screen (Amersham Biosciences) in an X-ray cassette 
(CAWO Photochemisches Werk or Rego X-Ray). After at least over night exposure, screens 
were scanned on a Typhoon Trio Variable Mode Imager (Amersham Biosciences) and 
analyzed using Typhoon Scanner Control v5.0 and ImageQuant TL 7.0 software 
(Amersham).  
As an alternative to Proteinase K treatment, reactions were quenched in 5 µl 2x STOP Buffer 
and directly analyzed on a gel. If necessary, 3 µl reaction aliquots (instead of 5 µl) could be 
taken at a given time point. They were subsequently treated with corresponding amounts of 
Proteinase K etc. 
 
Modifications -­‐ For testing the influence of Mg2+ ions, pre-cleared HeLa cell extract was depleted of 
ATP and 10-20 mM MgCl2 or 10-20 mM EDTA pH 8.0 were added before using it in 
the pre-tRNA splicing assay. 
 -­‐ Complementation of HsCLP1 K127A with recombinant wild type CLP1:  
2 µl of recombinant wild type CLP1 protein (GST-HsCLP1 0.1 or 2 mg/ml, Hs His6-
CLP1 [purified by Stefan Weitzer] 0.4 mg/ml, C. elegans wild type CLP1 [purified by 
Bastian Schmidt] 0.4 mg/ml or 0.4 µl of 2.4 mg/ml) were added to 4 µl NTAP-HsCLP1 
K127A TEV eluate. Then, 4 µl NaCl solution (100/350/600/850/1350/2350/4850 mM 
stock solutions to achieve 100/200/300/400/600/1000/2000 mM final concentration) 
were added slowly under constant shaking. The samples were incubated 10 min at 
30°C and then microdialyzed 1 h against RNAi Buffer. 5 µl of the samples were used 
for the pre-tRNA splicing assay described above. As controls, samples without 
recombinant CLP1 (H2O instead) and non-microdialyzed samples were included. 
 -­‐ ATP Titration:  
To test different ATP concentrations in the assay, 1 µl 10 mM ATP, 0.75 µl 10 mM 
ATP + 0.25 µl H2O, or 0.5 µl 10/5/1/0.1/0.01/0.001 mM ATP + 0.5 µl H2O or 1 µl H2O 
were mixed with 0.5 µl 1 µM body-labeled S. cerevisiae pre-tRNAPhe and 1 µl 
Reaction Buffer 2. The mixture was incubated 1.5 min at 95°C, followed by 20 min at 
room temperature. 0.2 µl RNasin RNase inhibitor (Promega) and 2.5 µl NTAP-
HsCLP1 wild type TEV eluate were added to each sample. The reactions were 
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incubated 60 min at 30°C and subsequently treated as standard assay samples. The 
final ATP concentrations equated to 0, 100 nM, 1, 10, 100, 500 µM, 1, 1.5, and 2 mM 
ATP. 
 -­‐ Inhibitor Assay:  
For specifically inhibiting CLP1, a compound (BIBT2797SE) designed and screened 
by Boehringer Ingelheim and tested by Stefan Weitzer was used. 8.5 µl NTAP-
HsCLP1 wild type TEV eluate were mixed with 3.4 µl Reaction Buffer 2 and 0.59 µl 
DMSO or inhibitor (300 µM or 3 mM stocks in DMSO to achieve 10 and 100 µM final 
concentrations, respectively). The samples were incubated 10 min at 30°C. Then, 
1.76 µl 100 µM ATP (10 µM final concentration) or H2O, 1.64 µl H2O, and 1.7 µl 1 µM 
body-labeled S. cerevisiae pre-tRNAPhe (denatured 1.5 min at 95°C and recovered  
20 min at room temperature before use) were added. Alternatively, 3.6 µl 10 mM ATP 
(2 mM final concentration) was used. The reaction was incubated 15/30/60 min at 
30°C and 1300 rpm and treated as standard assay samples.  
 
Reaction Buffer 1 100 mM KCl, 5.75 mM MgCl2, 2.5 mM DTT, 5 mM ATP, 6.1 
mM Spermidine-HCl pH 8.0 (Sigma). Always prepared 
fresh. 
Reaction Buffer 2  
 
223 mM KCl, 12.8 mM MgCl2, 5.66 mM DTT, 13.7 mM 
Spermidine-HCl pH 8.0 (Sigma). Always prepared fresh, 
mixed 1:1 with 10 mM NTP stock solutions. 
RNAi Buffer 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM 
MgCl2, 10% (v/v) glycerol, 1 mM DTT (added fresh), 0.1 mM 
AEBSF serine protease inhibitor (Sigma; added fresh). 
Stored at 4°C. 
2x FA Buffer 10% (v/v) EDTA pH 8.0, 90% (v/v) formamide (Merck), 
bromophenol blue and xylene cyanol ad libitum. Stored at  
-20°C. 
2x STOP Buffer 50 mM Tris-HCl pH 8.0, 8 M urea, bromophenol blue ad 
libitum. Stored at -20°C. 
Proteinase K Assay Solution 140 µl Proteinase K Solution plus 6.86 ml Proteinase K 
Buffer 
Proteinase K Buffer 200 mM Tris-HCl pH 7.5, 25 mM EDTA pH 8.0, 300 mM 
NaCl, 2% (w/v) SDS 
Proteinase K Solution 100 mg Proteinase K (Applichem) in 7.14 ml Proteinase K 
Storage Buffer. Stored at -20°C. 
Proteinase K Storage Buffer 50 mM Tris-HCl pH 8.0, 5 mM CaCl2, 50% (v/v) glycerol 
 
5.5.2. Kinase Assay 
To test CLP1 kinase activity, 0.5 µl 3x Reaction Mix, 1.5 µl H2O and 0.5 µl 3’ end labeled 
siRNA duplex as a substrate (approx. 50 nM: eventually more if labeling was older than 32P 
half life) were mixed. 2.5 µl of cell extracts, TEV eluates, beads in RNAi Buffer, or 
recombinant CLP1 solution were added and the reaction was incubated at 30°C for 60 min. 
The reaction was stopped by adding 5 µl 2x FA Buffer and putting the samples to ice or at  
-20°C. 3-5 µl were boiled at 95°C for 5 min and separated in a 15% Urea-PAGE. Gels were 
transferred to a plastic sheet, covered with Saran wrap, and exposed to a Storage Phosphor 
Screen (Amersham Biosciences) in an X-ray cassette (CAWO Photochemisches Werk or 
Rego X-Ray). After approx. 1 h exposure, screens were scanned on a Typhoon Trio Variable 
Mode Imager (Amersham Biosciences) and analyzed using Typhoon Scanner Control v5.0 
and ImageQuant TL 7.0 software (Amersham). 
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Alternatively, multiple reactions were set up and at given time points, 5 µl samples were 
taken out. If necessary, the reactions were scaled up, for example, if beads after co-
immunoprecipitations were used as samples. 
 
Modification (Inhibitor Assay)  
For specifically inhibiting CLP1, a compound (BIBT2797SE) designed and screened by 
Boehringer Ingelheim and tested by Stefan Weitzer was used. 8.5 µl NTAP-HsCLP1 wild 
type TEV eluate were mixed with 3.4 µl Reaction Buffer 2 and 0.59 µl DMSO or inhibitor (300 
µM or 3 mM stocks in DMSO to achieve 10 and 100 µM final concentrations, respectively). 
The samples were incubated 10 min at 30°C. Then, 1.76 µl 100 µM ATP (10 µM final 
concentration) or H2O, 1.64 µl H2O, and 1.7 µl 3’ end labeled siRNA duplex as a substrate 
(approx. 50 nM) were added. The reaction was incubated 15/30/60 min at 30°C and  
1300 rpm and treated as standard assay samples.  
 
3x Reaction Mix 400 mM KCl, 23 mM MgCl2, 50 mM DTT, 10 mM ATP, 2 mM GTP,  
0.3 µl/37.5 µl RNasin RNase inhibitor (Promega) 
RNAi Buffer 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM MgCl2, 10% 
(v/v) glycerol, 1 mM DTT (added fresh), 0.1 mM AEBSF serine protease 
inhibitor (Sigma; added fresh). Stored at 4°C. 
2x FA Buffer 10% (v/v) EDTA pH 8.0, 90% (v/v) formamide (Merck), bromophenol 
blue and xylene cyanol ad libitum. Stored at -20°C. 
 
5.5.3. Testing for HsCLP1 Protein Kinase Activity 
A pre-tRNA splicing assay buffer was prepared by mixing 1.5 µl 1 M KCl, 0.086 µl 1 M MgCl2, 
0.038 µl 1 M DTT, 0.46 µl 200 mM Spermidine-HCl pH 8.0, and 15 µl H2O or unlabeled  
100 nM S. cerevisiae pre-tRNAPhe. The mixture was heated to 95°C for 1.5 min and was then 
incubated at room temperature for 20 min. 1 µl [γ-32P]-ATP (3000 Ci/mmol 10 mCi/ml; 
PerkinElmer) was added. 3 µl of the mix were taken out and mixed with 3 µl of either NTAP-
HsCLP1 wild type or K127A TEV eluates. The samples were incubated 30 min at 30°C and 
1300 rpm. The reaction was stopped by adding 6 µl 2x SDS Sample Buffer. The samples 
were boiled at 95°C for 5 min, and 5 µl each were loaded onto 10% and 15% SDS-PAA gels, 
respectively. After the run the gels were transferred to Whatman filter papers (Whatman 
Chromatography Paper 3 mm Chr), covered with Saran wrap, vacuum dried 30 min to 2 h at 
80°C in a Bio-Rad Model 583 Gel Dryer and finally exposed to a Storage Phosphor Screen 
(Amersham Biosciences) in an X-ray cassette (CAWO Photochemisches Werk or Rego X-
Ray). The marker bands were visualized on the screen by putting a droplet of an old 
radioactive sample next to them. After 30 min to over night exposure, screens were scanned 
on a Typhoon Trio Variable Mode Imager (Amersham Biosciences) and analyzed using 
Typhoon Scanner Control v5.0 and ImageQuant TL 7.0 software (Amersham).   
 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) glycerol,  
50 mM DTT, bromophenol blue ad libitum. Stored at -20°C. 
 
5.5.4. ATP Hydrolysis Assay 
In order to find out whether the HsCLP1 K127A could hydrolyze ATP and release ADP, we 
performed an ATP hydrolysis assay using the Discoverx ADP Hunter Plus Assay (Amersham 
Biosciences) according to manufacturer’s instructions. The required kinase assay was 
performed as described in Table A2 (see Appendix). As controls, purified C. elegans CLP1 
[by Bastian Schmidt] and T4 Polynucleotide Kinase (10000 U/ml; New England Biolabs) plus 
the corresponding 10x Reaction Buffer (New England Biolabs) were used. For calibration, 
ADP standard dilutions were prepared.  
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Detection was performed in a black 96-well plate (Nunc) by adding 10 µl Reagent A and then 
20 µl Reagent B. The plate was incubated approx. 35 min at room temperature and then the 
fluorescence intensity (excitaton at 535 nm, emission at 590 nm) was determined in a Tecan 
GENios Pro plate reader. 
 
3x Reaction Buffer without ATP 3x Reaction Mix: 400 mM KCl, 23 mM MgCl2, 50 mM 
DTT, 2 mM GTP, 0.3 µl/37.5 µl RNasin RNase inhibitor 
(Promega) 
RNAi Buffer 30 mM HEPES-KOH pH 7.4 (at 6°C), 100 mM KCl, 5 mM 
MgCl2, 10% (v/v) glycerol, 1 mM DTT (added fresh),  
0.1 mM AEBSF serine protease inhibitor (Sigma; added 
fresh). Stored at 4°C. 
 
5.5.5. Investigating Putative TSEN Protein Phosphorylation 
For testing whether one or more of the TSEN proteins could be phosphorylated, we mixed  
5 µl of NTAP-HsCLP1 wild type TEV eluate with 1 µl NEBuffer Pack for Protein 
MetalloPhosphatases (PMP) (10X) (New England Biolabs), 1 µl 10 mM MnCl2 (New England 
Biolabs), and 1 µl Lambda Protein Phosphatase (New England Biolabs, 400000 U/ml) or 
H2O, filled up with H2O to 10 µl and incubated the reaction 1 h at 30°C. Eventually, the 
samples were also treated with 1 µl Alkaline Phosphatase (Roche, 20 U/µl) and the 
corresponding 10x Buffer (Roche; no MnCl2) and incubated 1 h at 30°C. Enzyme 
concentrations were measured and the appropriate amount of Purified BSA (from 0.1% (w/v) 
or 10 mg/ml solution, Roche and New England Biolabs) was added to the untreated samples 
to equal out the total protein amount. The samples were mixed with 10 µl 2x SDS Sample 
Buffer, boiled, and loaded onto a 10% or 7.5% SDS-PAGE. A Western Blot with antibodies 
directed against the TSEN proteins was performed for detection. 
 
2x SDS Sample Buffer 25 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 10% (v/v) glycerol, 50 mM 
DTT, bromophenol blue ad libitum. Stored at -20°C. 
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6. Results 
6.1. CLP1 -/- Mouse Embryonic Fibroblasts are impaired in pre-tRNA 
Cleavage in vitro. 
After HsCLP1 was first identified in our laboratory as an RNA kinase and implicated in pre-
tRNA processing in vitro, the group of Josef Penninger provided us with tissue-specific 
conditional knock-out mice. The CLP1 gene was flanked by loxP sites and excised by the 
Cre recombinase that mediated recombination between the loxP sites. Tissue-specific 
expression of the Cre recombinase was induced by tamoxifen. For examination in vitro, 
primary mouse embryonic fibroblasts (pMEFs) were isolated from “floxed” mice and the 
tamoxifen-induced CLP1 knock-out was performed in tissue culture. 
We first tested nuclear extracts prepared from wild type and CLP1 -/- MEFs for their 
RNA kinase activity. In such a kinase assay, a 21 nucleotide-long RNA duplex, radioactively 
labeled at the 3’ end of one strand, was incubated with cell extracts. In the reaction, RNA 
duplexes became phosphorylated at their 5’ end due to CLP1’s kinase activity. We monitored 
phosphorylation by gel electrophoresis since the additional phosphate group makes the RNA 
duplex migrate faster than its non-phosphorylated counterpart. Therefore, CLP1’s kinase 
activity can be detected as an increased electrophoretic mobility of its RNA substrate  
(Fig. 8A). Using this kinase assay, we could confirm the absence of any dsRNA kinase 
activity in the knock-out cells (Fig. 8B). 
Subsequently, we examined pre-tRNA processing of control and CLP1 knock-out 
extracts in a pre-tRNA splicing assay. Radioactively labeled pre-tRNAPhe derived from  
S. cerevisiae was incubated with the cell extracts and ATP (Fig. 8C). After the reaction, 
proteins were removed by treatment with proteinase K, the reaction products were separated 
by gel electrophoresis and detected by phosphorimaging. In extracts prepared from CLP1 -/- 
cells, generation of mature tRNA was greatly reduced, as reported previously (Weitzer and 
Martinez, 2007b). Surprisingly, the levels of 5’ and 3’ exon halves generated by cleavage of 
the pre-tRNA by the TSEN complex were significantly lower upon incubation with extracts 
prepared from CLP1 knock-out MEFs as compared to the wild type (Fig. 8D). This result 
indicated that CLP1 could perform more tasks in pre-tRNA processing than the mere 
phosphorylation of the 3’ exon to prepare it for ligation by the yeast-like pathway. 
 
 

 _______________________________________________________________________________________ 63 
 
Fig. 8: CLP1 knock-out Cells show significantly reduced pre-tRNA Cleavage in vitro. (A) Schematic 
representation of and example for the “kinase assay”. A 21-nt RNA duplex (siRNA) was radioactively labeled by 
annealing [α-32P]-pC to the 3’ end of one strand (indicated by a red asterisk (*) and a red line). This substrate was 
then incubated at 30°C with either cell extracts or (semi-)purified protein samples containing the CLP1 RNA 
kinase which phosphorylates the 5’ hydroxyl groups with ATP as a cofactor, transferring the γ-phosphate group to 
the RNA duplex (green P). The addition of this phosphate group to the labeled RNA strand results in faster 
migration in a 15% denaturing urea polyacrylamide gel, caused by the additional negative charge. After 
phosphorimaging, the 5’ phosphate is observed as a downward shift of the 21-nt band. Positions of  
5’ phosphorylated (5’ P) and unphosphorylated (5’ OH) duplexes are indicated. (B) Kinase activity of nuclear 
extracts prepared from primary fibroblasts (control = CLP1 gene flanked by loxP sites; MmCLP1 knock-out = 
CLP1 deleted by tamoxifen-induced Cre-recombination) was assayed by incubating a 3’ labeled 21-nt RNA 
duplex 60 min with the extracts used in (A). Positions of 5’ phosphorylated (5’ P) and unphosphorylated (5’ OH) 
duplexes on a 15% denaturing polyacrylamide gel are indicated. In lane 1, the RNA duplex was loaded without 
extract, representing time 0. Data by Stefan Weitzer. (C) Schematic representation of the “pre-tRNA splicing 
assay”. An internally (“body”) radioactively labeled (using [α-32P]-GTP; indicated by red asterisks (*)), intron-
containing S. cerevisiae pre-tRNAPhe was used as a substrate. This substrate was then incubated at 30°C with 
either cell extracts or (semi-)purified protein samples containing the CLP1-TSEN pre-tRNA splicing endonuclease 
complex. The complex cleaves the pre-tRNA (indicated by arrowheads) and leaves a 5‘ and a 3‘ tRNA exon half 
plus the intron. In the yeast-like ligation pathway, the 3‘ exon is phosphorylated by CLP1 (with ATP as a cofactor) 
and ligated to the 5’ exon to produce mature tRNA with an incorporated exogenous phosphate (green P). All 
these tRNA fragments can be detected after separating the pre-tRNA cleavage reactions on a 10% denaturing 
urea polyacrylamide gel. (D) The body-labeled intron-containing S. cerevisiae pre-tRNAPhe was incubated with 
nuclear extracts prepared from the primary fibroblasts used in (B) in the presence of 2 mM ATP for the times 
indicated. Pre-tRNA cleavage was monitored by electrophoresis on a denaturing 10% polyacrylamide gel and 
detected by phosphorimaging. Different tRNA fragments are labeled at the right. In lane 1, the pre-tRNAPhe was 
loaded without extract, representing time 0. Data by Stefan Weitzer. 
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6.2. CLP1 Kinase Activity is required for efficient tRNA Exon 
Generation in vitro. 
After the confirmation that CLP1 is indeed involved in tRNA maturation by examination of the 
knock-out MEFs, it seemed obvious to ask whether CLP1’s kinase function (in contrast to the 
mere presence of the protein) directly impacted on pre-tRNA processing. To address this 
problem, Toshikatsu Hanada (research group of Josef Penninger) generated a knock-in 
mouse in which the wild type CLP1 was replaced with a mutated version. This “kinase-dead” 
CLP1 harbors a point mutation in the Walker-A motif which, together with the Walker-B 
domain also present in CLP1, is implicated in ATP/GTP binding (Noble et al., 2007; Tanabe 
et al., 1996). The lysine-to-alanine mutation of residue 127 (K127A) renders the RNA kinase 
inactive (Weitzer and Martinez, 2007b). From the knock-in mouse, Toshi isolated embryonic 
fibroblasts and immortalized them to adapt them to tissue culture (CLP1 K127A iMEFs). 
When we incubated a pre-tRNA substrate with nuclear extracts prepared from wild 
type and CLP1 K127A MEFs in the presence of ATP, we could observe a significant 
reduction of tRNA exon levels, suggesting that MmCLP1 kinase activity is required for pre-
tRNA intron excision (Fig. 9A). In support of this result, ectopic overexpression of wild type 
HsCLP1 in the kinase-dead MEFs partially restored tRNA exon generation in nuclear 
extracts (Fig. 9A,B,D). This rescue of activity can be additionally assessed by comparing the 
levels of mature tRNA generated (Fig. 9A,C). In contrast, extracts from MEFs overexpressing 
HsCLP1 K127A or from mock transfected MEFs generated levels of tRNA exons and mature 
tRNA comparable to the levels obtained with untransfected kinase-dead MEFs  
(Fig. 9A,B,C,D). In addition to the tRNA splicing phenotype, we examined the effect of the 
K127A mutation on CLP1 kinase activity in a kinase assay, confirming the defect in RNA 
phosphorylation for the mutant (Fig. 9E). Upon introduction of wild type HsCLP1 into the 
kinase-dead MEFs, RNA phosphorylation was also restored, whereas overexpression of 
HsCLP1 K127A or mock transfection were unable to rescue kinase activity (Fig. 9E).  
In a second, independent approach, we set out to confirm these results in HeLa cells. 
We knocked down CLP1 with two different siRNAs directed against the 3’ untranslated 
region (3’ UTR) of the mRNA and, in a second round of transfection, introduced wild type or 
K127A HsCLP1 into these cells. In support of the results obtained with MEFs, we found a 
significant reduction of tRNA exon halves upon CLP1 knock-down whereas untransfected or 
control knock-down (siGFP) cells exhibited normal pre-tRNA cleavage efficiency (Fig. 10A). 
In fact, we could also rescue the RNAi effect by overexpressing wild type HsCLP1 in knock-
down HeLa cells (Fig. 10A,D). The difference between the knock-down and rescue samples 
is most prominent at 30 min of incubation, both at the levels of mature tRNA and exon halves 
(Fig. 10B,C).  
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Analogous to the experiments conducted in MEFs, we performed a kinase assay to monitor 
the effect of CLP1 knock-down and rescue independent from its role in pre-tRNA processing. 
Phosphorylation of the double-stranded RNA substrate occurred with significantly slower 
kinetics in CLP1 knock-down extracts compared to untransfected and control knock-down 
samples (Fig. 10E; lanes 3-5, 6-8, and 9-11). In CLP1 knock-down cells transfected with an 
expression vector encoding HsCLP1 K127A or control transfected, phosphorylation was 
almost abolished (Fig. 10E; lanes 12-14 and 18-20). In contrast, when wild type HsCLP1 was 
introduced into the knock-down cells, phosphorylation was not only restored but enhanced 
(Fig. 10E; lanes 15-17). 
To restrict our experiments to the pre-tRNA processing pathway, we immuno-
precipitated the TSEN complex containing CLP1 as an integral component from wild type 
and kinase-dead MEFs. To assay the immunoprecipitates for pre-tRNA processing, we 
affinity-selected the TSEN-CLP1 complex with an antibody directed against HsTSEN2, which 
cross-reacts with MmTSEN2. After purification, the immunoprecipitates were incubated with 
a pre-tRNA substrate. Strikingly, the difference in cleavage efficiency displayed by the input 
samples (nuclear extracts from wild type and K127A MEFs) is also detected in the 
immunoprecipitates, showing reduced pre-tRNA cleavage in the CLP1 K127A pull down  
(Fig. 11A). In the corresponding kinase assay, CLP1 K127A input and immunoprecipitate 
were unable to phosphorylate the RNA substrate in contrast to wild type input and immuno-
precipitate (Fig. 11B). These results further confirm that CLP1 is present in the immuno-
precipitated TSEN complex and plays a role during exon generation in the pre-tRNA 
processing pathway. 
All observed effects could theoretically be attributed to reduced TSEN or CLP1 
mRNA or protein levels in the kinase-dead MEFs. In order to rule out the former possibility, 
we performed quantitative real-time PCR on total RNA extracted from CLP1 wild type and 
K127A MEFs to determine the mRNA levels of TSEN2, TSEN15, TSEN34, TSEN54, and 
CLP1. We could not detect reduced mRNA levels of CLP1 or the TSEN genes in kinase-
dead MEFs compared to the wild type (Fig. 11D); thus, we attributed the observed deficiency 
in tRNA exon generation to CLP1 kinase activity being required at this processing stage. 
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Fig.9: Mouse Embryonic Fibroblasts harboring mutant CLP1 exhibit deficient pre-tRNA Cleavage in vitro.  
(A) The body-labeled intron-containing S. cerevisiae pre-tRNAPhe was incubated with nuclear extracts prepared 
from CLP1 wild type (wt) and mutant (K127A) MEFs in the presence of 2 mM ATP for the times indicated. MEFs 
K127A were transfected with the gcDNA 3.1 myc vector with or without inserts as displayed and harvested 48 h 
later. Pre-tRNA cleavage was monitored by electrophoresis on a denaturing 10% polyacrylamide gel and detected 
by phosphorimaging. Different tRNA fragments are labeled at the right. The asterisk (*) indicates an unspecific 
band unrelated to pre-tRNA splicing. In lane 1, the pre-tRNAPhe was loaded without extract, representing time 0. 
(B) Quantification of 5’ and 3’ exon bands in (A); plotted relative (in %) to the sum of pre-tRNA at time 0 plus 
exons. (C) Quantification of mature tRNA bands in (A); plotted relative (in %) to the sum of pre-tRNA at time 0 
plus mature tRNA. (D) Western Blot performed on the extracts used in (A) with an antibody directed against  
c-myc to confirm protein overexpression. Double asterisks (**) in lane 1 indicate unspecific band. (E) Kinase 
activity was assayed by incubating 3’ labeled 21-nt RNA duplex 60 min with the extracts used in (A). Positions of 
5’ phosphorylated (5’ P) and unphosphorylated (5’ OH) duplexes on a 15% denaturing polyacrylamide gel are 
indicated. In lanes 1 and 2, control samples were loaded as size markers. 
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Fig. 10: CLP1 knock-down Cells show reduced tRNA Exon Generation in vitro. (A) The body-labeled intron-
containing S. cerevisiae pre-tRNAPhe was incubated with whole cell extracts prepared from HeLa cells in the 
presence of 2 mM ATP for the times indicated. The cells were transfected with siRNAs directed against the  
3’ UTR of HsCLP1 (siCLP1) or with a control siRNA (siGFP) as indicated. In a second transfection 48 h later, 
gcDNA 3.1 myc with or without inserts was included as displayed. Cells were harvested 48 h later. Pre-tRNA 
cleavage was monitored by electrophoresis on a 10% denaturing polyacrylamide gel and detected by 
phosphorimaging. Different tRNA fragments are labeled at the right. The asterisk (*) indicates an unspecific band 
unrelated to pre-tRNA splicing. In lane 1, the pre-tRNAPhe was loaded without extract, representing time 0. (B) 
Quantification of 5’ and 3’ exon bands in (A); plotted relative (in %) to the sum of pre-tRNA at time 0 plus exons. 
(C) Quantification of mature tRNA bands in (A); plotted relative (in %) to the sum of pre-tRNA at time 0 plus 
mature tRNA. (D) Western Blot performed on the extracts used in (A) with an antibody directed against c-myc to 
confirm protein overexpression. Double asterisks (**) indicate unspecific staining. (E) Kinase activity was assayed 
by incubating a 3’ labeled 21-nt RNA duplex for the time indicated with the extracts used in (A). Positions of  
5’ phosphorylated (5’ P) and unphosphorylated (5’ OH) duplexes on a 15% denaturing polyacrylamide gel are 
indicated. In lanes 1 and 2, control samples were loaded as size markers. 
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Fig. 11: Pre-tRNA Cleavage is reduced in TSEN2 Immunoprecipitates from CLP1 K127A MEFs although 
TSEN mRNA Levels are unaffected. (A) The body-labeled intron-containing S. cerevisiae pre-tRNAPhe was 
incubated with nuclear extracts prepared from CLP1 wild type (wt) and mutant (K127A) MEFs in the presence of 2 
mM ATP for the times indicated (Input) or subjected to co-immunoprecipitation with an HsTSEN2 antibody cross-
reacting with MmTSEN2 before assaying pre-tRNA cleavage on the beads. Exon generation was monitored by 
electrophoresis on a denaturing 10% polyacrylamide gel and detected by phosphorimaging. Different tRNA 
fragments are labeled at the right. (B) Kinase activity of inputs and immunoprecipitates from (A) was assayed by 
incubating them 60 min with a 3’ labeled 21-nt RNA duplex. Positions of 5’ phosphorylated (5’ P) and 
unphosphorylated (5’ OH) duplexes on a 15% denaturing polyacrylamide gel are indicated. In lanes 1 and 2, 
control samples were loaded as size markers. (C) Total RNA extracted from CLP1 wild type (wt) and mutant 
(K127A) MEFs was examined on a 1% agarose gel for quality control before cDNA synthesis. Highly abundant 
18S and 28S rRNA are annotated at the right. (D) Quantitative real-time PCR results comparing mRNA levels of 
MmCLP1, MmTSEN15, MmTSEN2, and TSEN54 from CLP1 wild type (wt) and mutant (K127A) MEF cDNA. 
mRNA levels were calculated by the ΔΔCt method normalizing to tubulin and are displayed relative to CLP1 wild 
type MEFs. Error bars were calculated including propagation of uncertainty in the normalization steps (see 
Materials and Methods for details).  
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6.3. Overexpression of CLP1 K127A exerts a Dominant Negative Effect 
on pre-tRNA Processing 
The results obtained so far and the fact that CLP1 is part of the tRNA splicing endonuclease 
complex posed the question whether the presence of a CLP1 K127A reduces tRNA cleavage 
efficiency of the TSEN complex in a dominant negative way. To address this issue, we 
overexpressed HsCLP1 K127A in wild type CLP1 MEFs or HeLa cells (Fig. 12C) and 
determined the effect on tRNA processing and RNA phosphorylation. In HeLa cells, we could 
observe a clear dominant negative effect of CLP1 K127A, both at the level of exon half and 
mature tRNA generation (Fig. 12A,F,G), suggesting that an excess of mutant CLP1 can 
reduce pre-tRNA processing efficiency regardless of the presence of wild type CLP1. Again, 
the most prominent differences between untransfected, mock or wild type HsCLP1 
transfected and HsCLP1 K127A transfected cells, regarding both exon and mature tRNA 
generation, occur after 30 min of incubation (Fig. 12F,G). Additional confirmation of a 
dominant negative effect of CLP1 K127A on tRNA processing arose from the corresponding 
kinase assay. The presence of HsCLP1 K127A significantly slowed down the kinetics of 
substrate phosphorylation as compared to untransfected and mock transfected cells  
(Fig. 12D; lanes 3-5, 6-8, and 9-11). Even at the end point (30 min) the substrate was not 
fully phosphorylated when HsCLP1 K127A was overexpressed (Fig. 12D; lane 11). In 
contrast, the presence of excess wild type HsCLP1 speeded up the phosphorylation kinetics 
(Fig. 12D, lanes 12-14). 
However, the dominant negative effect was hardly detectable (if present at all) in 
MEFs. After transfection of HsCLP1 K127A, we prepared nuclear extracts und subjected 
them to pre-tRNA splicing and kinase assays. We were able to observe a mild reduction of 
tRNA exon halves generated in HsCLP1 K127A transfected cells as compared to 
untransfected and mock transfected cells, which is barely visible in Fig. 12B and just 
quantifiable in Fig. 12H. Conversely, we could not detect a dominant negative effect when 
considering the amount of mature tRNA generated in these assays (Fig. 12B,I). The mature 
tRNA levels obtained with HsCLP1 K127A transfected cells even exceed those of mock 
transfected MEFs. In spite of the latter, the dominant negative effect seemed to be 
detectable at least to some extent when assaying for CLP1 kinase activity. In the kinase 
assay, the HsCLP1 K127A sample appeared to display reduced phosphorylation of the 
kinase substrate when compared to untransfected or mock transfected cells (Fig. 12E), 
indicating that overall CLP1 kinase activity is indeed lower but possibly not low enough to 
also affect pre-tRNA processing.  
Despite the unconvincing results obtained with MEFs, we found a clear dominant 
negative effect of CLP1 in pre-tRNA processing in HeLa cells, further supporting the concept 
of CLP1 having an alternative role in this pathway. 
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Fig.12: CLP1 K127A exerts dominant negative Effects on pre-tRNA Processing. (A) The body-labeled intron-
containing S. cerevisiae pre-tRNAPhe was incubated with whole cell extracts prepared from HeLa cells in the 
presence of 2 mM ATP for the times indicated. The cells were transfected with gcDNA 3.1 myc with or without 
inserts as displayed and harvested 48 h later. Pre-tRNA cleavage was monitored by electrophoresis on a 10% 
denaturing polyacrylamide gel and detected by phosphorimaging. Different tRNA fragments are labeled at the 
right. In lane 1, the unspliced pre-tRNAPhe was loaded, representing time 0. (B) Nuclear extracts were prepared 
from CLP1 wild type MEFs transfected with gcDNA 3.1 myc with or without inserts as displayed and harvested  
48 h later. Extracts were assayed as described for (A). (C) Western Blot performed on the extracts used in (A) 
with an antibody directed against c-myc to confirm protein overexpression. (D) Kinase activity was assayed by 
incubating a 3’ labeled 21-nt RNA duplex for the time indicated with the extracts used in (A). Positions of  
5’ phosphorylated (5’ P) and unphosphorylated (5’ OH) duplexes on a 15% denaturing polyacrylamide gel are 
indicated. In lanes 1 and 2, control samples were loaded as size markers. (E) Kinase activity of extracts used in 
(B) was assayed for 60 min as described for (D). (F) Quantification of 5’ and 3’ exon bands in (A); plotted relative 
(in %) to the sum of pre-tRNA at time 0 plus exons. (G) Quantification of mature tRNA bands in (A); plotted 
relative (in %) to the sum of pre-tRNA at time 0 plus mature tRNA. (H) Quantification of 5’ and 3’ exon bands in 
(B); plotted as in (F). (I) Quantification of mature tRNA bands in (B); plotted as in (G). 
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6.4. TSEN2 Immunoprecipitates depleted of ATP exhibit reduced pre-
tRNA Cleavage 
From the results obtained so far, a role of CLP1 in addition to the phosphorylation of the  
5’ hydroxyl of the 3’ exon half required for ligation via the yeast-like pathway as described 
previously (Weitzer and Martinez, 2007b) seemed likely. Since CLP1 needs to bind and 
hydrolyze ATP through its Walker-A and Walker-B motifs for its kinase function, we 
hypothesized that the presence and absence of ATP could also impact on the efficiency of 
tRNA exon generation, potentially explaining the fact that presence and absence of a 
functional CLP1 kinase impact on pre-tRNA cleavage. Hence, we decided to deplete HeLa 
cell extracts of ATP by treatment with apyrase or hexokinase, two ATP-consuming enzymes, 
co-immunoprecipitate the TSEN-CLP1 complex with an antibody directed against HsTSEN2 
and subject the immunoprecipitates to the pre-tRNA splicing assay (Fig. 13A) as described 
before. Strikingly, pre-tRNA cleavage efficiency was greatly reduced in extracts depleted of 
ATP, using both apyrase and hexokinase, as compared to non-depleted extracts (Fig. 13B; 
lanes 10-14 and 15-19 or 20-25 and 25-29, respectively). Since hexokinase treatment 
reduced tRNA exon generation even more efficiently than apyrase treatment (Fig. 13C), we 
used hexokinase for performing the subsequent ATP depletion reactions. However, the 
percentages reflecting the ratio of exon levels to pre-tRNA at 0 min do not reflect the high 
turnover (together with some degradation) achieved in the presence of ATP. Yet, the 
substantial difference in pre-tRNA cleavage observed in presence or absence of ATP 
mimicks and even outmatches the effects observed in MEFs and HeLa cells described 
before, reinforcing that CLP1’s kinase activity significantly affects the efficiency of tRNA exon 
generation by the TSEN proteins. 
 
The observation that ATP is required for efficient tRNA exon generation opened up the 
question whether ATP needs to be present for CLP1 to assemble into the TSEN 
endonuclease complex or whether binding of ATP to CLP1 is sufficient to stimulate pre-tRNA 
cleavage. Thus, we co-immunoprecipitated the TSEN complex from ATP-depleted HeLa cell 
extracts, adding several non-hydrolyzable ATP analogues (Fig. 14A) to the pre-tRNA splicing 
reactions. Already in the input samples, tRNA exon levels were reduced in the absence of 
ATP, reflecting the results obtained in immunoprecipitates (Fig. 14B; lanes 1-4 and 5-8 or  
13-16 and 17-20, respectively). Upon addition of AMPcPP, an ATP analogue with a non-
hydrolyzable α-β phosphodiester bond, the amounts of exons generated were comparable to 
the ones obtained in the presence of ATP (Fig. 14C). In contrast, extracts assayed in the 
presence of AMPPcP, a β-γ non-hydrolyzable ATP analogue, exhibited reduced pre-tRNA 
cleavage (Fig. 14C), suggesting that ATP hydrolysis is an essential event for CLP1’s novel 
function in pre-tRNA cleavage. 
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Another question addressed by Fig. 14 is whether adding ATP back to depleted samples 
after co-immunoprecipitation could restore the amounts of generated exon halves 
comparable to a situation where ATP had always been present, for example as in  
Fig. 13B. Examining lanes 13-16 in Fig. 14A clearly suggests that this is indeed the case, 
although a direct comparison is missing. These results strongly argue against a complete 
disassembly of the pre-tRNA splicing endonuclease complex upon ATP depletion because 
the disintegrated complex components would not stay attached to the immunoprecipitated 
TSEN2 but would probably be lost during the washing steps and thus, it would not be 
possible to restore pre-tRNA cleavage by addition of ATP to the processing reactions. Thus, 
the dissociation of one or more proteins from the complex as a consequence of ATP 
depletion, which reduces pre-tRNA clevage efficiency, appears to be unlikely. 
 
We next asked whether depleting ATP after co-immunoprecipitation of the TSEN-CLP1 
complex, rather than depleting ATP in the input extracts, would provide further evidence for 
an implication of ATP hydrolysis in pre-tRNA cleavage. Whereas the removal of ATP before 
co-immunoprecipitation could affect co-purification efficiency of individual complex 
components, ATP depletion after affinity selection could bring about complex disassembly. 
Although the first results argue against a change of complex composition, we performed 
another TSEN2 affinity selection, followed by ATP depletion with hexokinase on 
immunoprecipitates (Fig. 15A). As expected from our previous results, in the absence of ATP 
pre-tRNA cleavage occurred significantly more slowly (Fig. 15B; lanes 9-12 and 17-20, see 
also in Fig. 15C). Removal of ATP after the TSEN2 affinity selection followed by back-
addition of ATP to the pre-tRNA splicing reactions resulted in exon levels that were 
comparable to those obtained with non-depleted samples (Fig.15B; lanes 9-12 and 13-16, 
and Fig. 15C), again arguing against a disassembly of the complex in the absence of ATP.  
We additionally tested the effect of adding ATP analogues in this experimental setup. 
In contrast to the observations made before (Fig.14), the use of AMPPcP but not AMPcPP 
resulted in higher pre-tRNA cleavage activity (Fig. 15C). This challenges the hypothesis of 
ATP hydrolysis during the endonuclease reaction and supports the necessity of ATP binding 
for efficient pre-tRNA cleavage. However, RNA degradation could have obscured the 
measurements (because only product bands were considered for quantification), rendering 
the graphs obtained from the ATP analogue experiments reliable only to a limited extent. 
Still, the differences in exon amounts in lanes 9 to 20 of Fig. 15B obtained in the presence or 
absence of ATP, are clearly discernible. In contrast, the variation between lanes 21-24 and 
25-28, respectively, is poorly noticeable. Consequently, it remained to be further elucidated 
whether ATP binding or hydrolysis mechanistically explains the effects observed with wild 
type and mutant CLP1. 
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Fig. 13: Depleting TSEN2 Immunoprecipitates of ATP affects the Efficiency of tRNA Exon Generation.  
(A) Schematic representation of the experimental setup. (B) HeLa cell extract was depleted of ATP with 0.05 U/ml 
apyrase (in the presence of 4 mM CaCl2) or 10 U/ml hexokinase (in the presence of 5 mM glucose) and co-
immunoprecipitated with an antiserum directed against HsTSEN2 or preimmune serum as a control as indicated. 
The immunoprecipitates or untreated extract (Input) were incubated with the body-labeled intron-containing  
S. cerevisiae pre-tRNAPhe and 2 mM ATP as indicated. Pre-tRNA cleavage was monitored by electrophoresis on 
a 10% denaturing polyacrylamide gel and detected by phosphorimaging. Different tRNA fragments are labeled at 
the right. (C) Quantification of 5’ and 3’ exon bands in (B); plotted relative (in %) to the sum of pre-tRNA at time 0 
plus exons. 
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Fig. 14: TSEN2 Immunoprecipitates seem to require a β-γ  hydrolyzable ATP for efficient pre-tRNA 
Cleavage. (A) Basic structures of AMPcPP (upper panel) and AMPPcP (lower panel). Figures taken from Jena 
Bioscience product data sheet. (B) HeLa cell extract was depleted of ATP with 10 U/ml hexokinase (in the 
presence of 5 mM glucose) and co-immunoprecipitated with an antiserum directed against HsTSEN2 or 
preimmune serum as a control as indicated. The immunoprecipitates or whole cell extract (Input) were incubated 
with the body-labeled intron-containing S. cerevisiae pre-tRNAPhe. 2 mM ATP, AMPcPP, or AMPPcP were 
included as indicated. Pre-tRNA cleavage was monitored by electrophoresis on a 10% denaturing polyacrylamide 
gel and detected by phosphorimaging. Different tRNA fragments are labeled at the right. (C) Quantification of  
5’ and 3’ exon bands in (B); plotted relative (in %) to the sum of pre-tRNA at time 0 plus exons. 
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Fig. 15: Pre-tRNA Cleavage can be restored after ATP Depletion and Co-Immunoprecipitation.  
(A) Schematic representation of the experimental setup. (B) HeLa cell extract was co-immunoprecipitated with an 
antiserum directed against HsTSEN2 or preimmune serum as a control as indicated. The immunoprecipitates 
were then depleted of ATP with 10 U/ml hexokinase (in the presence of 5 mM glucose) on the beads and 
incubated with the body-labeled intron-containing S. cerevisiae pre-tRNAPhe and 2 mM ATP, AMPcPP, or 
AMPPcP as indicated. Untreated extracts served as control. Pre-tRNA cleavage was monitored by 
electrophoresis on a 10% denaturing polyacrylamide gel and detected by phosphorimaging. Different tRNA 
fragments are labeled at the right. The asterisks (*) indicate unspecific bands unrelated to pre-tRNA splicing.  (C) 
Quantification of 5’ and 3’ exon bands in (B); plotted relative (in %) to the sum of pre-tRNA at time 0 plus exons. 
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6.5. Excess free Mg2+ does not fully explain the ATP-mediated 
Differences in Exon Generation 
ATP is known to chelate Mg2+ much more strongly than ADP (O'Sullivan and Perrin, 1964). 
Thus, lack of ATP or ATP depletion by hexokinase releases Mg2+ into the buffer. Yoda et al. 
(Yoda et al., 2010) refer to unpublished data showing that excess free Mg2+ can inhibit 
cleavage efficiency of the RNA-induced silencing complex (RISC), which would explain the 
enhancing effect of ATP on target mRNA cleavage. Since those facts might provide an 
explanation for the ATP-mediated differences in pre-tRNA cleavage we observed previously, 
we tested this hypothesis by adding excess MgCl2 or EDTA as Mg2+ chelator to pre-tRNA 
splicing reactions. However, since we used cell extracts for the assay, final Mg2+ 
concentrations in the reactions could not be determined.  
Apart from the reproducible reduction of pre-tRNA cleavage activity in the absence of 
ATP (Fig. 16A; lanes 1-5 and 6-10), we found that adding EDTA to HeLa cell extracts in 
absence of ATP diminished exon generation to a similar extent as depletion of ATP  
(Fig. 16A; lanes 6-10, 11-15, and 16-10). Prior to the addition of EDTA, we treated the cell 
extracts with hexokinase to induce the described release of bound Mg2+, and omitted ATP 
from the buffer. Adding increased amounts of EDTA leading to lower free Mg2+ concentration 
reduced the pre-tRNA cleavage activity (Fig. 16B). Thus, the removal of free Mg2+ by addition 
of 20 mM EDTA interferes with exon generation more pronouncedly than do lower amounts 
of EDTA, where more released Mg2+ is still available in the buffer. However, addition of 
EDTA to cleavage reactions could not abolish the stimulatory effect of ATP on pre-tRNA 
cleavage (Fig. 16A; lanes 6-10), suggesting that Mg2+ could, in addition to the lack of ATP, 
play an inhibitory role in pre-tRNA cleavage.   
In addition to administering EDTA to extracts depleted of ATP, we also added excess 
MgCl2 to untreated extracts in the presence of ATP. Both MgCl2 concentrations reduced 
exon generation less efficiently than depletion of ATP, whereby higher Mg2+ concentrations 
caused a stronger decrease of cleavage activity (Fig. 16B). These results are consistent with 
previous observations (Yoda et al., 2010) but since the levels of exon halves generated in 
the presence of ATP and excess Mg2+ are still significantly higher than in the absence of ATP 
(Fig. 16B), the amount of available Mg2+ alone cannot account for the reduction of pre-tRNA 
cleavage activity in the absence of ATP. 
Taken together, these results illustrate that elevated or reduced Mg2+ concentrations 
can interfere with pre-tRNA cleavage to a certain extent in our assay. Furthermore, in 
addition to ATP, a certain amount of Mg2+ seems to be required for efficient exon generation 
in addition to ATP.  
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Fig. 16: Excess of free Mg2+ does not fully explain the ATP-mediated Differences in Exon Generation.  
(A) The body-labeled intron-containing S. cerevisiae pre-tRNAPhe was incubated with HeLa cell extracts in the 
presence of 2 mM ATP for the times indicated. Where marked, extracts were depleted of ATP with 10 U/ml 
hexokinase (in the presence of 5 mM glucose) and MgCl2 or EDTA were added in indicated amounts. Pre-tRNA 
cleavage was monitored by electrophoresis on a 10% denaturing polyacrylamide gel and detected by 
phosphorimaging. Different tRNA fragments are labeled at the right. The asterisks (*) indicate unspecific bands 
unrelated to pre-tRNA splicing. (B) Quantification of 5’ and 3’ exon bands in (A); plotted relative (in %) to the sum 
of pre-tRNA at time 0 plus exons. 
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6.6. A semi-purified CLP1-TSEN Complex requires a β-γ  hydrolyzable 
NTP for efficient pre-tRNA Cleavage 
In order to obtain clearer results enabling to differentiate between binding and hydrolysis of 
ATP and to exclude interference by turnover or degradation frequently experienced in 
experiments with co-immunoprecipitations or crude cell extracts, we decided to use a semi-
purified CLP1-TSEN complex. We purified wild type or mutant MmCLP1 fused to a TAP-tag 
at its N-terminus (Fig. 17A) from stable overexpression HEK293 cell lines (gifts from Tilmann 
Bürckstümmer, CeMM, Vienna). We also generated HeLa cell lines stably overexpressing 
wild type and mutant NTAP-HsCLP1 as described (Burckstummer et al., 2006) and depicted 
in Fig. 17A.  
Throughout the purification of the wild type or K127A CLP1-TSEN complexes, we 
analyzed aliquots by pre-tRNA splicing and kinase assays and Western blotting  
(Fig. 17B,C,D). Since we lost the pre-tRNA cleavage and kinase activities (Fig. 17B; right 
panel, lanes 13-18, and Fig. 17C; right panel, lanes 9-11) after the second purification step 
(elution from the Streptavidin Magnetic Particles), we decided to do only one-step 
purifications for the following assays. We could again confirm the difference in pre-tRNA 
cleavage activity between wild type and K127A CLP1-containing TSEN complexes. At each 
purification step, the exon half generation was hardly detectable in affinity purifications of 
tagged MmCLP1 K127A, whereas cleavage occurred to a much higher level in TSEN 
complexes containing tagged wild type MmCLP1 (Fig. 17B). Mutant and wild type input 
samples showed comparable pre-tRNA cleavage activities due to the presence of untagged 
wild type CLP1 (Fig. 17B; lanes 1-6). The same findings apply to the phosphorylation of 
dsRNA substrates in the kinase assays (Fig. 17C).  
The purification steps were also followed on Western blots (Fig 17D). Before elution 
from the IgG Sepharose, the Protein G tag cross-reacted with the secondary antibody  
(Fig. 17D; lanes 1-9); in later steps, we detected the complex with an antibody against 
MmCLP1 (Fig. 17D; lanes 10-18). Since expression of NTAP-MmCLP1 K127A was lower 
than that of the wild type, we adjusted the amount of input cells accordingly for the following 
purifications. The size difference between the wild type and K127A protein (Fig. 17D; lanes 8 
and 9) arises from the absence of an additional myc-tag in the wild type construct. 
 
In HeLa cells, the stable overexpression of wild type and K127A NTAP-HsCLP1 was 
monitored by Western blotting in extracts of unsorted (Fig.18A) and GFP-sorted (Fig. 18B) 
cells enriched for the presence of the expression vector that harbors the GFP gene. After 
purification of the wild type or K127A NTAP-HsCLP1 together with their interactors, we were 
able to examine the differences in pre-tRNA cleavage and kinase activities between wild type 
and K127A NTAP-CLP1 complexes in more detail. Strikingly, pre-tRNA cleavage was almost 
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completely abolished when NTAP-CLP1 K127A was used as a bait (Fig. 18C; lanes 12-16, 
and Fig. 18D; lanes 11-13). Further, we confirmed the absence of CLP1 kinase activity from 
the CLP1 K127A semi-purified complexes (Fig. 18E,F). For NTAP-MmCLP1 we could not 
validate equal protein levels in the TEV eluate due to the absence of a myc-tag mentioned 
earlier (Fig. 18G). However, NTAP-HsCLP1 wild type and K127A are present in equal 
amounts in the input samples (Fig. 18H), ruling out that unequal amounts of CLP1 caused 
the differences in exon generation.  
In addition to the NTAP-CLP1 cell lines, we created HeLa cells stably overexpressing 
NTAP-HsTSEN2, which were used to purify the CLP1-TSEN complex via a different complex 
component. The expression levels of NTAP-TSEN2 were lower than the ones observed for 
the NTAP-CLP1 proteins (Fig. 18H), which might explain the reduced pre-tRNA cleavage in 
comparison to NTAP-HsCLP1 wild type (Fig. 18D). Accordingly, RNA phosphorylation 
activity was also lower (Fig. 18F). However, NTAP-TSEN2 complexes exhibited considerably 
higher pre-tRNA cleavage and RNA kinase activities than NTAP-CLP1 K127A complexes, 
again suggesting that CLP1 kinase modulates pre-tRNA cleavage efficiency by the TSEN 
proteins. 
In order to determine the number of proteins contained after the one-step purification 
and to confirm the presence of all four TSEN proteins in the TEV eluates to rule out that the 
lack of one or more of them in NTAP-HsCLP1 K127A complexes caused the reduction of 
pre-tRNA cleavage activity, we analyzed the TEV eluates by mass spectrometry. The 
analysis detected and identified about 270 different proteins in the NTAP-HsCLP1 wild type 
and K127A TEV eluates, among them HsTSEN2, HsTSEN34, HsTSEn54, and HsTSEN15 
(see Appendix). 
Since the semi-purified NTAP-CLP1 complexes were suitable for comparing CLP1 
wild type and K127A, we also wanted to examine the cofactor requirements for efficient pre-
tRNA cleavage. Therefore, we incubated the NTAP-CLP1 wild type TEV eluates with 
different NTPs, ADP, AMP, and the non-hydrolyzable ATP analogues AMPcPP, AMPPcP, 
and AMPPnP. Fig. 19A and B clearly show that the NTAP-MmCLP1 complex can execute 
efficient pre-tRNA cleavage in the presence of ATP, AMPcPP, and GTP, whereas exon 
generation is drastically reduced with the β-γ non-hydrolyzable analogues AMPcPP and 
AMPPnP, ADP, AMP, and without any other NTP. These results support the previous 
hypothesis that ATP (or GTP) hydrolysis by CLP1 impacts on its role in pre-tRNA splicing. 
We repeated the experiment with NTAP-HsCLP1 complexes and included additional 
NTPs in the assay. However, the results displayed in Fig. 19C and D are less defined in 
comparison to the NTAP-MmCLP1 complex. Nevertheless, it is discernible that pre-tRNA 
cleavage occurs efficiently in the presence of GTP, UTP, and ATP. Moreover, the exon 
levels generated with AMPcPP are still significantly higher than the ones generated in the 
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presence of AMPPcP. The amount of exon halves produced in the presence of ADP is in 
between highest and lowest levels, and CTP and AMP show effects similar to the complete 
absence of any NTP. Although the results obtained using the human NTAP-CLP1 were not 
completely defined, they still are in accordance with the previous observations and support 
that ATP hydrolysis is a crucial event for CLP1’s novel role in pre-tRNA processing. Table 14 
summarizes the impact of different cofactors on pre-tRNA cleavage by the mouse and 
human CLP1-TSEN complex. 
 
 NTAP-MmCLP1 NTAP-HsCLP1 
ATP efficient efficient 
GTP efficient efficient 
UTP not tested efficient 
CTP not tested inefficient 
ADP inefficient average 
AMP inefficient inefficient 
AMPcPP efficient efficient 
AMPPcP inefficient inefficient 
AMPPnP inefficient not tested 
no NTP inefficient inefficient 
         Table 14: Pre-tRNA Cleavage Efficiency in the Presence of various Cofactors. See text for details. 
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Fig. 17: A semi-purified MmCLP1-TSEN Complex is functional in pre-tRNA Cleavage and shows Kinase 
Activity. (A) Schematic representation of the N-terminally TAP-tagged CLP1 wild type/K127A or TSEN2 proteins. 
For purification, the protein G moiety is bound to IgG sepharose. The protein is then eluted by cleavage with the 
TEV protease at its specific site introduced C-terminally to the protein G tag. For a second purification step, the 
streptavidin binding peptide (SBP) was bound to streptavidin magnetic particles and eluted by competitive binding 
to biotin. The TAP constructs, except for NTAP-MmCLP1, also contain a myc-tag that was used for Western blot 
detection. (B) Aliquots (not normalized for total protein concentration) were taken at single purification steps as 
labeled (Input = cleared cell lysate; untransf. = untreated HEK 293 cells) and assayed for their pre-tRNA cleavage 
capacity by incubating them with the body-labeled intron-containing S. cerevisiae pre-tRNAPhe for the times 
indicated. Pre-tRNA cleavage was monitored by electrophoresis on a 10% denaturing polyacrylamide gel and 
detected by phosphorimaging. Left panel: first purification step; right panel: second purification step plus Input as 
control. Different tRNA fragments are labeled in between. (C) Kinase activity was assayed by incubating a  
3’ labeled 21-nt RNA duplex for the time indicated with the samples taken for (B). Positions of 5’ phosphorylated 
(5’ P) and unphosphorylated (5’ OH) duplexes on a 15% denaturing polyacrylamide gel are indicated. In lanes 1 
and 2, control samples were loaded as size markers. Left panel: first purification step; right panel: second 
purification step plus Input as control. (D) Western blots following the single purification steps. In lanes 1-9, the 
protein G moiety cross-reacts with the secondary antibody against rabbit IgG; in lanes 10-18, an antibody directed 
against MmCLP1 was used for detection. 
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Fig. 18: The semi-purified NTAP-CLP1 K127A-TSEN Complex exhibits reduced pre-tRNA Cleavage 
Activity. (A) Western blot confirming stable overexpression of the TAP-tagged proteins as indicated before 
sorting of GFP-positive cells. GFP is expressed from all cells with randomly integrated pRV-NTAP plasmids. In 
the first cell lines (left panel), the myc-tag was missing in NTAP-HsCLP1 and HsTSEN2 cells died. Thus, a 
second round of cell lines was performed (right panel). Detection was performed with the secondary antibody 
against rabbit IgG cross-reacting with the protein G tag. (B) Western blot confirming stable overexpression of the 
TAP-tagged proteins as indicated after sorting of GFP-positive cells. NTAP-HsCLP1 wild type contains the  
myc-tag; NTAP-HsTSEN2 sample is from the second cell line. Detection as in (A). (C) The body-labeled intron-
containing S. cerevisiae pre-tRNAPhe was incubated with NTAP-MmCLP1 wild type and K127A TEV eluates in the 
presence of 2 mM ATP for the times indicated. TEV eluates from untreated HEK 293 cells (untransfected) were 
used as a control. Pre-tRNA cleavage was monitored by electrophoresis on a 10% denaturing polyacrylamide gel 
and detected by phosphorimaging. Different tRNA fragments are labeled at the right. (D) NTAP-HsCLP1 wild type 
and K127A and NTAP-HsTSEN2 TEV eluates were assayed as in (C). TEV eluates from HeLa cells stably 
expressing the pRV-NTAP vector without insert (empty vector) were used as a control. Different tRNA fragments 
are labeled at the left. (E) Kinase activity was assayed by incubating a 3’ labeled 21-nt RNA duplex for 60 min 
with the eluates used in (C) (Input = cleared cell lysates). Positions of 5’ phosphorylated (5’ P) and 
unphosphorylated (5’ OH) duplexes on a 15% denaturing polyacrylamide gel are indicated. In lanes 1 and 2, 
control samples were loaded as size markers. (F) Kinase activity of eluates used in (D) was assayed for the time 
indicated as described for (E). (G,H) Western blots confirming protein amounts in Input (= cleared cell lysates) 
and TEV eluates used for (C)-(F) detected with an antibody against the myc-tag that is missing in NTAP-MmCLP1 
wild type (G; lane 2). The asterisks (*) mark bands stained unspecifically. 
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Fig. 19: The semi-purified CLP1-TSEN Complex requires a β-γ  hydrolyzable ATP for efficient pre-tRNA 
Cleavage. (A) The body-labeled intron-containing S. cerevisiae pre-tRNAPhe was incubated with NTAP-MmCLP1 
wild type TEV eluate in the presence of 2 mM ATP or other nucleotides and non-hydrolyzable analogues as 
labeled for the times indicated. Pre-tRNA cleavage was monitored by electrophoresis on a 10% denaturing 
polyacrylamide gel and detected by phosphorimaging. Different tRNA fragments are labeled at the right.  
(B) Quantification of 5’ and 3’ exon bands in (A); plotted relative (in %) to the sum of pre-tRNA at time 0 plus 
exons. (C) NTAP-HsCLP1 wild type TEV eluate was assayed as described for (A). (D) Quantification of 5’ and  
3’ exon bands in (C); plotted as in (B). 
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6.7. Specific Inhibition of CLP1 decreases pre-tRNA Cleavage 
Efficiency 
Previously, a specific small molecule inhibitor for the kinase activity of CLP1 was obtained by 
screening a compound library (Frank Büttner, Boehringer Ingelheim Biberach, unpublished 
results). 6 compounds out of about 26000 displayed inhibitory activity on a recombinantly 
expressed HsHis6-CLP1 and were further tested in our laboratory. In these experiments, 
BIBT2797SE turned out to be the most potent inhibitor of HsCLP1 (Stefan Weitzer, 
unpublished results).  
Upon further examination of the optimal reaction conditions in the standard kinase 
assay, optimal inhibition was observed at 1 mM BIBT2797SE (subsequently referred to as 
“inhibitor”) and 10 µM ATP (Fig. 20A). At higher ATP concentrations, the inhibitor was 
significantly less efficient (Fig. 20A). We hypothesized that specific inhibition of CLP1’s 
kinase activity would decrease pre-tRNA cleavage as does CLP1 K127A. However, the 
standard ATP concentration in the pre-tRNA splicing assay is 2 mM, thus, we first had to 
figure out how much ATP was needed to obtain reasonable exon levels. ATP titration 
experiments (Fig. 20B) showed that exon generation still occurred at sufficient rates when 
lowering the ATP concentration from 2 mM to 10 µM (Fig. 20B; lane 7). At lower 
concentrations of ATP, pre-tRNA cleavage was almost undetectable (Fig. 20B; lanes 8-10). 
Consequently, we decided to use 10 µM ATP in our inhibitor assays.   
We incubated the NTAP-HsCLP1 TEV eluate with the pre-tRNA substrate and ATP at 
two concentrations of inhibitor, which, remarkably, resulted in a significant reduction of exon 
halves generated (Fig. 20C). The effect was rather mild when adding 10 µM inhibitor but 
became significantly stronger in the presence of 100 µM inhibitor (Fig. 20D). In the 
corresponding kinase assay (Fig. 20E), the inhibition is barely detectable and only visible 
after 60 min of incubation at a concentration of 100 µM inhibitor (Fig. 20E; lane 11). The fact 
that the inhibitor specifically interferes with CLP1’s kinase activity further supports the idea 
that CLP1 together with the TSEN proteins carries out pre-tRNA cleavage enhancing the 
endonucleolytic activity of the complex. 

 _______________________________________________________________________________________ 101 
 
Fig. 20: Specific Inhibition of CLP1’s Kinase Activity results in a Decrease in tRNA Exon Generation.  
(A) Kinase activity of cytoplasmic HeLa cell extract (1 mg/ml) was assayed by incubating a 3’ labeled 21-nt RNA 
duplex 60 min in the presence of ATP and BIBT2797SE (“inhibitor”) as indicated. Positions of 5’ phosphorylated 
(5’ P) and unphosphorylated (5’ OH) duplexes on a 15% denaturing polyacrylamide gel are indicated. In lane 1, 
the RNA duplex was loaded without extract. Data by Stefan Weitzer. (B) The body-labeled intron-containing  
S. cerevisiae pre-tRNAPhe was incubated with NTAP-HsCLP1 wild type TEV eluate in the presence of different 
ATP concentrations. Pre-tRNA cleavage was monitored by electrophoresis on a 10% denaturing polyacrylamide 
gel and detected by phosphorimaging. Different tRNA fragments are labeled at the right. (C) The NTAP-HsCLP1 
wild type TEV eluate was assayed for pre-tRNA cleavage in the presence of 10 µM ATP and/or inhibitor as 
indicated. In the reactions without inhibitor, the inhibitor solvent DMSO was added in respective amounts. Exon 
generation was monitored and detected as in (B). (D) Quantification of 5’ and 3’ exon bands in (C); plotted relative 
(in %) to the sum of pre-tRNA at time 0 plus exons. (E) Kinase activity was assayed by incubating a 3’ labeled  
21-nt RNA duplex 60 min with the samples used in (C). Positions of 5’ P and 5’ OH duplexes are indicated. In 
lanes 1 and 2, control samples were loaded as size markers. 
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6.8. Can CLP1 K127A still bind and hydrolyze ATP? 
In order to test whether there is a link between the RNA kinase activity of CLP1 and the 
requirement of ATP hydrolysis for efficient pre-tRNA cleavage, we tried to characterize the 
ability of CLP1 K127A to bind and/or hydrolyze ATP. For this purpose, we expressed 
recombinant wild type and K127A GST-HsCLP1 in E. coli and purified it via Glutathione 
Sepharose (Fig. 21A,B). Both eluates were enriched for proteins of the correct size, but a 
significant amount of the protein was still bound to the affinity matrix after elution. Moreover, 
some proteins of lower molecular weight, most likely degradation products, were still present 
in the eluates (Fig. 21A,B; lanes 9-11). Nonetheless, in both GST-HsCLP1 wild type eluates 
we could detect significant kinase activity, which was absent in the GST-HsCLP1 K127A 
eluates (Fig. 21C).  
We further used the recombinant proteins for a kinase assay performed in a smaller 
reaction volume in the presence of [α-32P]-ATP. We separated the reaction products, 
supposedly ATP converted to ADP, by thin layer chromatography. All ATP was apparently 
converted to ADP (Fig. 21D), when both wild type and mutant CLP1 were added. However, 
the intensity of the ADP signal obtained upon addition of GST-HsCLP1 K127A but not wild 
type enzyme was greatly reduced (Fig 21D; lane 8). These results leave several questions 
unanswered, but, at first glance, indicate that CLP1 K127A is not deficient in ATP hydrolysis. 
Further characterization of the mutant CLP1 proved difficult because several ATP-protein 
crosslinking experiments and ATP hydrolysis assays failed for technical reasons (see 
Appendix). 
 
6.9. Do ATP Depletion and CLP1 K127A affect TSEN Complex 
Architecture? 
A possible explanation for the decrease of pre-tRNA cleavage activity detected upon ATP 
depletion or mutation of CLP1 could be that the assembly of the TSEN complex is inhibited 
or that its disassembly is promoted in a manner dependent on CLP1 and ATP. 
To address this question, we separated extracts obtained from HeLa cells 
overexpressing myc-TSEN2 or myc-TSEN15 (Fig. 22A) by centrifugation in glycerol 
gradients. After centrifugation and fractionation of the gradients, the tagged proteins were 
detected by Western blotting. For myc-TSEN2, the peak shifted from fractions 2 and 3  
(Fig. 22B; upper panel) to fractions 3 and 4 upon treatment of the sample with hexokinase 
(Fig. 22B; lower panel). For the myc-TSEN15 extracts, a similar shift from fraction 6 to 5 was 
observed (Fig. 22C). However, we considered these marginal changes to be too insignificant 
to account for a change in complex architecture. We further confirmed the results presented 
in Fig. 22A-C by separating ATP-depleted and non-depleted HeLa cell extract (without 
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overexpressed proteins) by centrifugation in glycerol gradients. Again, the shift of HsTSEN2 
(detected with an antibody raised against the protein) from fractions 8 and 9 (Fig. 22D; upper 
panel) to fractions 6 and 7 upon hexokinase treatment (Fig. 22D; lower panel) was 
considered to be insignificant again. From these data we concluded that ATP depletion does 
not induce a change of TSEN complex structure. 
Mass spectrometry analysis of NTAP-HsCLP1 wild type and K127A TEV eluates 
revealed that all four TSEN proteins were present both in wild type and mutant samples (see 
Appendix). Since the peptide counts for the proteins identified in the TEV eluates do not 
strictly correlate with the actual protein amount contained in the samples, we additionally 
examined the NTAP-HsCLP1 wild type and K127A TEV eluates by Western blotting, probing 
with antibodies directed against HsTSEN2, HsTSEN34, and HsTSEN54. To our surprise, the 
amount of all three TSEN proteins was much lower in the NTAP-HsCLP1 K127A sample, 
although NTAP-CLP1 amounts were similar as detected by Western blotting probing for the 
myc-tag (Fig. 22E). This finding severely challenges the data obtained from glycerol gradient 
centrifugations and also questions the hypothesis that the cleavage deficiency is not the 
consequence of a change in complex architecture. 
 
6.10. Could the TSEN Proteins be posttranslationally modified? 
On our Western blots, we noticed that HsTSEN2 seemed to migrate at a size larger than 
expected during SDS-PAGE. Therefore, we hypothesized that HsTSEN2 could carry 
posttranslational modifications, such as phosphate groups on serine or tyrosine residues. In 
support of this idea, HsTSEN2 and HsTSEN54 have been detected in a screen for putative 
substrates of two protein kinases involved in the DNA damage response, ATM (ataxia 
telangiectasia mutated) and ATR (ATM and Rad3-related) (Matsuoka et al., 2007). In order 
to find out whether HsTSEN2 present in the NTAP-HsCLP1 wild type TEV eluate was 
phosphorylated, we incubated the eluate with alkaline phosphatase or lambda protein 
phosphatase prior to analysis by Western blotting. 
Remarkably, we could indeed detect a change in the migration behavior on  
10% SDS-PAA gels upon phosphatase treatment (Fig. 22E; left panel). Furthermore, double 
bands seen for untreated eluates merged to one lower band after phosphatase addition on a 
7.5% SDS-PAA gel (Fig. 22E; right panel). These data suggest that HsTSEN2 is 
phosphorylated at probably more than one residue because the shift is rather prominent. 
Whether HsTSEN54 and the other TSEN proteins also carry phosphate groups in our eluates 
and their potential physiological roles are interesting questions to be investigated in the 
future. 
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Fig. 21: Recombinantly expressed CLP1 shows Kinase Activity and hydrolyzes ATP. (A,B) Purification of 
GST-tagged HsCLP1 wild type (A) and K127A (B) from E. coli. The single purification steps were followed by 10% 
SDS-PAGE and Coomassie staining of aliquots. Uninduced = bacterial extract before IPTG induction; induced = 
bacterial extract after IPTG induction; Input pull down = cleared bacterial lysate before loading onto glutathione 
sepharose; Flow-through = remaining supernatant after protein binding to glutathione sepharose; Wash 1 and 
Wash 2 = flow-through after pull down; Wash 3 = flow-through after transfer to chromatography column; Eluate 1 
and Eluate 2 = purified protein eluted from the sepharose with reduced glutathione; Beads = remaining 
glutathione sepharose after elution. Protein sizes (in kDa) of a marker mix are indicated. (C) The protein eluates 1 
and 2 from (A) and (B) were concentrated about 10-fold and assayed for their kinase activity by incubating them 
60 min with a 3’ labeled 21-nt RNA duplex. Positions of 5’ phosphorylated (5’ P) and unphosphorylated (5’ OH) 
duplexes on a 15% denaturing polyacrylamide gel are indicated. In lanes 1 and 2, control samples were loaded as 
size markers. (D) A kinase assay was performed with concentrated (approx. 0.5 mg/ml) protein eluates 2 from (A) 
and (B) or T4 polynucleotide kinase and [α-32P]-ATP in the presence of a cold 21-nt RNA duplex as indicated.  
[α-32P]-ATP or –ADP were separated by TLC on a HPTL cellulose plate. As size markers, [α-32P]-ATP and 3.5 
mM ATP and ADP were used; the latter were visualized under UV light and their positions were marked. 
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Fig. 22: Investigating CLP1-TSEN Complex Stability and Phosphorylation Status. (A) Western blot 
confirming overexpression of myc-HsTSEN2 and myc-HsTSEN15. (B, C) Extracts from HeLa cells transfected 
with gcDNA 3.1 myc + HsTSEN2 (B) or HsTSEN15 (C) were incubated with hexokinase (lower panels) or left 
untreated (upper panels) and separated on a 5%-20% glycerol gradient. 12 fractions were taken, proteins were 
precipitated with acetone, and examined on Western blots using an antibody directed against c-myc. Fraction 
numbers and approximate protein sizes of samples are indicated (Input = HeLa extract before gradient run), as 
well as fraction numbers, sizes, and sedimentation coefficient (S) of standard proteins included in the gradient 
centrifugation. (D) HeLa cell extracts were incubated with hexokinase (lower panel) or left untreated (upper panel) 
and separated on a 5%-15% glycerol gradient. 13 fractions were taken, proteins were precipitated with acetone, 
and examined on Western blots using an antibody directed against HsTSEN. Fraction numbers and protein sizes 
of samples and standards are indicated as in (B, C). (E) NTAP-HsCLP1 wild type and K127A TEV eluates were 
examined on Western blots with antibodies directed against c-myc, HsTSEN2, HsTSEN34, and HsTSEN54 (all 
three by Gramsch Laboratories). (F) NTAP-HsCLP1 wild type TEV eluate was treated with alkaline phosphatase 
or lambda protein phosphatase and then examined on Western blots after 10% (left panel) or 7.5% (right panel) 
SDS-PAGE. BSA was included as indicated to equalize protein amounts in all samples. Detection was performed 
with an antibody directed against HsTSEN. 
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6.11. Could CLP1 have additional Protein Kinase Activity? 
An alternative explanation accounting for the differences in pre-tRNA cleavage efficiency 
observed with mutant and wild type CLP1 is that CLP1, in addition to its function as an RNA 
kinase, also phosphorylates proteins. Although this seems unlikely, CLP1 could 
phosphorylate the TSEN proteins and, as a consequence, modify TSEN complex structure 
and/or activity. Thus, the reduced exon generation in the presence of CLP1 K127A could be 
explained. 
 In a preliminary experiment, we incubated the NTAP-HsCLP1 wild type and K127A 
TEV eluates with [γ-32P]-ATP and analyzed the samples by SDS-PAGE. Interestingly, we 
could detect some differences between the patterns obtained with CLP1 wild type and 
K127A samples (Fig. 23), especially at approximately 30 kDa (Fig. 23A) and 22 kDa  
(Fig. 23B). The bands are present in CLP1 wild type samples but are absent in incubations 
with the mutant, allowing speculation about putative protein kinase substrates of the RNA 
kinase CLP1. The differences between presence and absence of non-radioactive pre-tRNA 
as a substrate for the TSEN-CLP1 complex are small. However, we cannot rule out that 
RNAs contained in the samples are phosphorylated and explain some of the bands. In any 
case, further experiments are needed to confirm the preliminary data presented here. 
 
 
Fig. 23: Investigating potential CLP1 Protein Kinase Activity. (A, B) A pre-tRNA splicing assay buffer was 
supplemented with [γ-32P]-ATP and cold S. cerevisiae pre-tRNAPhe as indicated. NTAP-HsCLP1 wild type or 
K127A TEV eluates were added as indicated. After incubation, the reactions were separated on 10% (A) or 15% 
(B) SDS-PAA gels and bands were visualized by phosphorimaging. Protein sizes (in kDa) are indicated at the left.
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7. Discussion 
Intron-containing pre-tRNAs are conserved throughout the kingdoms of life; thus, intron 
removal and exon half ligation to produce mature tRNAs are essential biological processes. 
Previous work has identified most of the proteins involved in tRNA splicing and has 
elucidated the corresponding biochemical mechanisms, both in S. cerevisiae and 
vertebrates. For the human RNA kinase CLP1, a function restricted to the postulated yeast-
like pre-tRNA maturation pathway in humans was assigned. However, our data suggest that 
CLP1 does not only perform the unique 3’ exon phosphorylation that prepares the exon for 
the subsequent ligation but that its kinase activity is additionally required to enhance pre-
tRNA cleavage by the TSEN complex. Therefore, CLP1 seems to play a bifunctional role in 
pre-tRNA processing. 
 
7.1. Requirement of CLP1 Kinase Activity for efficient tRNA Exon 
Generation 
Our investigation of CLP1 kinase-dead MEFs resulted in the discovery of a significant 
reduction in tRNA exon levels as compared to wild type cells (Fig. 9). This result explains 
previous findings made in CLP1 deficient mouse cells in which pre-tRNA cleavage also was 
greatly reduced (Fig. 8) and indicates that the kinase activity of CLP1 (and not only the 
presence of the protein) is specifically responsible for this effect. This interesting finding was 
confirmed by siRNA mediated depletion of CLP1 in HeLa cells resulting in clearly decreased 
pre-tRNA cleavage activity (Fig. 10). Besides the less efficient generation of exon halves, the 
levels of mature tRNA are reduced in both experimental systems. This effect is in 
accordance with data obtained in the course of the initial identification and characterization of 
CLP1 (Weitzer and Martinez, 2007b). Thus, the putative bifunctional role of CLP1 adds an 
additional layer of complexity to the original findings since the reduction in exon levels was 
not observed at that time.  
Interestingly, the decrease of mature tRNA generation we observed upon interference 
with CLP1 activity is even more prominent than the changes detected for exon half 
generation. However, this can be explained by the addition of two negative effects, one 
upstream of the other. Therefore, the decline in mature tRNA generated reflects both the 
reduction in pre-tRNA cleavage and probably the defect in ligation due to missing 3’ exon 
phosphorylation.  
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Further evidence for a regulatory role of CLP1 during pre-tRNA cleavage arises from the fact 
that we could, at least to a certain extent (Fig. 10B,C), rescue the deficiency in exon 
generation by transient overexpression of wild type CLP1 in trans (Fig. 9 and 10). Wild type 
levels of exon generation could not be restored, explicable by decreased transfection 
efficiency and inefficient incorporation of ectopically expressed CLP1 into the endogenous 
TSEN complex. However, the rescue is clearly detectable for kinase activity of CLP1 (Fig. 9E 
and 10E). The presence of additional CLP1 activity in HeLa cells RNAi depleted of CLP1 
even elevates the rate of substrate phosphorylation to levels above wild type (Fig. 10E). 
In addition to the two Walker-A domain mutants (K127A and S128A) generated and 
used in previous experiments (Ramirez et al., 2008; Weitzer and Martinez, 2007b), we 
created several additional mutated versions of CLP1 harboring point mutations both inside 
and outside of the Walker-A and Walker-B motifs to identify the domains responsible for the 
reduction of tRNA exon generation. Some of the mutants (see Fig. 5 for positional 
information) have already been characterized in yeast and archeal CLP1 homologs (Jain and 
Shuman, 2009; Ramirez et al., 2008) or are supposed to influence structure or activity based 
on structural analysis of yeast CLP1 (Noble et al., 2007). Other mutations were introduced to 
serve as negative controls. Upon overexpression of mutant CLP1 proteins both in HeLa cells 
and MEFs, we could not obtain clear results, neither regarding pre-tRNA cleavage nor kinase 
activity (see Appendix). Thus, these results need to be refined in the future. 
 
7.2. Dominant Negative Effect of CLP1 K127A in pre-tRNA Cleavage 
The K127A mutation in CLP1 does not only cause a reduction of pre-tRNA cleavage activity 
in a background where wild type CLP1 is absent (knock-in mouse cells) but can also exert a 
dominant negative effect over the wild type protein. CLP1 K127A overexpression reduced 
pre-tRNA cleavage despite the presence of endogenous wild type CLP1. The effect is 
evident in HeLa cells (Fig. 12A,F). Furthermore, we again detected decreased mature tRNA 
levels. In accordance to the addition of inhibitory effects described previously, the dominant 
negative effect is more prominent at the level of mature tRNA generation, further supporting 
the dual function of CLP1 in pre-tRNA processing (Fig. 12A,G). However, with respect to 
kinase activity of CLP1, a dominant negative effect is barely detectable (Fig. 12D), probably 
because the assay is not sensitive enough to detect a reduction in kinase activity in the 
presence of wild type CLP1. 
In contrast to the results obtained with HeLa cells, we could not reproduce the 
dominant negative effect in MEFs upon overexpression of HsCLP1 K127A (Fig. 12B,E,H,I). 
Although it seems unlikely that the effect is present in one and absent in another mammalian 
system, we cannot rule out that this result is e.g. attributable to the marginal differences 
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between mouse and human CLP1 proteins. However, the failure to detect a dominant 
negative effect for CLP1 K127A MEFs could also be due to poor transfection efficiency or 
protein expression. 
Despite that, the dominance of the mutant allele over the wild type underlines the 
importance of CLP1 in pre-tRNA processing. In this respect it is not surprising that both the 
CLP1 knock-out and CLP1 K127A knock-in mice exhibit deleterious phenotypes (Toshikatsu 
Hanada and Josef Penninger, unpublished data).  
 
7.3. Is there a Link between ATP Effects and the CLP1 K127A Mutation? 
Due to the fact that CLP1 is a protein that binds and hydrolyzes ATP or GTP through its 
Walker-A and Walker-B motifs (Noble et al., 2007; Tanabe et al., 1996), we hypothesized 
that depletion of the pre-tRNA splicing endonuclease complex of ATP could mimick the effect 
of the CLP1 K127A mutant. Indeed, this was the case, both when we removed ATP before 
and after immunoprecipitating the TSEN complex via TSEN2 from HeLa cells (Fig. 13 and 
15). Interestingly, we found that ATP back-addition after its depletion could fully restore pre-
tRNA cleavage (Fig. 14 and 15). This finding strongly argues that the absence of ATP does 
not affect the assembly or disassembly of the complex. If the association of the different 
components were ATP-dependent, the complex would not have formed in the absence of 
ATP and the subunits would be, if so at all, only loosely attached to each other. Washing the 
complex several times before assaying the pre-tRNA cleavage activity would probably 
destroy this loose association. Therefore, it seems unlikely that ATP (or CLP1 kinase activity) 
exerts its effects via a structural change of complex organization. However, we cannot rule 
out that the single subunits stay unspecifically associated with each other even in the 
absence of ATP and that they rearrange into a more active conformation upon addition of 
ATP. To rule out the latter possibilities, washing should be performed under more stringent 
conditions and supernatants or flow-through samples need to be checked for the presence or 
absence of complex components. 
We could also show that efficient pre-tRNA cleavage requires ATP hydrolysis rather 
than mere binding of ATP (Fig. 14). The need for a β-γ hydrolyzable NTP was confirmed in 
experiments using the NTAP-CLP1 complex (Fig. 19). 
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7.4. The Influence of Mg2+ on pre-tRNA Cleavage 
It was shown that RISC (RNA-induced silencing complex) cleavage activity is inhibited by 
Mg2+ liberated upon ATP depletion, resulting in a lack of ATP as a Mg2+ chelator (O'Sullivan 
and Perrin, 1964; Yoda et al., 2010). Therefore, we asked whether this could also be the 
case for the effects observed for pre-tRNA cleavage. In fact, we could show that high levels 
of available Mg2+ apparently reduce tRNA exon generation (Fig. 16). However, chelating free 
Mg2+ by addition of EDTA inhibited pre-tRNA cleavage to a similar extent. Still, adding 
considerable amounts of EDTA and Mg2+ to splicing reactions did not affect pre-tRNA 
cleavage activity as much as ATP depletion. 
Although our results are at least in part consistent with the findings described by 
Yoda et al., we concluded that an inhibitory effect of excessive Mg2+ on pre-tRNA cleavage 
cannot be ruled out. However, the influence of Mg2+ on pre-tRNA cleavage activity cannot 
completely explain the considerable decrease in exon amounts generated upon ATP 
depletion. We think that, if Mg2+ plays a role at all, the major part of the reduction of pre-tRNA 
cleavage activity upon ATP depletion is still attributable to the absence of ATP. Moreover, 
this explanation is consistent with the data obtained from experiments using the kinase-dead 
MEFs and from the CLP1 knock-down in HeLa cells because it seems unlikely that a change 
in cellular Mg2+ concentrations occurs and gives rise to the observed phenotypes. 
Additionally, the requirement of ATP hydrolysis for efficient pre-tRNA cleavage would be hard 
to explain by a Mg2+ effect, unless the used non-hydrolyzable ATP analogues also differed 
significantly with respect to their Mg2+ chelating capacities. 
 
7.5. NTP Requirements of a semi-purified CLP1-TSEN Complex 
Since we repeatedly observed unspecific RNA degradation in our pre-tRNA splicing assays 
using TSEN immunoprecipitates and considering that results obtained with different 
immunoprecipitation batches are hard to compare, we turned to purify TAP-tagged wild type 
and K127A CLP1 complexes by a one-step affinity purification from stably expressing cell 
lines. The second purification step was omitted because it led to a complete loss of pre-tRNA 
cleavage activity (Fig. 17), probably due to very inefficient elution with biotin. We were able to 
recapitulate the results obtained with kinase-dead MEFs and CLP1 knock-down HeLa cells 
with wild type and K127A semi-purified CLP1-TSEN complexes (Fig. 18). The presence of all 
four TSEN proteins was confirmed by mass spectrometry performed after in-solution digest 
of the NTAP-HsCLP1 wild type and K127A TEV eluates. Interestingly, tRNA exon generation 
was lower in NTAP-HsTSEN2 TEV eluates as compared to NTAP-HsCLP1 wild type TEV 
eluates. This could be due to somewhat lower expression of NTAP-HsTSEN2 or lower 
TSEN2 protein levels in the final TEV eluate, as detected by Western blotting.  
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Furthermore, we could confirm that efficient pre-tRNA cleavage requires  
β-γ hydrolyzable ATP or GTP (Fig. 19). This is striking because the pre-tRNA splicing 
endonuclease complex with bound, uncleaved tRNA does not contain any obvious  
5’ hydroxyl RNA substrate that CLP1 could phosphorylate. Hence, CLP1’s RNA kinase 
activity is in principle dispensable at this stage, unless CLP1 hydrolyses its NTP cofactor for 
another reason as will be discussed below. We extended the pre-tRNA cleavage analysis to 
additional NTPs, ADP, and AMP. As expected, with ADP and AMP tRNA exon halves could 
only be inefficiently produced, which can be easily explained by them lacking a hydrolyzable 
γ-phosphate group. Using UTP and GTP, exon levels generated were similar or even above 
the ones obtained in the presence of ATP. CTP was not a good substitute for ATP or GTP, 
but stimulating pre-tRNA cleavage only insignificantly lower than, for example, UTP. Most 
likely, the minimal structural differences between CTP and UTP do not cause a significant 
difference in exon generation. 
 
7.6. The Effect of a CLP1 Inhibitor on pre-tRNA Cleavage 
In order to confirm that the deficiency in pre-tRNA cleavage is indeed owing to the absence 
of CLP1’s kinase activity, we tried to achieve a similar reduction in tRNA exon generation by 
specifically inhibiting CLP1’s kinase activity with the small molecule compound BIBT2797SE, 
which was identified in a High-Throughput screen for CLP1 inhibitors performed by 
Boehringer Ingelheim. Since the inhibitor is only effective at low ATP concentrations, we had 
to assure first that pre-tRNA cleavage still occurs to a reasonable extent under those 
conditions. Finally, we could observe a decrease in pre-tRNA cleavage upon addition of the 
inhibitor, which was most prominent at high BIBT2797SE concentrations (Fig. 20). Hence, 
this result is a very specific indication for a link between the kinase activity of CLP1 and tRNA 
exon generation. Nonetheless, some doubts remain concerning the specificity of the inhibitor 
at these high concentrations (10 and 100 µM). For example, in addition to inhibiting CLP1’s 
kinase activity, BIBT2797SE could modulate the activity of other (protein) kinases present in 
the TEV eluates (e.g. ILK, PTK 9, pyruvate kinase). However, this potential unspecific 
inhibitory effect does not really question the concept of CLP1’s influence on pre-tRNA 
cleavage but merely the specific proof of this effect. 
We tried to prove the assumed link between tRNA exon generation deficiency upon 
ATP depletion and the kinase activity of CLP1 by complementing the NTAP-CLP1 K127A 
TEV eluate with recombinant wild type CLP1 to restore activity. To facilitate incorporation of 
wild type CLP1 (provided in trans) into the complex, we attempted to denature the mutant 
complex by high salt concentrations, provide wild type CLP1, and renature the complex by 
Discussion 
_______________________________________________________________________________________ 116 
dialysis before assaying for pre-tRNA cleavage activity. However, no conclusive results were 
obtained (see Appendix).  
 
7.7. Characterization of the CLP1 K127A Mutant 
In order to link the results obtained from tRNA splicing assays in the presence of non-
hydrolyzable analogues and from CLP1 mutant and RNAi knock-down experiments, we 
hypothesized that CLP1 K127A was unable to hydrolyze ATP but still able to bind to it. We 
tried to confirm the latter by crosslinking [α-32P]-ATP to recombinant wild type and K127A 
CLP1 by UV radiation but failed to detect any radioactively labeled proteins in SDS-PAGE 
(data not shown), suggesting technical problems with the assay. Hence, we attempted to see 
the putative difference in ATP-to-ADP conversion between wild type and K127A CLP1 in a 
fluorescence-assisted ATP hydrolysis assay. Even after several optimizations, the assay did 
not reveal consistent and reproducible results (see Appendix).  
Finally, we tried to separate radioactive ADP from ATP by TLC after performing a 
kinase assay with recombinant wild type and mutant CLP1. This method worked at last, but 
showed that both CLP1 wild type and K127A converted the supplemented ATP to ADP  
(Fig. 21). This result allows various interpretations: Either, the detection method is too 
sensitive or too little ATP was added to the assay, so that a putative defect in hydrolysis 
could not be observed. In this case, one would have to repeat the experiment and include 
higher levels of (cold) ATP and/or do a time course. On the other hand, if the result were 
true, it would mean that CLP1 K127A is still capable of hydrolyzing ATP (but cannot 
phosphorylate siRNAs) and that the deficiency in kinase activity is caused by another effect, 
such as structural changes. However, most likely other unspecific ATPases were contained 
in the purified protein batch, performing the observed conversion of ATP to ADP. 
 
7.8. Is the pre-tRNA Cleavage Deficiency caused by a Change in 
Complex Architecture? 
Our results suggest that if some kind of complex rearrangement causes the decreased exon 
generation, this could have different answers, depending on the method used. In principle, 
CLP1, with its catalytic center possibly close to the active site of the tRNA splicing 
endonuclease, could cause a structural rearrangement of the complex, mediating its 
transition into a more active conformation and thereby enhancing pre-tRNA cleavage 
efficiency. However, from the co-immunoprecipitation data we concluded that an impact on 
complex assembly seemed unlikely, which was supported by glycerol gradient centrifugation 
experiments, where only minor changes in the sedimentation behavior could be detected in 
the presence or absence of ATP (Fig. 22). From these results one can conclude that neither 
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complex assembly nor stability is affected because otherwise, the addition of ATP after 
purification of the ATP-depleted complexes should not restore exon generation. Moreover, if 
this were true, the complex components would be expected to sediment differently in the 
presence or absence of ATP. Still, these findings cannot rule out a (minor) change in 
complex architecture resulting in an increased pre-tRNA cleavage activity. 
However, all these results were challenged by the surprising detection of reduced 
TSEN protein amounts in the NTAP-HsCLP1 TEV eluates (Fig. 22E) most likely not resulting 
from a minor change in the complex structure. Clearly, this result suggests that complex 
assembly is affected when CLP1 is lacking its kinase activity. Could it be the case that such 
a massive reduction in TSEN protein amounts in the NTAP-Hs CLP1 K127A TEV eluate 
results in the minor change of the sedimentation properties observed upon ATP depletion? 
Assuming that the restoration of full pre-tRNA cleavage activity upon ATP addition to 
depleted and washed immunoprecipitates is caused by the TSEN subunits staying 
unspecifically attached to each other under mild washing conditions, this would be one way 
of explaining the diverging results.  
Another explanation to bring the conflicting results in line could be that the K127A 
mutation exerts a stronger effect than ATP depletion alone. Accordingly, the presence of 
mutated CLP1 would affect pre-tRNA cleavage by modifying the complex structure, whereas 
the absence of ATP would only inhibit pre-tRNA cleavage. For example, CLP1’s kinase 
activity could be required for dissociation of the complex after it has accomplished its 
cleavage reaction or for releasing the spliced exon halves. In addition, CLP1 itself could have 
a structural role in the complex. However, this somehow implies that we have been looking at 
two different, although related, effects displaying the same phenotype in the pre-tRNA 
splicing assay. 
 
7.9. Could Phosphorylation of the TSEN Proteins play a Role in tRNA 
Splicing? 
Interestingly, Fig. 22F shows that TSEN2 seems to be phosphorylated in the NTAP-HsCLP1 
TEV eluate. Phosphorylation of TSEN2 at serine 240 has been detected by Matsuoka and 
coworkers in a screen for targets of the DNA damage response kinases ATM and ATR 
(Matsuoka et al., 2007). By similarity, three other serines (408, 411, 415) are annotated as 
putative phosphorylation sites (Swiss-Prot database). In addition to TSEN2, also TSEN54 
(serines 230 and 235) appeared as a target of ATM/ATR (Matsuoka et al., 2007). 
Additionally, two more phosphoserines (225 and 249) on TSEN54 were identified in a 
phosphoproteome screen (Gauci et al., 2009). In the same screen, also TSEN34 appeared 
to have three phosphoserines (134, 135, and 136). For TSEN15, no phosphorylation sites 
have been detected.  
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Does TSEN phosphorylation by ATM/ATR suggest a role for the TSEN proteins in the DNA 
damage response? In any case, this would be an interesting link since DNA damage would, 
sooner or later, also impact on the formation of mature tRNAs, among the numerous other 
effects it causes in a cell. Could the TSEN proteins act as “signal receivers” in this respect? 
Does phosphorylation affect their activity and impact on pre-tRNA cleavage? Could TSEN 
phosphorylation even constitute the regulatory activity that switches between the mammalian 
and the yeast-like ligase activity under certain conditions? The simple finding of TSEN2 
phosphorylation opens up these various questions that could be the starting point for further 
investigations. Analyzing the phosphorylation status of the remaining TSEN proteins in the 
NTAP-HsCLP1 wild type and K127A TEV eluates could be an initial experiment to answer 
these questions. 
 
7.10. Could CLP1 have additional Protein Kinase Activity? 
The discovery of phosphorylation of the TSEN proteins in the light of ATP hydrolysis being 
required during pre-tRNA cleavage led to another question: Is it possible that CLP1 acts not 
only on RNAs but also on proteins? Although this seems implausible, we cannot rule it out 
since functional overlaps between RNA and protein modifying enzymes have already been 
described for the human PIR1 protein, acting both as an RNA and protein phosphatase 
(Deshpande et al., 1999).  
In a preliminary experiment, we indeed found a differential pattern of putatively 
phosphorylated proteins between the NTAP-HsCLP1 wild type and K127A TEV eluates  
(Fig. 23). Interestingly, the addition of an intron-containing pre-tRNA is not needed to trigger 
the appearance of the bands, suggesting that CLP1 as a potential protein kinase is 
constitutively active. Nonetheless, the putative phosphorylation could also be carried out by 
other protein kinases present in the TEV eluates, such as ILK, PTK 9 or pyruvate kinase (for 
details see mass spectrometry results in the Appendix). 
However, we do not know whether the bands observed on the gel correspond in fact 
to RNAs that could serve as a substrate for CLP1 as well. This would provide another 
explanation for the requirement of ATP hydrolysis in pre-tRNA cleavage: An unidentified 
RNA component that is part of the pre-tRNA splicing endonuclease complex could be 
phosphorylated by CLP1 and thus modulate the exon generation efficiency of the complex. 
To further elucidate these ideas, one could specifically degrade either protein or RNA in the 
samples after the reaction and examine the band patterns on RNA and protein gels. 
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7.11. Does the CLP1 K127A Mutation affect the Subcellular Localization 
of the pre-tRNA Splicing Endonuclease Complex Components? 
Since evidence has emerged that pre-tRNA splicing in yeast occurs in the cytoplasm 
(Yoshihisa et al., 2007; Yoshihisa et al., 2003) and also the transport between nucleus and 
cytoplasm has been shown to take part in pre-tRNA processing (Hopper et al., 2010; 
reviewed in Hopper and Shaheen, 2008), the actual subcellular localization of this process is 
controversially discussed. However, data from Xenopus laevis (De Robertis and Olson, 
1979), mouse (Winicov and Button, 1982) and human cells (Laski et al., 1983; Paushkin et 
al., 2004; Peebles et al., 1983; Rauhut et al., 1990) suggest that pre-tRNA splicing is a 
nuclear event in vertebrates. Additionally, CLP1 was found to localize predominantly to the 
nucleus (Stefan Weitzer, unpublished data, and de Vries et al., 2000). This prompted us to 
hypothesize that a relocalization of one or more components of the CLP1-TSEN complex 
could cause the reduction of pre-tRNA cleavage.  
We set out to investigate this hypothesis by immunofluorescence microscopy in CLP1 
wild type and K127A MEFs with antibodies directed against CLP1 and the TSEN proteins. 
However, we could not obtain significant signals above background levels with most 
antibodies, thus leaving the data obtained from our immunofluorescence experiments 
unreliable (see Appendix). It also seems unlikely that one can biochemically detect an effect 
in extracts that is caused by different compartmentalization of its enzymes. 
 
7.12. Outlook 
We have shown that efficient pre-tRNA cleavage by the tRNA splicing endonuclease 
complex is dependent on the activity of the RNA kinase CLP1, an integral component of this 
complex. In support of this, we found that removing ATP from the cleavage reaction in vitro 
causes a similar effect.  
The reason why CLP1’s kinase activity and ATP might be needed for efficient tRNA 
exon generation remains unclear, although I obtained data suggesting that the stability of the 
complex could be affected. However, the model underlying our data needs to be elucidated 
by further experiments. In addition to various experimental concepts outlined in the 
respective sections, we could analyze the sedimentation behavior of TSEN/CLP1 in extracts 
prepared from wild type and kinase-dead MEFs to examine complex stability in CLP1 wild 
type and mutant backgrounds.  
To reveal the kinetic aspects of the pre-tRNA cleavage deficiency, experiments 
determining Km and kcat of the TSEN complex should be performed. CLP1’s possible function 
as a protein kinase could be assessed by carrying out pre-tRNA splicing assays in the 
presence of lambda protein phosphatase, by performing an in vivo labeling with radioactive 
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ortho-phosphate, and by specifically trying to detect phosphopeptides by mass spectrometry, 
for example, on the NTAP-CLP1 TEV eluates. Finally, the putative phosphorylation of the 
TSEN proteins could be the starting point for an investigation of novel aspects and 
uncharacterized links between pre-tRNA splicing and other biological processes, such as the 
DNA damage response.  
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11. Appendix 
11.1. Mass Spectrometry Results 
# Name 
Accession  
Number 
Molecular  
Weight 
Peptides in 
TEV eluate 
    wt mut 
1 clathrin, heavy polypeptide (Hc), isoform CRA_a gi|119614801 192 kDa 31 55 
2 filamin-A isoform 1 gi|116063573 280 kDa 38 59 
3 cytoplasmic dynein 1 heavy chain 1 gi|33350932 532 kDa 34 59 
4 keratin, type II cytoskeletal 2 epidermal gi|47132620 65 kDa 33 38 
5 tubulin beta chain gi|29788785 50 kDa 21 23 
6 heat shock cognate 71 kDa protein isoform 1 gi|5729877 71 kDa 24 26 
7 myosin-9 [Homo sapiens] gi|12667788 227 kDa 39 42 
8 chain c human immunoglobulin M gi|166007160 57 kDa 15 13 
9 immunoglobulin light chain gi|149673887 23 kDa 9 9 
10 heat shock protein HSP 90-beta gi|20149594 83 kDa 19 26 
11 eukaryotic translation initiation factor 3 subunit A gi|4503509 167 kDa 20 27 
12 heat shock 70 kDa protein 1A/1B gi|167466173 70 kDa 16 22 
13 elongation factor 1-alpha 1 gi|4503471 50 kDa 13 14 
14 valosin-containing protein gi|111305821 89 kDa 17 25 
15 tubulin alpha-1B chain gi|57013276 50 kDa 16 16 
16 eukaryotic translation elongation factor 1 gamma gi|15530265 50 kDa 16 15 
17 60 kDa heat shock protein, mitochondrial gi|31542947 61 kDa 19 24 
18 T-complex protein 1 subunit theta gi|48762932 60 kDa 15 26 
19 chaperonin containing TCP1, subunit 3 (gamma) gi|14124984 60 kDa 15 16 
20 peptidyl-prolyl cis-trans isomerase A  gi|10863927 18 kDa 11 11 
21 t-complex polypeptide 1 gi|36796 60 kDa 13 16 
22 T-complex protein 1 subunit epsilon gi|24307939 60 kDa 13 21 
23 T-complex protein 1 subunit beta gi|197692147 57 kDa 14 17 
24 T-complex protein 1 subunit delta gi|38455427 58 kDa 10 21 
25 monoclonal IgM antibody heavy chain gi|41388180 64 kDa 10 12 
26 immunoglobulin kappa heavy chain gi|2765421 52 kDa 6 7 
27 heat shock protein HSP 90-alpha isoform 1 gi|153792590 98 kDa 10 14 
28 elongation factor 2 gi|4503483 95 kDa 11 15 
29 78 kDa glucose-regulated protein gi|16507237 72 kDa 14 19 
30 immunoglobulin heavy chain gi|10334587 41 kDa 7 7 
31 
stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein), 
isoform CRA_b 
gi|119594603 68 kDa 8 22 
32 T-complex protein 1 subunit eta isoform a gi|5453607 59 kDa 11 17 
33 fatty acid synthase gi|119610151 273 kDa 4 20 
34 heat shock 70kDa protein 4, isoform CRA_b gi|119582699 88 kDa 9 17 
35 acute morphine dependence related protein 2 gi|14517632 58 kDa 13 14 
36 ATP-citrate synthase isoform 2 gi|38569423 120 kDa 10 19 
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37 tRNA-splicing endonuclease subunit Sen54 TSEN54 gi|108389176 59 kDa 11 10 
38 Ig G1 H Nie gi|229601 49 kDa 2 3 
39 actinin, alpha 4, isoform CRA_a gi|119577213 105 kDa 6 15 
40 carbamoyl-phosphate synthetase 1, mitochondrial, isoform CRA_b gi|119590899 165 kDa 5 13 
41 inosine-5'-monophosphate dehydrogenase 2 gi|66933016 56 kDa 10 11 
42 chain A, galectin-1 gi|42542977 15 kDa 6 8 
43 eukaryotic translation initiation factor 3 subunit E gi|4503521 52 kDa 7 10 
44 polyribonucleotide 5'-hydroxyl-kinase Clp1 isoform 1 gi|5803029 48 kDa 5 11 
45 integrin-linked protein kinase gi|4758606 51 kDa 8 11 
46 epiplakin 1 gi|13548675 553 kDa 8 10 
47 unnamed protein product HSPA9 gi|221042022 72 kDa 7 11 
48 lupus La protein gi|10835067 47 kDa 9 8 
49 eIF-3 p110 subunit gi|1931584 105 kDa 7 11 
50 60 kDa SS-A/Ro ribonucleoprotein isoform 2 gi|31377800 61 kDa 6 9 
51 40S ribosomal protein S2 gi|15055539 31 kDa 5 6 
52 D-3-phosphoglycerate dehydrogenase gi|23308577 57 kDa 8 10 
53 peroxiredoxin-1 gi|4505591 22 kDa 6 9 
54 parvin, alpha, isoform CRA_c gi|119588931 47 kDa 5 7 
55 tRNA-splicing endonuclease subunit Sen2 isoform 1 TSEN2 gi|13376882 53 kDa 9 6 
56 PIMT isozyme I gi|1332399 25 kDa 4 7 
57 unnamed protein product gi|16554039 65 kDa 4 3 
58 eukaryotic translation initiation factor 3, subunit 9 eta, isoform CRA_c gi|119607645 93 kDa 7 11 
59 actin, beta gi|14250401 41 kDa 7 10 
60 chain A, laminin receptor precursor gi|161761214 28 kDa 7 7 
61 ribosomal protein L5, isoform CRA_b gi|119593494 28 kDa 5 8 
62 EEF1D protein gi|14043783 71 kDa 5 8 
63 tetratricopeptide repeat protein gi|1688076 55 kDa 4 14 
64 heat shock protein beta-1 gi|4504517 23 kDa 5 8 
65 immunoglobulin heavy chain constant region gi|10799664 36 kDa 4 3 
66 tRNA-splicing endonuclease subunit Sen34 TSEN34 gi|116875840 34 kDa 6 6 
67 BCL2-associated athanogene 3, isoform CRA_a gi|119569767 61 kDa 4 9 
68 eukaryotic translation initiation factor 3 subunit K gi|10801345 25 kDa 3 6 
69 ribosomal protein S4, X-linked, isoform CRA_a gi|119592221 43 kDa 5 8 
70 
guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1, 
isoform CRA_c 
gi|119574079 43 kDa 4 6 
71 40S ribosomal protein S3a gi|4506723 30 kDa 5 6 
72 
ARP1 actin-related protein 1 homolog A, centractin alpha (yeast), isoform 
CRA_b 
gi|119570071 43 kDa 4 8 
73 transferrin receptor (p90, CD71), isoform CRA_b gi|119574056 90 kDa 6 8 
74 ras suppressor protein 1 isoform 1 gi|6912638 32 kDa 5 7 
75 heterogeneous nuclear ribonucleoprotein M, isoform CRA_c gi|119589327 78 kDa 5 7 
76 eukaryotic translation initiation factor 3, subunit 7 zeta, isoform CRA_b gi|119580514 64 kDa 5 7 
77 ribosomal protein S5, isoform CRA_b gi|119592989 22 kDa 5 7 
78 PWP1-interacting protein 4 gi|14579002 41 kDa 5 8 
79 26S protease regulatory subunit 7 gi|4506209 49 kDa 5 7 
80 chain A, muscle L-lactate dehydrogenase M chain gi|13786849 37 kDa 5 5 
81 neuroblast differentiation-associated protein AHNAK isoform 1 gi|61743954 629 kDa 4 7 
82 40S ribosomal protein S3 gi|15718687 27 kDa 2 8 
83 multifunctional protein CAD gi|1228049 243 kDa 0 11 
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84 protein Rei,Bence-Jones gi|229526 24 kDa 2 3 
85 PA2G4 protein gi|116283988 45 kDa 5 7 
86 nucleophosmin isoform 1 gi|10835063 33 kDa 4 5 
87 LIM and senescent cell antigen-like-containing domain protein 1 gi|13518026 37 kDa 3 4 
88 dynactin subunit 2 gi|5453629 45 kDa 4 10 
89 26S proteasome subunit p97 gi|1060888 100 kDa 4 5 
90 DnaJ (Hsp40) homolog, subfamily A, member 1, isoform CRA_d gi|119578931 42 kDa 4 4 
91 40S ribosomal protein S18 gi|11968182 18 kDa 5 5 
92 myosin regulatory light chain MRCL3, isoform CRA_b gi|119622084 20 kDa 5 6 
93 eukaryotic translation initiation factor 3, subunit 2 beta, isoform CRA_a gi|119627957 31 kDa 5 5 
94 tat-associated protein gi|1096067 31 kDa 3 5 
95 ferritin heavy chain gi|56682959 21 kDa 5 4 
96 nuclear factor NF-kappa-B p100 subunit isoform b gi|117320527 97 kDa 4 4 
97 clathrin light chain A isoform a gi|4502899 24 kDa 3 3 
98 proteasome (prosome, macropain) subunit, beta type, 1, isoform CRA_a gi|119567805 24 kDa 3 5 
99 Ig L-chain V-region gi|27552515 23 kDa 3 4 
100 eukaryotic translation initiation factor 3, subunit 3 gamma, isoform CRA_b gi|119612363 42 kDa 2 7 
101 ribosomal protein gi|337518 22 kDa 2 5 
102 DNA-binding protein B gi|181486 40 kDa 4 4 
103 hsc70-interacting protein gi|19923193 41 kDa 3 5 
104 Valyl-tRNA synthetase gi|15215421 140 kDa 3 5 
105 eukaryotic translation initiation factor 3 subunit M gi|23397429 43 kDa 3 5 
106 chain A, Cyclophilin B gi|1310882 20 kDa 3 6 
107 tubulin, beta 2C gi|23958133 50 kDa 4 3 
108 DNAJB1 gi|49168458 38 kDa 3 6 
109 40S ribosomal protein S12 gi|14277700 15 kDa 3 4 
110 SERPINE1 mRNA binding protein 1 gi|12803339 44 kDa 2 5 
111 eukaryotic initiation factor 4A-I gi|4503529 46 kDa 0 8 
112 26S protease regulatory subunit 6A gi|21361144 49 kDa 0 6 
113 nucleolin, isoform CRA_c gi|119591368 59 kDa 4 0 
114 60S acidic ribosomal protein P2 gi|4506671 12 kDa 4 4 
115 calcium binding and coiled-coil domain 2, isoform CRA_b gi|119615114 55 kDa 3 5 
116 proteasome (prosome, macropain) subunit, alpha type, 1, isoform CRA_b gi|119588883 34 kDa 3 4 
117 unnamed protein product gi|34527275 54 kDa 4 4 
118 phenylalanyl-tRNA synthetase beta chain gi|124028525 66 kDa 4 5 
119 glyceraldehyde-3-phosphate dehydrogenase gi|31645 36 kDa 2 5 
120 STIP1 homology and U-box containing protein 1, isoform CRA_b gi|10441867 27 kDa 3 5 
121 eukaryotic translation elongation factor 1 beta 2, isoform CRA_a gi|4503477 25 kDa 2 4 
122 14-3-3 protein epsilon gi|5803225 29 kDa 2 6 
123 eukaryotic translation initiation factor 3 subunit L gi|7705433 67 kDa 3 4 
124 PSMA7 protein gi|116283481 27 kDa 3 5 
125 MYL6 protein gi|113812151 16 kDa 2 5 
126 ribosomal protein S10, isoform CRA_a gi|119624187 20 kDa 3 3 
127 diff6,H5,CDC10 homologue gi|1040689 47 kDa 2 3 
128 
proteasome (prosome, macropain) 26S subunit, ATPase, 5, isoform 
CRA_a 
gi|119614675 43 kDa 2 3 
129 4F2 heavy chain antigen gi|177216 58 kDa 2 5 
130 40S ribosomal protein S20 isoform 1 gi|226246671 16 kDa 2 3 
131 dnaJ homolog subfamily A member 2 gi|5031741 46 kDa 2 5 
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132 poly(rC)-binding protein 1 gi|222352151 37 kDa 0 4 
133 SYNCRIP protein gi|116283697 51 kDa 4 0 
134 CD5L gi|37182111 38 kDa 4 0 
135 peroxiredoxin-2 isoform a gi|32189392 22 kDa 0 5 
136 chain A, A subunit of protein phosphatase 2a and small T antigen of Sv40 gi|149243188 64 kDa 0 4 
137 peptidyl-prolyl cis-trans isomerase F, mitochondrial precursor gi|5031987 22 kDa 3 3 
138 chain A, 14-3-3 gamma gi|82407948 28 kDa 2 3 
139 HNRPF protein gi|16876910 46 kDa 2 3 
140 
proteasome (prosome, macropain) 26S subunit, ATPase, 1, isoform 
CRA_b 
gi|119601826 45 kDa 2 2 
141 proteasome subunit alpha type-2 gi|4506181 26 kDa 2 4 
142 heat shock 105kDa/110kDa protein 1, isoform CRA_b gi|119628884 97 kDa 3 4 
143 40S ribosomal protein S17 gi|4506693 16 kDa 2 5 
144 OCP2 gi|1017813 17 kDa 0 3 
145 eukaryotic translation initiation factor eIF3, p35 subunit gi|3264861 29 kDa 0 3 
146 immunoglobulin J chain gi|114319027 20 kDa 2 2 
147 Parvin, beta gi|127801538 42 kDa 0 5 
148 desmoplakin I gi|1147813 332 kDa 0 5 
149 proteasome subunit beta type-4 gi|22538467 29 kDa 0 6 
150 adenylyl cyclase-associated protein 1 gi|5453595 52 kDa 0 5 
151 BAG family molecular chaperone regulator 2 gi|4757834 24 kDa 0 5 
152 ribosomal protein S19 gi|16924231 17 kDa 2 3 
153 RPS21 protein gi|17390310 9 kDa 2 3 
154 26S proteasome non-ATPase regulatory subunit 11 gi|28872725 47 kDa 2 4 
155 X-ray repair cross-complementing protein 5 gi|10863945 83 kDa 2 4 
156 ribosomal protein, large, P0, isoform CRA_a gi|119618576 31 kDa 2 3 
157 26S protease regulatory subunit 6B isoform 2 gi|24430155 44 kDa 2 3 
158 40S ribosomal protein S13 gi|4506685 17 kDa 2 3 
159 spectrin beta chain, brain 1 isoform 1 gi|112382250 275 kDa 0 2 
160 nucleosome assembly protein 1-like 1, isoform CRA_b gi|119617721 41 kDa 0 4 
161 sorcin, isoform CRA_b gi|119597317 12 kDa 0 3 
162 40S ribosomal protein S28 gi|4506715 8 kDa 0 2 
163 chain H, anti-Hiv-1 Fab 447-52d gi|270047622 25 kDa 2 2 
164 40S ribosomal protein S14 gi|5032051 16 kDa 0 3 
165 heterogeneous nuclear ribonucleoprotein K, isoform CRA_b gi|119583080 51 kDa 0 4 
166 PTK9 protein tyrosine kinase 9, isoform CRA_c gi|119578274 48 kDa 0 4 
167 hypothetical protein LOC196463, isoform CRA_b gi|119618459 65 kDa 0 3 
168 peroxiredoxin-4 gi|5453549 31 kDa 0 3 
169 chain C, Mj5 Fab gi|218681905 24 kDa 3 2 
170 eukaryotic translation initiation factor 2 subunit 1 gi|4758256 36 kDa 2 3 
171 glucosidase, alpha; neutral AB, isoform CRA_a gi|119594451 105 kDa 2 3 
172 peroxiredoxin 3, isoform CRA_a gi|119569781 25 kDa 2 3 
173 filaggrin-2 gi|62122917 248 kDa 2 2 
174 immunoglobulin kappa 1 light chain gi|170684606 23 kDa 2 2 
175 heat shock 10kDa protein 1 (chaperonin 10), isoform CRA_d gi|119590563 8 kDa 3 2 
176 RPL14 protein gi|118142835 15 kDa 2 2 
177 
chain A, phosphorylation independent interactions between 14-3-3 and 
exoenzyme S 
gi|161172138 26 kDa 2 2 
178 immunoglobulin kappa 4 light chain gi|170684576 24 kDa 2 2 
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179 60S ribosomal protein L15 gi|15431293 24 kDa 2 2 
180 proteasome subunit beta type-2 gi|4506195 23 kDa 2 2 
181 
PCF11, cleavage and polyadenylation factor subunit, homolog (S. 
cerevisiae), isoform CRA_b 
gi|119595490 173 kDa 3 0 
182 immunoglobulin heavy chain gi|46254016 18 kDa 3 0 
183 SDF2 like protein 1 gi|11275389 24 kDa 0 3 
184 alpha-2-macroglobulin precursor gi|177870 163 kDa 0 2 
185 chromosome 14 open reading frame 166, isoform CRA_c gi|119586065 29 kDa 2 0 
186 heat shock protein gp96 precursor gi|15010550 90 kDa 0 4 
187 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1, isoform CRA_b gi|119621300 75 kDa 0 2 
188 moesin, isoform CRA_b gi|119625804 67 kDa 0 4 
189 clathrin light chain B isoform a gi|4502901 23 kDa 0 3 
190 ribosomal protein L23a, isoform CRA_a gi|119571516 22 kDa 0 3 
191 coatomer protein gi|1002369 138 kDa 0 3 
192 chromosome 1 open reading frame 19, isoform CRA_a TSEN15 gi|119611579 19 kDa 2 2 
193 Chromosome 22 open reading frame 28 gi|12652799 55 kDa 2 2 
194 ribosomal protein L22, isoform CRA_b gi|119591925 11 kDa 2 2 
195 ribosomal protein S6 gi|123231377 10 kDa 2 2 
196 Ig kappa chain NIG93 precursor gi|7438712 23 kDa 2 2 
197 vimentin gi|62414289 54 kDa 2 2 
198 chain A, human mitochondrial single-stranded DNA binding protein gi|2624694 15 kDa 2 2 
199 ribosomal protein L29, isoform CRA_a gi|119585586 18 kDa 2 2 
200 chain L, humanized Anti-Ifn-Gamma Fab gi|4139695 23 kDa 2 2 
201 LanC lantibiotic synthetase component C-like 1 (bacterial), isoform CRA_b gi|119590894 46 kDa 0 2 
202 immunoglobulin kappa light chain variable region gi|224925962 12 kDa 2 2 
203 ubiquitin A-52 residue ribosomal protein fusion product 1 gi|13569612 16 kDa 2 2 
204 hCG1994130, isoform CRA_b gi|119570641 29 kDa 2 2 
205 immunoglobulin kappa light chain variable region gi|70798799 11 kDa 2 0 
206 ribosomal protein L6, isoform CRA_a gi|119618410 17 kDa 0 2 
207 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 13, isoform 
CRA_b 
gi|119581639 43 kDa 0 3 
208 proteasome subunit beta type-6 precursor gi|23110925 25 kDa 0 2 
209 kinesin-related protein gi|1155084 119 kDa 0 2 
210 proteasome 26S non-ATPase subunit 12 isoform 1 variant gi|62896917 53 kDa 0 3 
211 eukaryotic translation initiation factor 3 subunit F gi|4503519 38 kDa 2 0 
212 tubulin alpha-1A chain gi|17986283 50 kDa 2 0 
213 immunoglobulin light chain gi|218783338 24 kDa 2 0 
214 ribosomal protein L3, isoform CRA_d gi|119580717 49 kDa 2 0 
215 RAN binding protein 5, isoform CRA_b gi|119629383 126 kDa 0 2 
216 dynein, cytoplasmic 1, intermediate chain 2, isoform CRA_b gi|119631605 68 kDa 0 3 
217 protein kinase C substrate 80K-H, isoform CRA_b gi|119604622 59 kDa 0 3 
218 pyruvate kinase, muscle, isoform CRA_c gi|119598292 60 kDa 0 3 
219 eukaryotic translation initiation factor 3 subunit G gi|49472822 36 kDa 0 3 
220 ribosomal protein S16, isoform CRA_a gi|119577296 14 kDa 0 3 
221 coatomer subunit delta isoform 1] gi|11863154 57 kDa 0 2 
222 proteasome (prosome, macropain) subunit, beta type, 7 gi|12653475 30 kDa 0 3 
223 protease, serine, 15, isoform CRA_b gi|119589558 106 kDa 3 0 
224 proteasome (prosome, macropain) subunit, alpha type, 3, isoform CRA_a gi|119601121 24 kDa 0 2 
225 IGH@ protein gi|49256427 51 kDa 0 2 
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226 proteasome subunit alpha type-5 gi|23110942 26 kDa 0 2 
227 pyruvate dehydrogenase E1-alpha subunit precursor gi|1051097 44 kDa 3 0 
228 tubulin, alpha 1 (testis specific), isoform CRA_a gi|119591124 48 kDa 0 2 
229 immunoglobulin kappa light chain VLJ region gi|21669463 29 kDa 0 2 
230 beta-cop homolog gi|5257007 107 kDa 0 2 
231 immunoglobulin kappa light chain gi|33235614 12 kDa 0 2 
232 ribosomal protein L11 gi|14719845 20 kDa 0 2 
233 aldehyde dehydrogenase 16 family, member A1, isoform CRA_a gi|119572867 32 kDa 0 2 
234 aldolase A, fructose-bisphosphate, isoform CRA_b gi|119600342 40 kDa 0 2 
235 family with sequence similarity 98, member B isoform 1 gi|109452587 46 kDa 0 2 
236 chain H, human Igg B12 gi|15825647 50 kDa 2 0 
237 HIST1H4H protein gi|111309351 11 kDa 2 0 
238 ADP-ribosylation-like factor 6 interacting protein 4, isoform CRA_c gi|119618781 33 kDa 2 0 
239 anti-rabies SOJA immunoglobulin heavy chain gi|27728681 52 kDa 2 0 
240 immunoglobulin heavy chain gi|46254039 18 kDa 2 0 
241 polyadenylate-binding protein 1 gi|46367787 71 kDa 0 2 
242 immunoglobulin heavy chain gi|29836870 12 kDa 0 2 
243 
transcription elongation factor B (SIII), polypeptide 1 (elongin C), isoform 
CRA_b 
gi|119607427 9 kDa 0 2 
244 nuclear factor p97) gi|1100994 97 kDa 0 2 
245 60S ribosomal protein L12 gi|4506597 18 kDa 0 2 
246 chain A, human dynein light chain Dnlc2a gi|157835121 12 kDa 0 2 
247 septin-9 isoform c gi|116256489 64 kDa 0 2 
248 proteasome (prosome, macropain) subunit, alpha type, 4, isoform CRA_b gi|119619571 25 kDa 0 2 
249 protein arginine methyltransferase 1, isoform CRA_a gi|119572903 40 kDa 0 2 
250 dynactin 3 (p22) gi|55958093 17 kDa 0 2 
251 chain L, human factor Ix Gla domain gi|42543068 23 kDa 2 0 
252 40S ribosomal protein S27 gi|4506711 9 kDa 0 2 
253 ribosomal protein L27a gi|13509323 12 kDa 0 2 
254 glutamyl-prolyl-tRNA synthetase, isoform CRA_a gi|119613715 171 kDa 0 3 
255 dynactin 1 (p150, glued homolog, Drosophila), isoform CRA_d gi|119620093 140 kDa 0 2 
256 p60 gi|1145799 48 kDa 0 2 
257 MAP4 protein gi|14250528 103 kDa 0 2 
258 importin7 gi|11544639 116 kDa 0 2 
259 tubulin alpha-1C chain gi|14389309 50 kDa 0 2 
260 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 gi|150439387 21 kDa 0 2 
261 poly(rC) binding protein 2, isoform CRA_c gi|119617114 37 kDa 2 0 
262 
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
gi|5802968 10 kDa 0 2 
263 
dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
gi|19923748 49 kDa 2 0 
264 proteasome (prosome, macropain) subunit, beta type, 5 gi|30582393 23 kDa 0 2 
265 protein transport protein Sec31A isoform 4 gi|116256336 122 kDa 0 2 
266 proteasome subunit p42 gi|1526426 44 kDa 0 2 
267 coatomer protein complex, subunit beta 2 (beta prime), isoform CRA_b gi|119599446 99 kDa 0 2 
268 Sec23 protein gi|1296664 86 kDa 0 2 
269 60S ribosomal protein L13 gi|15431295 24 kDa 0 2 
Table A1: Mass Spectrometry Results. Peptides identified in NTAP-HsCLP1 wild type (wt) and K127A (mut) 
TEV eluates after in-solution digest and mass spectrometry analysis. Pre-tRNA splicing complex components are 
highlighted in yellow. 
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11.2. Figures 
 
Fig. A1: (A) Western blot confirming overexpression of the myc-tagged mutant CLP1 proteins in HeLa cells as 
indicated. Detection was performed with an antibody directed against c-myc. (B) Kinase activity was assayed by 
incubating a 3’ labeled 21-nt RNA duplex 60 min using immunoprecipitates on anti-c-myc agarose. Extracts for 
co-immunoprecipitation were prepared from HeLa cells transfected with gcDNA 3.1 myc with or without inserts as 
displayed and harvested 48 h later (Input = cleared cell lysates). Positions of 5’ phosphorylated  
(5’ P) and unphosphorylated (5’ OH) duplexes on a 15% denaturing polyacrylamide gel are indicated. In lane 1, 
the RNA substrate was loaded without prior incubation with extract. (C) Kinase activity was assayed as in (B) with 
nuclear extracts prepared from CLP1 wt and K127A MEFs (as indicated) transfected with gcDNA 3.1 myc with or 
without inserts as displayed and harvested 48 h later. In lanes 1 and 2, control samples were loaded as size 
markers. (D) The body-labeled intron-containing S. cerevisiae pre-tRNAPhe was incubated with the nuclear 
extracts used in (C) in the presence of 2 mM ATP for the times indicated. Pre-tRNA cleavage was monitored by 
electrophoresis on a denaturing 10% polyacrylamide gel and detected by phosphorimaging. Different tRNA 
fragments are labeled at the right. In lane 1, the pre-tRNAPhe was loaded without extract, representing time 0. 
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Fig. A2: (A) The body-labeled intron-containing S. cerevisiae pre-tRNAPhe was incubated with the NTAP-HsCLP1 
K127A in the presence of 2 mM ATP. Before the assay, the samples were incubated with different recombinant 
CLP1 wild type proteins as indicated and increasing NaCl concentrations (from 100 mM to 2 M) to denature the 
complex. For renaturing, salt was removed by microdialysis (exept samples labeled with w/o µD). See Materials 
and Methods for assay details. Pre-tRNA cleavage was monitored by electrophoresis on a denaturing  
10% polyacrylamide gel and detected by phosphorimaging. In lane 1, the pre-tRNAPhe was loaded without extract. 
(B) Immunofluorescence in CLP1 wild type (left panel) and K127A MEFs (right panel). Green = background signal 
from secondary α-rabbit IgG coupled to AlexaFluor 488; blue = DAPI staining. Cells were imaged at 63-fold 
magnification. See Materials and Methods for experimental details. (C) Immunofluorescence as in (B). Green = 
(unspecific) signal from α-MmCLP1 antibody and/or secondary α-rabbit IgG coupled to AlexaFluor 488; blue = 
DAPI staining. 
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Fig. A3: (A) ADP standard curve obtained with the ATP hydrolysis assay kit. Curve parameters are indicated. 
RFU = relative fluorescence units. Experimental details are described in Table A2. (B) ADP generation with 
varying substrate concentrations. Substrate (A4 = AAAA 4-mer) concentrations are indicated. Error bars represent 
mean standard deviations from fluorescence measurement. (C) ADP generation with varying ATP concentrations 
as indicated. Error bars represent mean standard deviations from fluorescence measurement. (D) ADP 
generation after incubating different CLP1 proteins (C.e. = recombinant C. elegans wild type CLP1) or T4 PNK 
with different substrates as indicated. Substrate concentrations are indicated. OH = 5’ hydroxyl RNA; P = 5’ 
phosphate RNA; (B) = NEB Buffer used instead of RNAi Buffer. See Table A2 for all details. 
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Rec. 
HsCLP1 
wild type 
or K127A 1 
Rec. 
HsCLP1 
wild type  
or K127A 2 
ADP 
Standard 1 
ADP 
Standard 2 
C. elegans 
CLP1  
wild type 
T4 PNK 1 T4 PNK 2 T4 PNK 3 T4 PNK Kit testing 1 
T4 PNK 
Kit testing 2 
Kinase or  
Standard 
  
(final ADP 
concen-
tration) 
4 µl rec. 
HsCLP1 
  
(0.5-0.7 
mg/ml) 
2 µl rec. 
HsCLP1  
 
(2 mg/ml) 
0.9 µl H2O 
or 225 µM 
ADP 
Standard 
(10 µM) 
0/0.9/4.4/8.
9 µl 225 µM 
ADP 
Standard 
(0/10/50/10
0 µM) 
2 µl  
C. elegans 
CLP1  
wild type  
(1 mg/ml) 
0.5 µl  
T4 PNK 
0.5 µl  
T4 PNK 
0.5 µl  
T4 PNK 
0.5 µl  
T4 PNK 
0.5 µl T4 
PNK 
1 mM ATP 
(final 
concen-
tration) 
1 µl  
(50 µM) 
1 µl  
(50 µM) 
1 µl  
(50 µM) 
1 µl  
(50 µM) 
1 µl  
(50 µM) 
1 µl  
(50 µM) 
1 µl  
(50 µM) 
1 µl  
(50 µM) 
1 µl  
(50 µM) 
0.2/1/2/4 µl 
(10/50/100/ 
200 µM) 
Reaction 
Buffer 
2 µl 3x 
Reaction 
Buffer 
without 
ATP 
- 
2 µl 3x 
Reaction 
Buffer 
without 
ATP 
2 µl 10x T4 
PNK Buffer 
2 µl 3x 
Reaction 
Buffer 
without 
ATP 
2 µl 10x 
T4 PNK 
Buffer 
2 µl 3x 
Reaction 
Buffer 
without 
ATP 
- 
2 µl 10x  
T4 PNK 
Buffer 
2 µl 10x  
T4 PNK 
Buffer 
Substrate 
 
(final 
concen-
tration) 
2 µl 20 µM 
siRNA GFP 
5’ OH or P 
(2 µM)  
 
[or H2O] 
2/10 µl  
100 µM A4 
(10/50 µM)  
or 2/10 µl  
20 µM 
21.5/21.7 
duplex  
(2/10 µM) 
- - 
2 µl  
20 µM 
siRNA GFP 
5’ OH or P 
(2 µM)  
 
[or H2O] 
2 µl  
20 µM 
siRNA 
GFP  
5’ OH or 
P  
(2 µM)  
[or H2O] 
2 µl  
20 µM 
siRNA 
GFP  
5’ OH or 
P  
(2 µM)  
[or H2O] 
2/10 µl 100 
µM A4  
(10/50 µM) 
or 2/10 µl 
20 µM 
21.5/21.7 
duplex 
(2/10 µM) 
0.1/0.4/2/ 
10 µl A4 
(0.5/2/10/ 
50 µM) 
0.4 µl  
100 µM A4 
(2 µM) 
RNAi Buffer 6 µl 7 µl 10 µl - - - - 7 µl - - 
H2O 5 µl ad 20µl 6.1 µl ad 20 µl 5 µl 5 µl 5 µl ad 20µl ad 20 µl ad 20 µl 
Incubation 
30°C 
60 min 
1300 rpm 
30°C 
60 min 
1300 rpm 
- - 
30°C 
60 min 
1300 rpm 
37°C 
60 min 
1300 rpm 
30°C 
60 min 
1300 rpm 
30°C 
60 min 
1300 rpm 
37°C 
30 min 
1300 rpm 
37°C 
30 min 
1300 rpm 
Table A2: Detailed Reaction Conditions used for Testing ATP Hydrolysis with the Discoverx ADP Hunter Plus Assay (Amersham Biosciences). 
 
